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Background: When psychosis emerges in young people there is a risk of poorer outcomes, and
access to evidence-based treatments is paramount. The current evidence base is limited. Antipsychotic
medications show only a small benefit over placebo, but young people experience more side effects
than adults. There is sparse evidence for psychological intervention. Research is needed to determine
the clinical effectiveness and cost-effectiveness of psychological intervention versus antipsychotic
medication versus a combined treatment for adolescents with psychosis.
Objectives: The objective of Managing Adolescent first-episode Psychosis: a feasibility Study (MAPS)
was to determine the feasibility of conducting a definitive trial to answer the question of clinical
effectiveness and cost-effectiveness of these three treatment options.
Design: This was a prospective, randomised, open-blinded, evaluation feasibility trial with a single blind.
Participants were allocated 1 : 1 : 1 to receive antipsychotic medication, psychological intervention or a
combination of both. A thematic qualitative study explored the acceptability and feasibility of the trial.
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Setting: Early intervention in psychosis services and child and adolescent mental health services in
Manchester, Oxford, Lancashire, Sussex, Birmingham, Norfolk and Suffolk, and Northumberland,
Tyne and Wear.
Participants: People aged 14–18 years experiencing a first episode of psychosis either with an
International Classification of Diseases, Tenth Revision, schizophrenia spectrum diagnosis or meeting the
entry criteria for early intervention in psychosis who had not received antipsychotic medication or
psychological intervention within the last 3 months.
Interventions: Psychological intervention involved up to 26 hours of cognitive–behavioural therapy
and six family intervention sessions over 6 months, with up to four booster sessions. Antipsychotic
medication was prescribed by the participant’s psychiatrist in line with usual practice. Combined
treatment was a combination of psychological intervention and antipsychotic medication.
Main outcome measures: The primary outcome was feasibility (recruitment, treatment adherence and
retention). We used a three-stage progression criterion to determine feasibility. Secondary outcomes
were psychosis symptoms, recovery, anxiety and depression, social and educational/occupational
functioning, drug and alcohol use, health economics, adverse/metabolic side effects and adverse/
serious adverse events.
Results: We recruited 61 out of 90 (67.8%; amber zone) potential participants (psychological
intervention, n = 18; antipsychotic medication, n = 22; combined treatment, n = 21). Retention to
follow-up was 51 out of 61 participants (83.6%; green zone). In the psychological intervention arm
and the combined treatment arm, 32 out of 39 (82.1%) participants received six or more sessions of
cognitive–behavioural therapy (green zone). In the combined treatment arm and the antipsychotic
medication arm, 28 out of 43 (65.1%) participants received antipsychotic medication for 6 consecutive
weeks (amber zone). There were no serious adverse events related to the trial and one related adverse
event. Overall, the number of completed secondary outcome measures, including health economics,
was small.
Limitations: Medication adherence was determined by clinician report, which can be biased. The
response to secondary outcomes was low, including health economics. The small sample size obtained
means that the study lacked statistical power and there will be considerable uncertainty regarding
estimates of treatment effects.
Conclusions: It is feasible to conduct a trial comparing psychological intervention with antipsychotic
medication and a combination treatment in young people with psychosis with some adaptations to the
design, including adaptations to collection of health economic data to determine cost-effectiveness.
Future work: An adequately powered definitive trial is required to provide robust evidence.
Trial registration: Current Controlled Trials ISRCTN80567433.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 4. See the NIHR Journals Library website for further project information.
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Plain English summary
Psychosis is a mental health problem that can involve hearing, seeing or believing things that othersdo not. Although many young people who experience psychosis recover well from their first
episode of psychosis, others can have more serious, longer-lasting problems. There has not been a large
amount of research into the treatment of psychosis in young people; therefore, it is important to test
different treatments against each other in clinical trials. ‘Feasibility’ trials, such as the one we carried
out [Managing Adolescent first-episode Psychosis: a feasibility Study (MAPS)], test whether or not it is
possible to run larger trials.
MAPS was a small trial that was run in seven locations in the UK. People who were aged 14–18 years
and experiencing psychosis were able to take part. Each participant was randomly assigned to receive
psychological treatment (cognitive–behavioural therapy and optional family therapy), antipsychotic
medication or a combination of both. All of the participants met with a trial research assistant three
times for assessments about well-being and symptoms. Some clinicians, participants and family members
were interviewed about their opinions of the trial and treatments. The trial also had patient and public
involvement; service user researchers were involved in design, interview data collection, analysis and
report writing.
Sixty-one young people took part in MAPS, which was around 68% of our target number. In total, 84%
completed the assessments with research assistants. The results showed that, overall, all treatments
were acceptable to young people and their family members. However, a higher percentage of young
people actually received the ‘minimum dose’ of psychological treatment than the ‘minimum dose’ of
antipsychotic medication (82% vs. 65%). Results showed that it was possible to run a larger trial such
as this. However, some changes would be required to run a larger trial, such as location (focusing on
urban areas with well established early intervention in psychosis teams), increasing involvement of
psychiatrists and increasing the age limit for participation to 25 years.
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The first episode of psychosis usually occurs at an age between 15 and 35 years, during adolescence or
young adulthood. Developing psychosis during this period can lead to significant personal, social and
economic costs. Research indicates that functional outcomes can be worse for psychosis developed
during adolescence than for psychosis developed in adulthood (especially when there have been
premorbid difficulties), with higher rates of suicide and suicide attempts, and greater economic costs
than other mental health conditions in adolescence. Providing access to evidence-based treatments for
young people with psychosis is paramount. However, the evidence base for antipsychotic medication is
limited to a small number of studies that suggest only a small benefit of antipsychotic medication over
placebo, and a greater risk of metabolic side effects for adolescents than for adults. There is sparse
evidence for psychological intervention, with only one small feasibility study of psychological intervention
in under-18-year-olds. The treatment recommendations in the National Institute for Health and Care
Excellence clinical guideline (CG155) for the treatment of psychosis and schizophrenia in children and
young people were drawn primarily from the larger adult psychosis evidence base, which was considered
sufficiently strong to make the current recommendations. However, in the light of the limited evidence
base for children and young people, the National Institute for Care Excellence made a specific research
recommendation for an evaluation of the clinical effectiveness and cost-effectiveness of antipsychotic
medication versus psychological intervention (cognitive–behavioural therapy and family intervention)
versus both treatments combined for an adolescent first episode of psychosis.
Objectives
The broad objective of Managing Adolescent first-episode Psychosis: a feasibility Study (MAPS) was
to produce quantitative and qualitative data to answer the question of how feasible it is to conduct
a study to examine the effectiveness of psychological intervention, antipsychotic medication or a
combined treatment in young people with a first episode of psychosis. Our specific objectives were
(1) to identify the willingness of clinicians to refer to the trial and the proportion of young people who
consented to take part and subsequently adhered to their treatment allocation; (2) to assess retention
at follow-up of the proposed primary outcome, the Positive and Negative Syndrome Scale, at the
end of treatment; (3) to determine the acceptability and feasibility of the three treatment options to
participants, their parents or carers and prescribing clinicians; (4) to determine the relevance and
validity of the candidate outcomes in preparation for a definitive trial; and (5) to test our randomisation
and blinding procedures.
Methods
Our trial design was a prospective randomised open-blinded evaluation feasibility trial. The trial was
conducted in early intervention in psychosis services and child and adolescent mental health services
across seven UK sites: Manchester, Oxford, Lancashire, Sussex, Birmingham, Norfolk and Suffolk, and
Northumberland, Tyne and Wear. Trial participants were randomised in a 1 : 1 : 1 ratio to psychological
intervention, antipsychotic medication or a combined treatment, and were stratified by centre and
family contact. Randomisation was via a web-based platform hosted by the Centre for Healthcare
Randomised Trials unit. All assessors were blind to allocation until all participants’ outcome measures
were completed.
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Participants were eligible if they were aged 14–18 years; were experiencing their first episode of
psychosis with current delusions or hallucinations; met either the International Classification of Diseases,
Tenth Revision, criteria for a schizophrenia spectrum diagnosis or the entry criteria for early intervention
in psychosis; were under the care of early intervention in psychosis services and/or child and adolescent
mental health services; and were able to provide written informed consent. Participants were not eligible
if they had an International Classification of Diseases, Tenth Revision, diagnosis of organic psychosis; had a
moderate to severe learning disability; had a primary diagnosis of alcohol or substance dependency; had
insufficient command of English to provide written informed consent; scored ≥ 5 points on the Positive
and Negative Syndrome Scale on conceptual disorganisation; presented with immediate risk to self or
others at the time of referral; and/or had received antipsychotic medication or psychological intervention
in the 3 months prior to referral.
Interventions were antipsychotic medication psychological intervention or a combined treatment.
Antipsychotic medications were prescribed by the participant’s usual care team psychiatrist. The
psychiatrist was asked to commence antipsychotic medication as soon as possible after randomisation,
and was free to make the decision about the type and dose of antipsychotic medication as well as the
change of antipsychotic in line with their usual practice.
Psychological intervention was a combination of cognitive–behavioural therapy and family intervention.
Up to 26 hours of cognitive–behavioural therapy was offered over a 6-month treatment window, with
an additional four booster sessions over the subsequent 6 months. Cognitive–behavioural therapy
was based on an integrative cognitive model of psychosis and was manualised with four phases of
engagement, assessment, formulation and change strategies. Family intervention was delivered by
the same cognitive–behavioural therapy therapist, with up to six sessions available over the 6-month
treatment window. Family intervention was optional; therefore, participants and families could decide
to decline this component of psychological intervention if they wished. The combined treatment was a
combination of antipsychotic medication and psychological intervention, as described.
Our primary outcome was feasibility data pertaining to recruitment rates, psychological intervention
and antipsychotic medication adherence, and retention to follow-up of the proposed primary outcome
for a definitive trial at the end of treatment. To evaluate the success of these feasibility criteria we
adopted a three-stage progression criterion that was approved by our independent Data Monitoring
and Ethics Committee, the Trial Steering Committee and the funder. Adherence to therapy was
determined via cognitive–behavioural therapy session records, and adherence to antipsychotic
medication was determined via screening of the participant’s medical records.
Our secondary outcomes were psychosis symptoms and dimensions of psychosis; service user-defined
recovery; anxiety and depression; social and occupational functioning; substance and alcohol use;
adverse effects of medication and metabolic side effects; potential adverse effects of trial participation;
(serious) adverse events; and health economics data. At baseline, we recorded the duration of untreated
psychosis and the Autism Spectrum Quotient.
Participants were followed up at 3, 6 and 12 months (those who were recruited after the first
16 months did not receive a 12-month follow-up assessment). We conducted a qualitative study nested
within MAPS to explore both the acceptability and the feasibility of the trial and the three treatment
options. Interviews were conducted with trial participants, their parents or carers and their prescribing
clinicians. The qualitative interviews and analyses were conducted with leadership from people with
personal or parental experience of psychosis spectrum difficulties. Data were thematically analysed
with inductive coding of the data at the manifest level to produce thematic representations of the
participants’ perspectives.
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Results
For our three-stage progression criterion, the green zone was achieved for 50% of the criterion and
the amber zone for 50% of the criterion. In total, 61 participants (aged 14–18 years; mean age range
16.2–16.4 years; standard deviation 1.3–1.4 years) were enrolled into the study: 18 were assigned
to psychological intervention, 22 to antipsychotic medication and 21 to the combination treatment.
The study referral to randomisation ratio was low, and overall recruitment was 67.8% of the target
(amber zone). We had low rates of attrition (< 20%) and high rates of retention (> 80%) at the 3- and
6-month follow-ups, with a rate of retention to follow-up at the end of treatment of 83.6% (green
zone). Retention was lower at longer-term follow-up. In the psychological intervention and combined
arms, 82.1% received six or more sessions of cognitive–behavioural therapy (green zone) and the
median number of sessions of cognitive–behavioural therapy was 14 for those in the psychological
intervention arm and 15 for those in the combined arm. In the antipsychotic arm and the combined
arm, 65.1% received antipsychotic medication for 6 consecutive weeks (amber zone). The mean
duration of antipsychotic prescription was 31.5 weeks (standard deviation 14.6 weeks, minimum
8.7 weeks and maximum 52 weeks).
Some participants crossed over from their allocated treatment arm. In the psychological intervention arm,
8 out of 18 (44%) participants crossed over. One participant met the deterioration criteria (1/18, 6%),
three (3/18, 17%) had an antipsychotic medication added to their treatment, two (2/18, 11%) participants
did not receive an adherent dose of therapy and had an antipsychotic medication added to their treatment
and two (2/18, 11%) participants did not receive an adherent dose of therapy. In the antipsychotic arm,
eight (8/22, 36%) participants crossed over. In six cases (6/22, 27%), this was because the participant was
not prescribed an antipsychotic. In addition, two (2/22, 9%) participants met the deterioration criteria.
In the combined arm, 10 (10/21, 48%) participants crossed over: nine (9/21, 42%) because they were
not prescribed an antipsychotic medicine and one (1/21, 5%) because they did not receive an adherent
dose of therapy. There were no serious adverse events related to the trial and one related adverse event.
We conducted a repeated-measures analysis of the proposed primary outcome (Positive and Negative
Syndrome Scale) and the secondary outcome (Questionnaire about the Process of Recovery) using a
mixed-effects model to account for the discrete timing of the follow-up assessments and adjust for
site and/or therapist. Safety outcomes were reported on the basis of as-treated status, defined as any
one session of cognitive–behavioural therapy or any one dose of antipsychotic medication descriptive
statistics are reported for safety outcomes. There were no significant differences in the Positive and
Negative Syndrome Scale total at 6 months between the three treatment arms. For the comparison of
the psychological intervention arm with the antipsychotic arm at 6 months, the Positive and Negative
Syndrome Scale total was lower in the psychological intervention arm, with a mean difference of
–7.79 points (95% confidence interval –16.02 to 0.45 points; p = 0.064). For comparisons between
the combined arm and monotherapies, the Positive and Negative Syndrome Scale total was lower in
the psychological intervention arm (mean difference –1.31, 95% confidence interval –9.92 to 7.30 points;
p = 0.766), but higher in the antipsychotic arm (mean difference 6.44, 95% confidence interval –2.44
to 15.32 points; p = 0.155). The completion rate of health economics data was low across the three
treatment arms.
Treatment beliefs varied within the group of prescribers interviewed, with both positive and negative
aspects of each main treatment type identified. However, there was a strong, clear consensus for the
perceived value of antipsychotic medication as a primary treatment for first episode of psychosis, with
cognitive–behavioural therapy and/or family intervention considered valuable adjuncts or secondary
treatment options. Although prescribers valued antipsychotic medication owing to its perceived
function of alleviating acute distress, symptomatology or risk more quickly than other treatments, the
potential harms to children and young people were also frequently highlighted as an important factor
in treatment decision-making and willingness to refer a young person to a randomised treatment trial.
Referring young people to the treatment trial was perceived by prescribers to be a clinical decision,
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whereby skilled clinical judgement was required to determine individually appropriate treatments for
what was a complex and emerging experience, and they were hesitant to relinquish clinical control.
Prescribers balanced the value of careful assessment and accurate diagnosis with the need for immediate
treatment to reduce risk and distress. Professional and organisational influences, such as duty of care
and prescribers’ own treatment beliefs, underpinned this decision-making process. Trial procedures also
influenced the acceptability of referring patients; clinicians perceived the trial as addressing an important
question for which evidence was lacking and for a population with clinical need for whom psychological
services were not routinely available. Close communication with the trial team, which included experienced
clinicians, and scope to retain clinical control over treatment choices were highly valued.
Young people perceived both antipsychotic medication and psychological interventions to be acceptable
treatment approaches. However, the specific benefits and mechanisms of action were viewed as potentially
different. Antipsychotic medications were perceived to have the potential to address symptoms, often
quickly, such as reducing cognitive intrusions and anxiety, but concerns were expressed around sedative side
effects. Cognitive–behavioural therapy was viewed as a more interactive treatment approach, hard to access
in routine care. Moreover, young people perceived benefits to functioning and improved understanding of
their experiences. Combining treatment was seen to have added benefits, with a perceived interaction
whereby antipsychotic medication enabled participants to engage with psychological interventions. Young
people were central to determining whether or not to take part in the trial, with support by family members.
Family members played an important role in monitoring engagement in treatment and outcomes.
Conclusions
This is the first trial to demonstrate that it is feasible to conduct a clinical trial to compare the clinical
effectiveness and cost-effectiveness of a psychological intervention with antipsychotic medication and
the combination of both in young people with a first episode of psychosis. However, adaptations are
required to ensure that a full-scale effectiveness trial is viable. Careful site selection with one or
more site leads being a psychiatrist employed by the local early intervention in psychosis service,
with prescribing responsibility for young people with first episode of psychosis, will (1) ensure swift
access to antipsychotic medication for those allocated to an antipsychotic arm; (2) minimise crossover
into ‘no-treatment’ for those in the antipsychotic monotherapy arm or into psychological intervention
only for those in the combined arm; and (3) ensure that consideration of prescribers’ opinions is
incorporated into the design of a definitive trial and ensure effective communication about trial
participants. Crossover may be further reduced by the removal of the 3-month deterioration criteria.
Adaptations are required and suggested for health economic data collection to ensure that a definitive
trial determines cost-effectiveness. Qualitative data speak to the importance of retaining a combined
treatment arm for both recruitment and retention of trial participants. Currently the World Health
Organization defines adolescence as up to the age of 25 years and consideration should be given
to increasing the upper age limit for a definitive trial, which would facilitate recruitment and ensure
value for money. An adequately powered effectiveness trial is required to provide robust evidence.
Trial registration
This trial is registered as ISRCTN80567433.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 4.
See the NIHR Journals Library website for further project information.
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The term psychosis is used to refer to a mental health problem that is characterised by a change to a
person’s perceptions, beliefs and/or reality testing. This may include experiencing distressing perceptions
that are not generated by an external stimulus, for example hearing a voice(s) speaking when another
person is not present. It may also include holding fixed and distressing beliefs that others consider
unusual: out of keeping with the social or cultural background of that person and lacking rational
grounds. The former is typically referred to as a hallucination and may occur in auditory, visual, tactile,
gustatory or olfactory sensory domains. The latter is typically referred to as a delusional belief. With
regard to delusional beliefs, various types are frequently reported, including ones that are persecutory
in nature,1 ideas of reference (seeing personal meaning in innocuous objects or events) and ideas of
importance/grandiosity.2 An individual with psychosis may experience both hallucinatory experiences
and delusional beliefs, and sometimes the delusional beliefs will relate to the hallucinatory experiences.
Both the International Classification of Diseases, Tenth Revision (ICD-10),3 and the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5),4 recognise hallucinations and delusions to be key
features of psychosis spectrum diagnoses, such as schizophrenia. Thought disorder is considered a core
cognitive symptom experienced by people with psychosis, involving abnormal features and patterns of
speech that can lead to difficulties in communication.5 Symptoms of thought disorder can be divided
into positive (e.g. loosening of associations and illogicality) and negative (e.g. loss of goal and poverty
of speech) symptoms.5
Hallucinations, delusions and thought disorder are commonly referred to as positive symptoms of
psychosis, as they are considered to be an additional perceptual or cognitive experience that are an
addition to the person’s mental state. Alongside the positive symptoms of psychosis, negative symptoms
may occur, which are considered to be the loss or absence of personal functions or characteristics.6 In
the DSM-5,4 negative symptoms are referred to as blunted affect (reduced emotional expressiveness),
alogia (reduced/changed ability to have social conversations), asociality (decreased social contact),
avolition (reduced energy/drive) and anhedonia (reduced pleasure from activities).4,7 Negative symptoms,
although considered a feature of psychosis and schizophrenia spectrum diagnoses, are also considered
to be transdiagnostic and within DSM-54 they feature across diagnoses including bipolar disorder, major
depressive disorder and autism spectrum disorder.8 Prevalence rates of negative symptoms vary, often
owing to differing definitions,9 from 41% to 57%,10,11 with social withdrawal and emotional withdrawal
most commonly reported in one study.10
Psychotic experiences, such as hallucinatory experiences and delusional beliefs, have been shown to
exist on a continuum, with psychosis-like experiences being reported by a significant proportion of
the general population.12,13 However, in the general population psychosis-like experiences may be less
concerning for the individual experiencing them; they may be fleeting or transitory and not necessitate
help-seeking or require support from services.12–16 In addition, the symptoms of psychosis feature as
part of other mental health conditions, including depression with psychotic features,17 bipolar disorder18
and autism.19 The early stages of psychosis are sometimes referred to as the prodromal period, which
tends to occur for 2–5 years before the onset of psychosis.20,21 However, the term prodromal can be
applied only once psychosis has been confirmed (i.e. retrospectively). A prospective approach is the
identification of people who meet the criteria for an ultra high-risk (UHR) mental state. These criteria
are commonly applied when state (attenuated psychotic symptoms or brief limited intermittent
DOI: 10.3310/hta25040 Health Technology Assessment 2021 Vol. 25 No. 4
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Morrison et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
1
psychotic symptoms) and/or trait factors (family history) for psychosis are present in the presence of a
drop in function, indicating that development of psychosis is a risk, but is not inevitable.22
A person experiencing psychosis may receive either an ICD-103 or a DSM-54 diagnosis, such as
schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, non-organic
psychosis unspecified or a mood disorder with psychotic features. The DSM-54 criteria for a diagnosis
of schizophrenia require the person to be experiencing two of the following: delusions, hallucinations,
disorganised speech, grossly disorganised or catatonic behaviour, or negative symptoms such as
affective flattening or paucity of thought or speech for at least 6 months (although this can be at an
attenuated level, so long as active psychotic symptoms have been present for 1 month).4 In addition,
these experiences must result in a deterioration in social, academic or vocational work and self-care
functioning. In other instances, the term psychosis may be used more as an umbrella term, when a
person may not have received a diagnosis but is experiencing symptoms that characterise psychosis,
as outlined above. In the context of a first episode of psychosis (FEP) and the early intervention in
psychosis service philosophy of embracing diagnostic uncertainty in the early phases of psychosis,
the term psychosis is often applied in the absence of a schizophrenia spectrum diagnosis.
First episode of psychosis in adolescence
FEP typically occurs in young adults. For those with a schizophrenia diagnosis, the age at onset
is usually between 15 and 35 years.23 However, data from community services for FEP in Australia,24
Finland25 and the UK26 indicate that the median age at onset lies between 22 and 23 years, with an
interquartile range (IQR) of 19–27 years. When psychosis occurs before the age of 18 years the term
‘early-onset psychosis’ (EOP) is typically used in the literature. Epidemiological data regarding the
prevalence of EOP are limited, and up-to-date estimates are required.23,27,28 The limited data are
partly because of challenges in the collection of epidemiological data on this population, including
misdiagnosis,27 reliance on retrospective data and the absence of effective community-based systems
for recording incidence from which accurate data can be obtained.23 However, estimates from available
data indicate that the prevalence of early-onset schizophrenia spectrum diagnoses is 1.6 to 1.9 per
100,000 children and adolescents.29–31 A useful data source to estimate the prevalence of psychosis
in adolescents is the records of services that provide treatment for FEP. Although now somewhat
outdated, information from the Early Psychosis Prevention and Intervention Centre (EPPIC) in
Melbourne, Australia, which was collected between 1993 and 2000, suggests that just under one-fifth
of those accepted into the service were aged ≤ 18 years.24 Those in the service who were aged
≤ 18 years received a range of diagnoses, as follows: schizophrenia (39.3%), schizophreniform disorder
(32.5%), bipolar I (9.4%), other psychoses (13.7%) and schizoaffective disorder (5.1%). Although we
have some indication of the prevalence of schizophrenia spectrum diagnoses in adolescence, data
on the epidemiology of more broadly defined psychosis, in which diagnostic uncertainty is embraced,
are lacking. Kirkbride et al.32 used data from ÆSOP (Aetiology and Ethnicity in Schizophrenia and
Other Psychoses), a large population-based case–control study in three English sites, to examine
variability in the incidence of psychotic illnesses across age, sex, ethnicity and site. They applied a
broad diagnostic approach to their inclusion criteria, and the 568 people examined in this study
included people with individual psychotic symptoms and those who met criteria for DSM-5 psychotic
illnesses and schizophrenia subclasses. They found that the incidence rate of psychoses in women
peaked between 16 and 19 years of age (in contrast to between 20 and 24 years for men).32 In another
study, Boeing et al.33 examined data from child and adolescent mental health services, hospital case
registers and admission and discharge data from the Scottish Executive in three areas of Central
Scotland (covering a population of approximately 1.75 million people). Similarly to Kirkbride et al.32 a
broad diagnostic approach was taken to inclusion in the study, that is participants were eligible if they
had ever been in contact with mental health services for a psychotic illness prior to their 18th birthday.
The authors found a 3-year prevalence of 5.9 incidences of EOP per 100,000 people in the general
population.33 Boeing et al.33 report that young people interviewed in their study were experiencing high
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levels of difficulty in both symptoms and functioning, as well as high levels of unmet clinical and social
needs, suggesting the need for a national planning framework to ensure the delivery of assertive and
integrative care across mental health, social care and educational/vocational services for young people
with psychosis.
A key feature of early intervention in psychosis (EIP) is embracing uncertainty about diagnosis in the
early stage of psychosis.34–36 For this reason, inclusion criteria for EIP services have not specified a
schizophrenia spectrum diagnosis.37 It has been argued that the early course of psychosis can be
characterised by changing symptoms and that application of a schizophrenia spectrum diagnosis is
difficult unless the person has been unwell for some time.37 Meta-analysis of reliability of prospective
diagnostic stability of FEP diagnoses demonstrates that both schizophrenia spectrum psychoses and
affective spectrum psychoses have high prospective stability.38 However, other FEP diagnoses have
low diagnostic stability.38 The validity of schizophrenia spectrum diagnoses in adolescence has been
questioned and, although research indicates that a schizophrenia diagnosis made in adolescence is
usually stable, other diagnoses, such as schizoaffective disorder and atypical psychoses, have been
shown to have poor predictive validity.38
Given the risk of stigma and discrimination related to psychiatric diagnoses, concern over false-positive
diagnoses has been raised.14 There is a recognition that embracing diagnostic uncertainty may result
in some service users later being given conditions other than psychosis, such as personality disorders
or post-traumatic stress disorder. However, McGorry et al.36 argue that EIP services should ensure
sufficient specialisation of staff to address the common needs of FEP service users and that EIP services
should transcend traditional diagnostic barriers, reflecting the clinical reality of comorbidity and
evolution of symptoms.36 Although historically embracing diagnostic uncertainty has been part of EIP
guidance and policy, there is a challenge for services in ensuring that this is carried out appropriately,
that is not misattributing organic psychosis or drug-induced or subclinical experience of psychotic
phenomena.14 Marhawa et al.39 note that EIP service users very frequently experience comorbid
mental health problems and/or are in the process of normal developmental, educational or vocational
transitions at the time of presenting to services. This combination of factors can make it challenging
to assess service users’ needs while embracing diagnostic uncertainty,40 as do the realities of service
provision in the context of limited resources and service boundaries and transitions. Harm caused by
stigma, discrimination and the adverse effects of antipsychotic (AP) medication has led to concern that
inaccurate inclusion of young people in EIP, who may later go on to be diagnosed with a mental health
problem other than psychosis, is a risk of adopting a diagnostic uncertainty approach to identifying
FEP.14 This complexity may be compounded in young people, in whom the prevalence of unusual
perceptual experiences is high, and differentiating psychosis from other conditions that are
neurodevelopmental, organic or mental health-related may be difficult.14,40
Personal, social and economic costs of psychosis in adolescence
Adolescence is a time of significant biological, cognitive and social development. People who develop
psychosis in adolescence generally experience poorer long-term outcomes than those who develop
psychosis as an adult.28,41 In particular, the probability of full remission is lower, and the long-term
outcomes poorer, among those who receive a schizophrenia diagnosis before the age of 18 years.41,42
A systematic review of 21 studies of long-term functional outcomes among people who develop
psychosis in adolescence found that schizophrenia diagnoses were associated with a significantly
higher rate of poor outcomes than those with other psychotic disorders.41 In addition, 50–60% of
people with early-onset schizophrenia diagnoses had poor outcomes.41 Premorbid difficulties and
developmental delays are considered to be important predictors of long-term outcomes for those
who develop psychosis in adolescence, as demonstrated by findings from two systematic reviews41,43
and one non-systematic review.44 The most recent and comprehensive review, published by
Diaz-Cadeja et al.,43 utilised outcome data from longitudinal studies of participants with a Diagnostic and
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Statistical Manual of Mental Disorders (DSM) (DSM-III, DSM-III-R, DSM-IV, DSM-IV-TR) or International
Classification of Diseases (ICD) (ICD-9 or ICD-10) diagnosis of schizophrenia or other psychotic diagnoses
that was made before the age of 18 years. A number of factors were found to be associated with a
poorer outcome across clinical, cognitive and/or biological outcomes, including premorbid difficulties,
higher symptom severity at baseline (in particular negative symptoms) and a longer duration of
untreated psychosis (DUP).43 Of concern, there is some indication that those who develop psychosis in
adolescence may have longer DUPs.24 The higher prevalence of negative symptoms and premorbid
difficulties seen in those who develop psychosis in adolescence leaves young people at a greater risk of
poor long-term outcomes.43,45
People with psychosis often face public stigma and discrimination, and in adult psychosis populations
the incidence of anticipated, experienced and internalised stigma has been shown to be high.46,47
Many young people report that their experiences have been made worse by stigma and the negative
stereotypes of psychosis that are reported by the media.45 Indeed, research has indicated that young
people who meet UHR criteria, even before the onset of psychosis, report internalised stigma that is
associated with depression.48
The risk of suicide and suicide attempts may be higher in adolescents with psychosis in young people
with other mental health conditions. In one Swedish cohort,49 the long-term risk of suicide was 4.5%
and the risk of attempting suicide was 25%. In the USA, data gathered from 102 young people
admitted to an adolescent inpatient unit between 2003 and 2006 showed that, overall, those with
psychosis had twice as many suicide attempts as those with other mental health conditions.50
Adolescent-onset psychosis and schizophrenia are associated with significant economic costs. Young
people with psychosis and schizophrenia accounted for 25% of adolescent psychiatric inpatient
admissions in England and Wales between 1998 and 2004.51
Although the evidence base for the personal and social costs points to worse outcomes for those who
develop psychosis in adolescence than for those who develop psychosis in adulthood, there is some
evidence to counter this. In a long-term follow-up of service users with a schizophrenia spectrum
diagnosis who received care from the EPPIC early intervention service, those who developed psychosis
in adolescence had significantly better global, social, occupational and community functioning and less
severe positive symptoms than those who developed psychosis in adulthood.52
Service structure for the treatment of a first episode of psychosis
in adolescence
In the UK, any adolescent aged ≥ 14 years who develops a FEP is eligible to receive treatment from EIP
services. However, young people with psychosis may also receive care from child and adolescent mental
health services (CAMHS) both in the community and in psychiatric inpatient settings.
Early intervention in psychosis
The early treatment of psychosis is considered as essential for recovery, and research indicates that
those who receive support from an EIP service have better outcomes than those who receive standard
care.53 As noted, this may be particularly indicated for young people, in whom the long-term effects of
a delayed DUP on functioning are indicated to be higher.
Early intervention in psychosis services were first established in the UK in 2001, with the aim of providing
holistic, evidence-based, biopsychosocial care for people aged 14–35 years with a FEP and their families.53
For this reason, EIP services are a key provider of care for young people with a FEP. The structure of EIP
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services has been influenced by the World Health Organization (WHO)-endorsed consensus statement
from the International Early Psychosis Association, which set standards and goals for the early intervention,
detection and treatment of psychosis.54 The objectives of the early psychosis declaration (EPD) were to
increase access and care for people with FEP, raise awareness of the importance of early intervention,
promote recovery, engage families and offer them support, and train primary care practitioners to both
recognise psychosis and understand the importance of early detection of psychosis. The EPD sets out the
values and ethos of EIP services, which are to promote recovery and hope by focusing on personal, social,
educational and employment outcomes, reducing stigma and respecting the strengths of service users and
their families.
Working with families is an essential component of EIP,54 and the National Institute for Health
and Care Excellence (NICE) clinical guideline [CG number 155 (CG155)]55 explicitly recommends family
intervention (FI) to be delivered for all families of young people with psychosis. Unfortunately, the rate
of delivery of FI is often low and, in the UK, an audit of EIP services found that 69% of families had
not been offered FI in the first 6 months following acceptance into EIP services, and, where FI was
offered, there was a relatively low uptake of 38%.56 A systematic review57 of the literature on the
barriers to and facilitators of implementing FI suggests that a number of factors may influence
families’ interest in FI, including whether or not they identify as a caregiver, the relevance of the
support offered to their needs, a desire to keep their family experiences private and the offer of
FI being made after their family member’s psychosis had resolved.57 The review also highlights that
families require flexibility in FI in regard to the length, location and type (individual FI vs. group) of
delivery. Furthermore, the review highlights that specific family needs should be considered, such as
working hours and diversity in language and ethnicity. The same review reported that for EIP service
staff a key concern was access to appropriate training, qualifications, supervision and resources to
deliver FI.57
Duration of untreated psychosis is associated with a number of functional outcomes,58 with positive
symptoms58 and suicidality59 and reducing DUP as priorities for EIP services. An analysis of care pathways
to EIP services found that people who received mental health support from CAMHS in the first instance
had a substantially longer DUP and longer delays in access to EIP services than people who had received
support initially from psychiatric hospitals or home-based treatment teams.60 This indicates that an
effective interface between EIP services and CAMHS is required to minimise treatment delay and
avoid the adverse affect of a long DUP on prognosis for adolescences with psychosis.
Since the inception of EIP services in the UK, a number of guidance documents have been produced
to inform EIP service delivery and practice. A total of 14 policy documents that were produced by the
Department of Health and Social Care, the NICE and the Initiative to Reduce the Impact of Schizophrenia
network were published between 2001 and 2016.34 Thematic analysis of these documents indicates that
the values set out by EPD are maintained as central to the delivery of EIP services; the core themes
across these 14 policy documents are ethical practice (respect for informed consent, privacy and
confidentiality), inclusivity (equal access to the service and reducing stigma and discrimination), being
patient and family centred and providing appropriate recovery-orientated treatment (avoiding overuse
of diagnosis, shared decision-making, responsibility and cost-effectiveness).34
In 2016, an audit of EIP services reported that there were 56 EIP services established across England.56
In 2015, the National Collaborating Centre for Mental Health was commissioned by NICE and NHS
England to develop a guide to the introduction of access and waiting time standards for EIP services.37
The access and waiting time standards apply to people aged 14–65 years with a FEP. Eight standards
have been set out for EIP services, which include allocation and engagement of people with confirmed or
suspected FEP within a 2-week period of referral, offer of cognitive–behavioural therapy for psychosis
(CBTp), FI and educational and support programmes for carers, supported employment programmes,
physical health assessments and interventions, and clozapine (Clozaril®, Mylan Pharmaceuticals Ltd,
Canonsburg, PA, USA) prescribing. The 2016 Healthcare Quality Improvement Partnership audit56 of
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the access and waiting time standards found that the proportion of people with FEP who had access to
the NICE standards was low across many of the domains, but that it was particularly low in relation to
engagement and assessment within 2 weeks, access to physical health assessments and interventions,
and access to psychological interventions (PIs). In addition, the audit highlighted that there was
considerable variation across the country in what was offered to service users.
Joint working between early intervention in psychosis services and child and adolescent
mental health services
Child and adolescent mental health services are commissioned to provide care for young people up
to the age of 18 years, and this includes young people with psychosis.61 The NICE CG (CG155)55
recommends that primary care services make an urgent referral to either CAMHS (up to the age
of 17 years) or an EIP service (aged ≥ 14 years) that has a consultant psychiatrist with training in
child and adolescent mental health. The literature on the prevalence of psychosis cases in CAMHS is
limited, so estimates are difficult to obtain. However, in 2011, audit data from Rethink (London, UK)62
indicated that just under half of the CAMHS teams who completed the survey were working with
young people with psychosis who were aged < 18 years. CAMHS is structured in four tiers, with
increasing complexity and specialism at each tier, as follows: non-mental health specialists working
in the community with children (tier 1), CAMHS specialists in community primary care settings with
children who experience mild mental health difficulties (tier 2), CAMHS specialists in multidisciplinary
community child psychiatry outpatient settings (tier 3) and highly specialised CAMHS clinicians
working in outpatient teams, day units or inpatient settings (tier 4).
UK policy for the treatment of psychosis stresses the importance of good communication between EIP
services and other service providers, such as CAMHS, in ensuring appropriate assessment.55 Examples
of effective joint working include the provision of CAMHS psychiatry and prescribing for EIP service
users aged ≤ 16 years; provision of EIP psychiatry for young people transitioning from CAMHS to adult
mental health services (AMHS); input into CAMHS by EIP service team members, including training
and attendance at CAMHS team meetings; and employment of FI therapists to work across CAMHS
and EIP services.62 Research conducted with UK primary care trusts (PCTs) and Strategic Health
Authorities suggests that joint working is most effective when CAMHS and EIP service staff engage
in joint training/education to align their philosophies, and that senior support from PCTs and Strategic
Health Authorities is required to facilitate effective working.62 Although there is evidence of effective
working, a report published by Rethink62 found that 67% of EIP staff reported that they did not have
training to work with 14- to 16-year-olds and 64% did not have training to work with 16- to 18-year-
olds, and half of the EIP teams reported that CAMHS was not a source for identification of psychosis.
There is evidence to indicate that some young people may experience the transition from CAMHS to
AMHS, such as EIP services, as an abrupt change that feels poorly planned.63,64 Research has found
that young people report largely negative experiences of the transition from CAMHS to AMHS, citing
factors including feeling underprepared for the change in care provider, feeling abandoned by services
and being unhappy with the quality of care received.63–65 A recent Education Policy Institute report66
obtained data from 47 out of 60 CAMHS in England on their current waiting times for assessment
and treatment. In 2017–18 the average median waiting time for treatment was 60 days. Waiting times
varied substantially across the country, with the 10 CAMHS teams with the longest median waiting
times to treatment reporting figures of 82–188 days in 2017–18. The authors concluded that there
is still a postcode lottery in the access to time treatment from CAMHS.66 Specifically, in relation to
EIP services, several challenges have been reported in relation to joint CAMHS/EIP service working,
including different philosophies,67 role confusion68 and different funding sources.69 Although having
separate EIP services and CAMHS is common across the UK, it has been argued that a unified service
should be offered for young people up to the age of 25 years given the high risk of mental health
issues starting between the ages of 15 and 25 years.69 There are examples of such services developing
in the UK, such as Forward-Thinking Birmingham (Birmingham, UK), which is an integrated service
covering the age range 0–15 years including EIP.
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Interventions for the treatment of a first episode of psychosis in adolescence
Access to evidence-based interventions for adolescents with psychosis is paramount. To date, the
mainstay of research and treatment for psychosis in adolescence has been AP medication, with a
limited number of studies of psychological treatments for people with psychosis who are under the
age of 25 years. To understand the efficacy and safety of both pharmacological and psychological
interventions, a number of helpful systematic reviews have been published that shall be considered
here, along with updates to the literature following publication of these reviews.70,71
Pharmacological treatment
Antipsychotic medication prescribing for young people with psychosis is increasing72 and, typically,
AP medication is the main treatment available for adolescents with psychosis.71 In the UK, NICE CG
(CG155)55 recommends that for children and young people with FEP oral AP medication should be
offered, and that the decision about the choice of AP medication should be made in collaboration with
the young person and their parents/carers.55
A number of systematic reviews and meta-analyses on the topic of AP treatment of psychosis in young
people have been published.70,71 In relation to current treatment practice in the UK, the NICE CG
(CG155) was informed by the systematic review and meta-analysis published by Stafford et al.71 This
review identified 19 studies of AP medication, seven of which were placebo-controlled trials and 12 of
which were head-to-head trials. A meta-analysis was conducted on the seven placebo-controlled trials,
with a total sample size of 1094 participants and a mean age of 15.5 years (range 15.4–20.0 years). The
drugs that were compared with placebo were quetiapine (Seroquel®; AstraZeneca UK Ltd, Cambridge,
UK), aripiprazole (Abilify®; Actavis Ltd, Dublin, Ireland), risperidone (Risperdal®; McGregor Cory Ltd,
Bracknell, UK), paliperidone (Invega®; Janssen: Pharmaceutical Companies of Johnson & Johnson,
Beerse, Belgium; and Cilag AG, Schaffhausen, Switzerland), amisulpride (Solian®; Delpharm Dijon,
Quetigny, France), olanzapine (Zyprexa®; Eli Lilly and Company, Indianapolis, IN, USA) and haloperidol
(Haldol®; Ortho McNeil, Raritan, NJ, USA). Results of the meta-analysis showed small benefits of AP
medication over placebo for positive and negative symptoms, depression and psychosocial functioning
and large effects for global symptoms. However, data quality across the studies was considered poor
and the authors highlight that the placebo groups also improved substantially.
A more recent systematic review and network meta-analysis identified 28 randomised controlled trials
(RCTs) of AP medication for children or adolescents with a diagnosis of schizophrenia, schizoaffective
disorder or schizophreniform disorder published from 1976 to 2017.70 The total number of participants
across the 28 RCTs was 3003, with a median age of 14.41 years (range 7.7–18.3 years). In total, the
studies included in the network meta-analysis provided data on 17 AP medications but the most
frequently studied were haloperidol, risperidone and olanzapine. Results of the pairwise meta-analyses
revealed that, compared with placebo, the following AP medications were significantly more effective
in reducing overall symptoms: olanzapine, risperidone, lurasidone (Latuda®; AndersonBrecon Ltd,
Hereford, UK), aripiprazole, quetiapine, paliperidone and asenapine (Sycrest®; Schering-Plough Labo
N.V., Heist-Op-Den-Berg, Belgium). Results of the network meta-analysis indicated that clozapine
was superior to all other AP medication for total, positive and negative symptoms. After clozapine,
olanzapine and risperidone had the greatest effect sizes of –0.74 and –0.62, respectively. However, as
olanzapine was associated with the highest weight gain, the authors recommended that it should be
avoided in children and young people. Network meta-analysis revealed that haloperidol, trifluoperazine
(Stelazine®; Mylan NV, Canonsburg, PA, USA), loxapine (Loxapine succinate®; Mylan) and ziprasidone
(Geodon®; Pfizer Inc., New York, NY, USA) were not more effective than placebo, and the authors
recommended that these drugs should not be used in children and adolescents. Findings from this
systematic review and network meta-analysis suggest benefits of AP medication over placebo (except
for haloperidol, trifluperazine, loxapine and ziprasidone) and provide useful data to inform decision-making
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regarding the selection of AP medication and their relative superiority in comparison with each other.
However, it should be noted that network meta-analysis relies on the use of indirect as well as direct
evidence, and for clozapine the majority of the evidence was indirect. Krause et al.70 also note limitations
to the quality of data, with 50% of the RCTs providing inadequate information about the randomisation
procedures and 75% not providing adequate information about allocation concealment. It should also
be noted that inspection of the included studies indicates that 7 out of the 28 studies did not use either
DSM or ICD-10 diagnostic criteria in application of clinical diagnoses; rather, the studies report that
the diagnostic criterion was clinical diagnosis. This may draw into question the homogeneity of the
participants included in the studies and the generalisability of the findings.
A review of the literature indicates that since publication of the systematic review and network
meta-analysis by Krause et al.70 two further trials of AP medication for young people with psychosis
have been conducted.73,74 The Tolerability and Efficacy of Antipsychotics (TEA) trial,74 conducted in
Denmark, was a head-to-head, double-blind RCT comparing the safety and efficacy of quetiapine-
extended release (ER) with aripiprazole in 12- to 17-year-olds with an ICD-10 schizophrenia spectrum
diagnosis. The total sample size, across seven university clinics, was 133 (55 allocated to quetiapine-
ER and 58 to aripiprazole). The primary outcome was a positive Positive and Negative Syndrome
Scale (PANSS) score at 12 weeks, and the results of the trial indicated that there was no significant
difference between medications in the primary outcome. However, in both groups positive PANSS
scores significantly reduced from baseline to 12 weeks, by approximately 5 points, which is a modest
reduction in PANSS score given that the minimum clinically important difference is thought to be about
15 points.75 Quetiapine-ER and aripiprazole had differing adverse effect profiles. The Quetiapine-ER
group had worse metabolic outcomes than aripirazole, with greater weight gain in the quetiapine-ER
group. Furthermore, an analysis of the homeostatic model of insulin resistance favoured aripiprazole.
However, there were significantly more cases of akathisia and sedation in the aripiprazole group. The
number of adverse events (AEs) was high in both groups. In the quetiapine-ER group, the following
percentages of AEs were reported: 79% experienced tremor, 92% had increased duration of sleep, 78%
experienced orthostatic dizziness, 80% experienced depression, 69% experienced tension/inner unrest,
76% experienced failing memory and 87% experienced weight gain. In the aripiprazole group, 91%
experienced tremor, 71% had increased duration of sleep, 81% experienced orthostatic dizziness, 77%
experienced depression, 88% experienced tension/inner unrest, 77% experienced failing memory and
68% experienced weight gain. The results of the trial contribute to the relatively limited literature on
head-to-head comparisons of AP medication for adolescents with FEP. However, concern has been
expressed about the quality of this trial, including the limitations on the conclusions that can be drawn
regarding the efficacy and safety given that one-third of participants were prescribed AP medication
in addition to those being studied.76 In the same year as the TEA trial, Correll et al.73 published a
double-blind, placebo-controlled, randomised withdrawal-design trial of oral aripiprazole maintenance
treatment. In this study, all 201 participants were cross-titrated to oral aripiprazole and were stabilised
on this medication for 17–21 weeks before randomisation in a 2 : 1 ratio to either oral aripiprazole or
placebo. The results showed that treatment with oral aripiprazole was associated with a significantly
longer time to exacerbation of symptoms of psychosis than treatment with placebo. Interestingly, the
rate of serious treatment-emergent adverse effects (TEAEs) and discontinuation because of TEAEs was
lower in the medication arm, although not significantly so.73
Adverse effects of pharmacological treatment
Antipsychotic medications are associated with a wide range of adverse effects, which include metabolic
effects (i.e. weight gain), cardiovascular effects, hyperprolactinaemia, antimuscarinic side effects (dry
mouth, blurred vision and cognitive impairment), sexual dysfunction and movement disorders.77 The
adverse effects of AP medication are associated with increased stigma, physical morbidity and mortality,
poor adherence to medication and reduced quality of life.77 A systematic review78 of the effects of AP
medication on brain volume in adult populations concluded that some of the structural brain changes
found in people with a schizophrenia diagnosis may be the result of AP medication. When considering
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the risk of adverse effects of AP medication for young people, there are biological differences between
adolescents and adults that are important to consider.79 Adolescence represents a time of social and
educational change. Medication side effects may affect important educational milestones. The stigma
of taking an AP medication may be challenging for a young person’s relationships. Compared with
adults, young people may be more susceptible to the adverse effects of AP medication,80 particularly in
relation to weight gain.81 A study by Correll et al.82 showed that 12 weeks of AP treatment in children
and adolescents who had less than 1 week’s prior AP exposure was associated with significant rates
of obesity and new-onset categorical glucose and lipid abnormalities. For example, a weight gain of
> 7% occurred in 56% of participants taking quetiapine and in 84% of participants taking olanzapine.82
Krause et al.70 make an explicit recommendation that this medication should not be used in young
people. Moreover, there is an indication that weight gain is associated with high rates of medication
discontinuation.71 In 2016, the NICE CG (CG155)55 was updated to include specific recommendations
in relation to olanzapine, advising clinicians who are choosing between olanzapine and other AP
medications to discuss with the young person and their parents or carers the increased likelihood of
greater weight gain with olanzapine, and that this is likely to happen soon after starting treatment.55
Summary of pharmacological treatment
Although there is some evidence to suggest benefits of AP medication over placebo for young people
with psychosis,70,71 the quality of the evidence is low.71 Head-to-head comparisons are limited and
inferences are often indirect, which limits the extent to which comparisons can be drawn between AP
medication. Study durations are short, which means that the long-term adverse effects of AP medication
in young people are unknown. Furthermore, the evidence base for AP medication is significantly limited
compared with the larger body of adult-derived data, the risks and benefits may be less favourable for
young people and the additional benefit of AP medication over placebo is small.71
Psychological intervention
Psychological interventions for young people with psychosis are recommended in the UK NICE guideline
(GC155);55 specifically, cognitive–behavioural therapy (CBT) and FI. The current guidelines suggest that
CBT and FI should be offered in conjunction with AP medication. However, if a young person and their
parents wish to try PI alone, the NICE CG (CG155) suggests that the care team should advise that PIs
are more effective when delivered in conjunction with AP medication, but offer individual CBT and FI if
the young person and family wish to pursue that option. In the next sections we will review both CBT
and FI, outlining the approaches, the evidence base and potential adverse effects.
Cognitive–behavioural therapy
Cognitive models suggest that the way that we interpret events has consequences for how we
feel and behave, and that interpretations are often maintained by thinking biases and behavioural
responses. Cognitive models of psychosis and psychotic experiences suggest that it is the way that
people interpret and respond to psychotic phenomena that accounts for distress and disability, rather
than the psychotic experiences themselves.83–85 Key elements of CBT include a shared individualised
formulation of the problem that can include reflection on life events that may contribute to the
development and/or maintenance of psychosis (such as trauma and deprivation), evaluating unhelpful
thoughts and conducting behavioural experiments.83 Morrison et al.83 place an emphasis on the importance
of a strong therapeutic relationship, normalising information, collaboration between client and therapist
and therapy being based on the client’s problem list and idiosyncratic goals. Brabban et al.86 suggest
10 key ethical considerations for CBT to ensure that it is recovery orientated: (1) collaboration, (2) use of
everyday language, (3) acknowledging the historical and developmental context of the client’s difficulties
(i.e. adverse life experiences) so as not to minimise the impact of these, (4) evaluating rather than
challenging beliefs, (5) applying caution with use of the stress-vulnerability model of psychosis and
schizophrenia, (6) validating the client’s experience using a psychological formulation, (7) delivering
hope to the client, (8) offering informed choice about engaging with CBT, (9) ensuring that CBT training
is extensive and specialist and (10) ensuring that there is access to continued supervision.
DOI: 10.3310/hta25040 Health Technology Assessment 2021 Vol. 25 No. 4
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Morrison et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
9
Family intervention
As noted above, a FEP often occurs in adolescence, which is a time when young people are typically
living with family members. For this reason, families often play a key role in supporting a person who is
experiencing psychosis, and the level of support may be greater in early psychosis and when people are
younger in age. FI is considered to be a psychoeducational intervention based on the behavioural
family therapy and cognitive behavioural approaches.87 This approach includes an assessment of family
understanding and appraisals of presenting difficulties; sharing the emerging psychological formulation
and agreeing a problem list and FI goals; psychoeducation to develop a common understanding,
including normalising and recovery-orientated information on presenting difficulties; problem-solving;
communication skills training; and relapse prevention planning.88 Families are often given between-
session tasks and are encouraged to hold family meetings to support skills practice.87 Family members
are also given information about local services and signposted to support for themselves, where
appropriate. The NICE CG (CG155) recommends that FI should be recovery focused; offer support,
education, problem-solving and crisis management; and be delivered over 10 sessions to the family
and young person (assuming that inclusion of the young person is practical).55
Efficacy and safety of psychological intervention for adolescents with psychosis
Although there is an established evidence base for CBT in adult psychosis populations,89–92 the
availability of studies to determine its efficacy in children and young people is limited.71,93 In adult
populations, meta-analyses show CBT to have small to moderate effects when delivered in combination
with AP medication.89–92 In relation to FI, NICE conducted a review of the literature for FI for adults
with psychosis and found that FI reduced the risk of relapse, the risk of hospital admission during
treatment and the severity of symptoms both during and up to 24 months following the intervention.92
To inform the NICE CG (CG155),55 Stafford et al.71 conducted a systematic review of PIs for the
treatment of psychosis and schizophrenia in children, adolescents and young adults. Searching the
literature up to July 2013, Stafford et al.71 identified eight trials of PI, of which seven included a
treatment arm with CBT or FI (one trial was of movement therapy vs. dance therapy). However, no
trials of PI (i.e. CBT or FI) carried out exclusively in an under-18 population were identified; rather, the
studies included in the review included participants up to the age of 25 years (mean age 23.2 years,
range 15–24 years). Meta-analysis of the data from these studies indicates no evidence of treatment
effects on symptoms and low-quality evidence for the combination of CBT and FI on the number of
days to relapse. In addition to the limited evidence base, the quality of studies in under-25-year-olds
was questionable, with a risk of detection bias from inadequate concealment of allocation across all
studies and four trials at high risk of selective reporting.71
Since the publication of the review by Stafford et al.,71 a further review has been produced by
Anagnostopoulou et al.93 that included studies of PIs published up to 2017. The aim of the review
was to evaluate the efficacy of PIs for young people with EOP (before the age of 18 years) in relation
to positive and negative symptoms, cognitive functioning and psychosocial functioning. The authors
included papers in which the study was a RCT and the participants were aged 12–18 years and had
received a schizophrenia spectrum diagnosis. The review identified one controlled trial of CBT versus
FI94 and one RCT of a psychoeducational group intervention for adolescents with psychosis and their
families,95 both in a strictly under-18-year-old population.
In their pilot controlled trial of CBT versus FI versus treatment as usual (TAU), Browning et al.94
recruited 30 adolescents with psychosis who had been admitted to a psychiatric inpatient unit and
allocated them to receive CBT and TAU (n = 10), FI and TAU (n = 10) or TAU only (n = 10). TAU
included, as a minimum, medication (although the authors do not specify whether this was AP
medication or other mental health medications), a nursing care plan and group-based activities on the
unit. CBT was adapted for young people by delivering shorter sessions twice per week. Participants
allocated to receive CBT could access 10 sessions. FI comprised five 1 hour-long sessions and was
delivered over 4–10 weeks. The study conducted by Browning et al.94 provides data to suggest that it
may be feasible to recruit young people to a study comparing PIs. However, there was a high risk of
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selection bias owing to the non-randomised design and the numbers recruited were too small to make
any inferences regarding efficacy, although there was an encouraging signal from the data that
participants in the PIs reported greater satisfaction ratings than those receiving TAU alone.
A secondary analysis of the SoCRATES trial,96 which recruited people with psychosis who had a recent
first or second inpatient admission, found that participants under the age of 21 years who had supportive
counselling showed significantly greater improvements at 3 months on the PANSS positive, PANSS general
and the PSYRATS (Psychotic Symptoms Rating Scales) delusions subscales than those who received CBT or
TAU.97 In addition, among those under the age of 21 years, the therapist-rated therapeutic alliance was
significantly poorer in the CBT group than in the supportive counselling group.97 The authors concluded
that PIs for people with early psychosis may need to consider age-related factors.97 Although these
findings contribute to the literature, it should be noted that this is a secondary analysis of the SoCRATES
study, which was not designed to evaluate these treatments specifically in young people with psychosis,
and so the conclusions that can be drawn are limited.
In their RCT of a group-based psychoeducational intervention for young people with psychosis and
their families, Calvo et al.95 recruited 55 young people and their families and randomly allocated them
to either a psychoeducational problem-solving group arm (n = 27) or a time-matched control arm
(n = 28). At the end of the intervention, young people in the psychoeducational intervention arm had
significantly fewer visits to accident and emergency and lower negative symptom scores than those in
the control arm; however, these results were not sustained at 2-year follow-up.95 The results of this
study are a signal that, as with adult populations, FI with adolescent populations and their families may
be effective in reducing relapse. However, to our knowledge, the study by Calvo et al.95 represents the
only trial of FI in an under-18-year-old population, and any inferences that can be drawn from this
study with a small number of participants is limited.
Overall, there is a paucity of evidence from which conclusions can be drawn about the efficacy of
CBT and FI for psychosis in children and young people. In producing the UK NICE CG (CG155),55 the
guideline development group considered if there were grounds for recommending that treatment with
PIs in young people should be any different from that in adults. Given the paucity of evidence for CBT
and FI in young people, the guideline development group utilised the data from the much larger adult
evidence base to make the recommendation to offer CBT and FI in conjunction with AP medication.
CBT trials have been criticised for poor reporting of adverse effects98 and data on the safety of PIs for
adolescents are lacking. There clearly remains an important need to address the question of efficacy
and safety of CBT and FI for this population.
Psychological intervention in the absence of antipsychotic medication
It has been argued that evidence from meta-analyses of adult psychosis studies demonstrates that
the superiority of AP medication over placebo has been overestimated and that the adverse effects of
AP medication have been underestimated.99 For this reason, there has been a growing interest in the
efficacy and safety of PIs in the absence of AP medication. A systematic review and meta-analysis of
psychosocial treatment with a time-limited postponement of AP medication versus initial AP treatment
found that psychosocial treatment may be effective in the absence of AP medication, with psychosocial
treatment having a small–medium effect size advantage over AP medication.100 Although the findings
from Bola et al.100 suggest that it is feasible to conduct research into psychosocial interventions in the
(short-term) absence of AP medication, the quality of the studies is limited, with only one RCT, and the
psychosocial interventions evaluated varied across the studies and represented treatment programmes
rather than specific PIs, such as CBT or FI.
In relation to CBT, Morrison et al.101 demonstrated that it was feasible and safe to recruit adults who
chose not to take AP medication to a RCT of CBT and TAU versus TAU alone. Data from this trial
showed that CBT may be effective in reducing symptoms in adults who choose not to take AP
medication, particularly in participants under 21 years old. However, the trial was not definitive and
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conclusions about the efficacy of CBT in this population are limited. The COMPARE (Cognitive behaviour
therapy Or Medication for Psychosis – A Randomised Evaluation) trial,102 a three-arm RCT for people
aged ≥ 16 years with FEP, allocated participants to AP monotherapy, CBT monotherapy or a combination
of both treatments. The results showed that over the 12-month follow-up period the PANSS scores were
significantly lower in the combined treatment group than in the CBT monotherapy group, but there
was no significant difference between AP medication and CBT, or between combined treatment and AP
medication.102 Participants who received CBT monotherapy had fewer non-neurological side effects and
less weight gain than those in the AP monotherapy and combined treatment groups, which may indicate
that CBT monotherapy leads to fewer adverse effects.102 However, although one-fifth of participants
in the COMPARE trial (15/75) were aged 16–18 years, there are no head-to-head studies of PI versus
AP medication in young people and, therefore, no data on which to draw conclusions about the clinical
effectiveness and cost-effectiveness of PI versus AP medication versus a combined treatment in young
people with psychosis.102 The COMPARE trial also did not include FI as a component of the PI.
Summary
In summary, when the UK NICE CG (CG155)55 was produced it was concluded that the available
evidence, including that from adult populations, was sufficiently strong to recommend a combination
of AP medication, CBT and FI as treatment for young people with psychosis.88 However, for young
people with psychosis, the risk-to-benefit ratio of AP medication appears less favourable, and research
is required to establish the potential for psychological treatments alone and in combination with AP
medication in this population. Consequently, CG15555 recommends research to determine the clinical
effectiveness and cost-effectiveness of psychological treatment alone, compared with AP medication
and compared with psychological treatment and AP medication combined.55
Rationale for the research
In response to the NICE guideline research recommendation, the National Institute for Health
Research (NIHR) Health Technology Assessment (HTA) programme put out a commissioned call
to answer the question of how feasible it is to conduct a study to examine the effectiveness of PI,
AP medication or a combination of the two in adolescents with a FEP. Managing Adolescence
first-episode Psychosis; a feasibility Study (MAPS) was commissioned by the HTA programme to
answer the research question from this commissioned call.
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Chapter 2 Methods
Used with permission from Morrison et al.103 This is an Open Access article under theCC BY-NC-ND 4.0 license (https://creativecommons.org/licenses/by-nc-nd/4.0/).
To answer the question of feasibility we employed both quantitative and qualitative research methods.
Objectives
We had six specific objectives across the main trial and qualitative work to enable a strong
understanding of the feasibility of running a definitive trial, as follows:
1. to identify the willingness of clinicians to refer to the trial, the proportion of young people referred
who are eligible and are willing to consent to the study, and the proportion of participants who
comply with the treatment allocation
2. to assess the rate of attendance at follow-up assessments
3. to identify characteristics of trial participants (to clarify selection criteria)
4. to determine how feasible and acceptable the interventions are for participants, parents and
clinicians, and the appropriateness of our treatment protocols
5. to assess the suitability of our randomisation and blinding procedures
6. to determine the relevance and validity of the measures to decide their acceptability for use in a
definitive trial.
We also aimed to estimate ranges of sample size parameters, finalise treatment manuals and outcome
measures, determine training/supervision requirements for research assistants (RAs) and therapists,
and assess the possibility for economies for scale.
Role of the funding source
MAPS (both main trial and qualitative studies) was funded by the NIHR HTA programme following a
commissioned call (15/31/04). The call specified the interventions, population, setting, comparator,
study design and important outcomes.
Approval
MAPS (both main trial and qualitative studies) was approved by the North West – Greater Manchester
East Research Ethics Committee (REC) on 6 February 2017 (reference 16/NW/0893). The trial was
also prospectively registered on the International Standard Randomised Controlled Trial Number
(ISRCTN) clinical trial registry (reference ISRCTN80567433) on 27 February 2017.
Patient and public involvement
Two MAPS co-applicants and one user-led researcher provided patient and public involvement (PPI),
contributing substantially to numerous facets of the trial. Rory Byrne contributed to the trial participant
information sheets and leaflets. Rory Byrne wrote the Plain English summary of the study for the ISRCTN.
The nested qualitative study was user led, with Rory Byrne contributing to the development of the
topic guide and participant information sheet, and informing the sampling approach and data analysis.
Rory Byrne conducted many of the participant, family/carer and clinician interviews. Transcription,
coding and analysis of qualitative interviews was led by Rory Byrne with support from Wendy Jones.
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Rory Byrne and Wendy Jones attended weekly team meetings in the central site (Manchester) to
provide input on processes and issues as they arose. A PPI representative sat on our independent Data
Monitoring Committee (iDMC) and Trial Steering Committee (TSC) and contributed to trial oversight
and recommendations.
Throughout the course of MAPS, we sought consultation and recommendations on trial processes from
the Psychosis Research Unit service user reference group, all members of which have personally
experienced psychosis. For example, the service user reference group provided feedback on the
outcome measures used in MAPS and documents such as consent forms, participant information
sheets and the trial feedback sheet.
Changes to outcomes post trial commencement
Throughout the course of the trial, there were a number of changes to the trial protocol, including
changes to the trial outcomes as agreed with our iDMC and TSC. Summaries of these changes are
shown in Table 1.











Objectives in the protocol amended to
state that we will:
1. estimate sample size parameters to
inform the design of a definitive trial
2. clarify training/supervision needs for
delivering interventions/assessments
3. finalise treatment manuals and
outcome measures
4. assess the possibility for economies of
scale and monitor time use of the RAs
The funder of MAPS requested that we
make additional revisions in keeping with
its policies and in view of the protocol
being a document in the public domain.
These requests were four revisions
requested by the trial funder to adhere to
their policies, given that the protocol is a
public document:
1. include an acknowledgement of
funder information
2. remove the following – expertise
and justification of support required,
justification of costs and NHS support
and treatment costs
3. remove/shorten PPI
4. note that on 24 March 2016 the MHRA
provided written formal notification
that a Clinical Trial Authorisation was
not required
The MHRA confirmed that this proposal is
not a clinical trial of an Investigational
Medicinal Product as defined by the EU
Directive 2001/20/EC and no submission to
the CTU at the MHRA is required
3 March 2017 V2: 22 February
2017
METHODS
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27 April 2017 1. Update to the inclusion criteria
2. Changes made to the follow-up
assessment and/or measures
3. Editorial revisions to the Health
Economics Questionnaire and
AQ-10 measure
4. Amendment made to the ANNSERS
questions (to minimise burden)
5. Provision of a £5 shopping voucher for
participants at three time points
6. Participant information sheet updated
to include information about
shopping vouchers
7. Consent form updated to include new
participant information sheet version
number and date






Addition of an educational film about
MAPS






1. Addition of another gender category
to the participant demographics form
2. Addition of demographics forms for:
i. clinician qualitative interviews
ii. family member/carer
qualitative interviews




12 March 2018 1. Update to protocol with refined success
criteria, following advice from the iDMC
and TSC










18 May 2018 1. Update to protocol with refined success
criteria, following advice from the iDMC
and TSC
2. Addition of a thank you postcard for
participants following trial completion
3. Addition of clinician survey




31 July 2018 1. Updates to protocol with (1) stop/
refine/go success criteria and (2) offer
of participant and family member
qualitative interviews via telephone
2. Updates to participant information
sheet to reflect:
i. offer of qualitative interview
by telephone
ii. those recruited after July 2018 will
have 3- and 6-month follow-ups only
iii. GDPR transparency statements
3. Updates to family member participant
information sheet to reflect:
i. offer of qualitative interview
by telephone
ii. GDPR transparency statements
4. Update to randomisation
allocation letters
21 August 2018 V5: 17 July 2018
ANNSERS, Antipsychotic Non-Neurological Side Effects Scale; AQ-10, Autism Spectrum Quotient; CTU, clinical trials
unit; iDMC, independent Data Monitoring Committee; GDPR, General Data Protection Regulation; MHRA, Medicines
and Healthcare products Regulatory Agency.
Note that substantial amendments were approved by the Health Research Authority and classified as Category A –
an amendment that has implications for, or affects, all participating NHS organisations.
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
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Feasibility randomised controlled trial
Trial design
MAPS was a Prospective Randomised Open Blinded Evaluation (PROBE) to explore the feasibility of
running a definitive trial of three treatment options for FEP in 14- to 18-year-olds. Participants were
allocated in a 1 : 1 : 1 ratio to receive AP medication monotherapy, PI monotherapy or a combination
of both treatments. MAPS was conducted over 27 months across seven UK sites. The recruitment
window ran from 1 April 2017 to 31 October 2018. All follow-up assessments were finalised by
31 May 2019. The current REC-approved trial protocol is available at www.journalslibrary.nihr.ac.uk/
programmes/hta/153104/#/.
Settings
MAPS was conducted within NHS secondary care mental health services, namely EIP services and
CAMHS. The seven UK sites were Manchester (central site); Birmingham; Lancashire; Oxfordshire and
Buckinghamshire; Norfolk and Suffolk; Northumberland, Tyne and Wear; and Sussex. The study started
with four sites: Manchester, Sussex and Oxford all commenced recruitment on 1 April 2017 and
Lancashire commenced recruitment on 8 June 2017. The remaining three sites were added in 2018 to
determine the feasibility of replicating effective recruitment approaches from the initial four sites.
Norfolk and Suffolk commenced recruitment on 9 May 2018, Birmingham on 31 May 2018 and
Northumberland on 20 June 2018.
MAPS sites differ considerably in their characteristics, including the levels of urbanisation and deprivation.
For example, the 2015 English Indices of Deprivation104 rank Birmingham and Greater Manchester third
and fifth, respectively, in having the highest proportions of neighbourhoods that are in the most deprived
10% of areas nationally, whereas Oxfordshire and Buckinghamshire have some of the lowest proportions
(35th and 38th, respectively, out of 39 Local Enterprise Partnerships).
Participants
Sixty-one participants were recruited from EIP services and CAMHS in six sites: Oxfordshire and
Buckinghamshire (n = 25 randomisations), Manchester (n = 21), Lancashire (n = 9), Sussex (n = 4),
Birmingham (n = 1) and Northumberland, Tyne and Wear (n = 1). No participants were recruited in
Norfolk and Suffolk.
Inclusion and exclusion criteria
We included young people who met all of the following criteria:
l aged 14–18 years (up until their 19th birthday)
l presented with FEP (defined as being within 1 year of presenting to services with psychosis)
l under the care of an EIP service or/and CAMHS
l scored ≥ 4 points on the PANSS105 for delusions and/or hallucinations at the baseline assessment to
ensure current symptoms of psychosis
l met the ICD-10 criteria for schizophrenia, schizoaffective disorder or delusional disorder (as diagnosed
by the treating consultant) or met the entry criteria for an EIP service
l able to provide written, informed consent and if under 16 years old have a parent/guardian willing
to provide additional consent for the MAPS team to contact the young person (for ethics reasons).
To ensure that our sample was representative of young people with FEP as a primary problem, we
excluded those who:
l had a diagnosis of ICD-10 organic psychosis
l had a moderate/severe learning disability
l had primary alcohol/substance dependence
METHODS
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l were non-English speaking (to ensure that participants were able to engage in assessments
and therapy)
l scored ≥ 5 points on the conceptual disorganisation item of the PANSS (as above)
l presented with immediate risk to themselves or others at the time of referral
l had received AP medication or structured PI within the last 3 months (to ensure treatment naivety).
Exclusion did not include comorbid diagnoses, such as autism spectrum disorders, personality disorders
or use of substances (e.g. cannabis or alcohol) (unless this was a primary alcohol/substance-dependence
diagnosis, as outlined above).
Data collection
Potential participants were informed of MAPS by a member of their care team and, if interested, were
asked for a verbal agreement for basic referral details to be provided to the research team and for a
member of the research team to contact them. For people under 16 years of age, the MAPS protocol
required the care team member to ask the young person’s parent/guardian to provide verbal consent
to be contacted by the research team initially. If verbal consent was provided, the care team member
shared with the RA basic referral information for the young person and contact details for the parent.
The RA would then contact the young person (aged 16–18 years) or parent (for under-16-year-olds) to
describe the study briefly and send them a participant information sheet. Each young person or parent
was given at least 24 hours to consider the participant information sheet. If interested, RAs would
arrange to meet the young person or parent at their preferred venue [including the individual’s home,
school/college, mental health services, general practitioner (GP) surgeries or youth offending services].
If there were any concerns about the individual’s home environment or risk to others, the initial
meeting would take place at an NHS site.
At the initial appointment, the RA discussed the participant information sheet with the young person or
parent and asked them to reflect on the information, ask questions and raise concerns to ensure that
the information was understood. Once the RA and individual were satisfied that all of the information
had been provided and understood, they would complete the parent/guardian consent to approach form
(parents of under-16-year-olds) or the participant consent form (16- to 18-year-olds). The RA read out
each statement on the form to the individual, checked their understanding and asked individuals to sign
their initials next to each statement if they agreed with it. Finally, the RA and young person/parent
provided their signatures and the date of consent at the bottom of the form. For individuals under
16 years old, once the parent/guardian had provided consent for their child to be contacted about
MAPS, the RA could meet the young person to complete the consent form, as described above.
All participants, regardless of their age, provided written informed consent to enter the trial.
Following the consent appointment, the RA completed the baseline assessment. RAs were advised to
minimise participant burden, that is ideally keep appointments to a maximum of 1.5 hours, avoid
multiple appointments for any one time point and prioritise participant choice. It was recognised that
for some participants the assessment battery may not be complete in full should the participant choose
to decline an assessment or opt for a single appointment. Participants completed the PANSS first,
before completing other self-report and physical health measures. Each participant was given a
personalised crisis card with details of their care co-ordinator, GP and other crisis support numbers
(e.g. Samaritans, Ewell, UK). All participants who attended baseline assessments received £10 for their
time and contribution to the research.
We designed a follow-up period of variable length, such that participants recruited in the first 16 months
were offered assessments at 3, 6 and 12 months post baseline, and those recruited thereafter were
offered assessments up to the end of treatment (6 months). RAs contacted participants or their parents
(with the participants’ consent) by telephone to arrange assessments. RAs confirmed and documented
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ongoing consent with participants prior to completing any measures. RAs began with the PANSS before
moving on to the other measures. Participants were given another copy of the personalised crisis card
and were compensated £10 at each follow-up appointment.
The RAs telephoned participants at 1.5, 4.5 and 9 months to maintain ongoing contact and engagement
with the follow-up appointments, and ascertain any changes in contact details (no clinical outcome data




Given that MAPS was a feasibility study, our key outcomes for informing a definitive trial were referral
and recruitment rates, therapy attendance and medication adherence (including discontinuation rates),
and completion of follow-up appointments and questionnaires.
Our iDMC, TSC and funder agreed a three-stage progression criterion to determine how successfully
each outcome was achieved and help make recommendations about proceeding to a definitive trial.
Recruitment, retention and adherence to PI and AP medication were evaluated and determined as
meeting one of three success levels:
l ‘green’ – indicating that progression to a definitive trial is possible without needing to substantially
change design or delivery
l ‘amber’ – indicating a need for more resources and/or new ideas for recruiting and retaining
participants and supporting treatment adherence
l ‘red’ – indicating that a definitive trial may not be economically viable.
Recruitment success was measured by determining the proportion of the target sample size achieved:
green criterion ≥ 80%, amber criterion 79–60% and red < 60%. Retention success was measured
by the proportion of participants who completed an end-of-treatment PANSS assessment: green
criterion ≥ 80%, amber criterion 79–60% and red < 60%. Satisfactory delivery of adherent therapy
was determined by the proportion of participants allocated to PI who received six or more sessions of
CBT: green criterion ≥ 80%, amber criterion 79–60% and red criterion < 60%. Satisfactory delivery of
AP medication was determined by the proportion of participants receiving an AP medicine for ≥ 6
consecutive weeks: green criterion ≥ 80%, amber criterion 79–60% and red criterion < 60%. It should
be noted that we included an AP dose below the limits in the British National Formulary (BNF) given
that this is frequently the approach for young people owing to the drugs being licensed for adults.
Secondary outcomes
The RAs collected secondary outcomes from participants via semistructured interviews and self-report
measures at each appointment to assess their acceptability and usefulness for inclusion in a definitive
trial, rather than assessing the efficacy or safety of treatments. RAs completed the measures in a
prioritised order that was agreed by the chief investigator. The measures are described below in
order of priority.
Symptoms of psychosis
Symptoms of psychosis, as assessed by the total score on the PANSS,106 are our provisional choice of
primary outcome measure for a definitive trial, although quantitative and qualitative data from this
trial will help inform the final decision. The PANSS is a semistructured assessment administered by
interview that assesses the severity of symptoms experienced by people with psychosis. PANSS score is
a commonly used primary outcome measure in studies of treatment for psychosis spectrum difficulties,
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which enables comparability with other relevant trials and inclusion of our results in systematic reviews
and meta-analyses, as appropriate. The PANSS has 30 items that are scored from 1 (‘absent’) to 7
(‘extreme’). Seven items pertain to positive symptoms (e.g. delusions and hallucinations), seven to
negative symptoms (e.g. blunted affect and social withdrawal) and 16 to general psychopathology
(e.g. anxiety and depression). We used the five-factor PANSS model developed by van der Gaag et al.,107
which divides the items into five subscales: positive symptoms, negative symptoms, disorganisation,
excitement and emotional distress. This model has been found to be more stable and represent a more
complex factor model than those previously published.
Demographic information
We developed a brief demographic questionnaire that participants were asked to complete at each
assessment. The questionnaire required participants to select statements that best characterised their
gender, highest level of education, current employment status, marital status, living arrangements,
ethnicity and religion/belief; participants were also asked to report their date of birth.
Recovery
We used the shortened 15-item version of the Questionnaire about the Process of Recovery (QPR),105
which was developed collaboratively with service users to assess recovery from psychosis. Participants
respond to the statements (such as ‘I feel that my life has a purpose’) on a five-point scale from
strongly disagree to strongly agree, according to their experiences in the last 7 days.
Duration of untreated psychosis
At the baseline appointment only, RAs completed a semistructured interview with participants to
identify when symptoms of psychosis began and when they first sought help. DUP was operationalised
as the number of months between the emergence of symptoms and the date participants received
CBTp/AP medication from their clinical service or were randomised into the trial (if they were
treatment naive).
Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS)108 is a reliable, valid measure of anxiety and
depression symptoms over the past 7 days. Statements include ‘I feel tense or wound up’ and ‘I feel
cheerful’. Participants rate the frequency/intensity of their symptoms using one of four multiple-choice
response options for each of the 14 statements. Anxiety and depression scores are calculated separately.
Social and educational/occupational functioning
The First Episode Social Functioning Scale (FESFS)109 was developed for use with people with FEP.
It has good reliability, validity and sensitivity to change. The FESFS assesses nine areas of functioning:
‘Living skills’, ‘Interacting with people’, ‘Friends and activities’, ‘Intimacy’, ‘Family’, ‘Relationships and
social activities at work’, ‘Work abilities’, ‘School relationships and social activities at school’ and
‘Educational abilities’. Participants are asked to rate their perceived capability and frequency of
engaging in these areas using four-point scales (e.g. from totally agree to totally disagree or from
never to always). Higher scores correspond to better social and educational/occupational functioning.
Autism spectrum disorders
At the baseline appointment only, participants completed the 10-item version of the Autism Spectrum
Quotient (AQ-10),110 which is recommended by NICE to measure diagnostic symptoms for autism
spectrum conditions in young people. Participants respond to statements including ‘I find it difficult
to work out people’s intentions’ on a four-point scale from ‘definitely agree’ to ‘definitely disagree’.
The scoring instructions provide a threshold score that indicates a possible need for a specialist
autism assessment.
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Health economic data
We used an economic patient questionnaire that was adapted from previous studies conducted
by the authors111,112 to gather information about the types of health and social care services
used by participants and the frequency of their contact with these services. We also used the
EuroQol-Dimensions, five-level version (EQ-5D-5L), health status questionnaire, a valid measure of
health outcomes in people with a schizophrenia diagnosis.113 Participants are asked to rate their
mobility, self-care, usual activities, pain/discomfort and anxiety/depression on the present day on a
five-point scale from no problems to extreme problems.
Substance use
The Alcohol Use Disorders Identification Test (AUDIT) was developed by WHO114 and is a reliable
measure for people with FEP.115 Participants respond to 10 statements about their alcohol use habits,
with predefined answers scored from 0 to 40. Higher scores correspond to more severe alcohol use
problems. The scale includes threshold scores for dangerous drinking habits. Participants also completed
the Drug Abuse Screening Test (DAST).116 Participants responded ‘yes/no’ to the 10 items, including
‘Are you always able to stop using drugs when you want to?’.
Dimensions of psychosis experiences
Participants completed the Specific Psychotic Experiences Questionnaire (SPEQ),117 which was developed
for use with young people. It has five subscales each containing 8–15 items, which assess paranoia,
hallucinations, cognitive disorganisation, grandiosity and anhedonia. Participants are asked to rate
their belief in or frequency of experiences from predefined response options. Each subscale is scored
separately, with higher scores corresponding to more severe symptoms.
Measurement of adverse events and potentially unwanted effects of trial participation
We used a number of methods to ensure a rigorous approach to recording and reporting adverse
physical health effects, adverse and serious adverse events (SAEs), and potentially unwanted effects of
trial participation throughout participants’ time in the trial, described in detail below.
Adverse effects of medication
At each assessment, RAs completed the Antipsychotic Non-Neurological Side Effects Scale (ANNSERS)118
with participants. This is a 44-item semistructured interview that determines the presence and severity
of side effects associated with AP medication, which are categorised into different subscales including
cardiovascular, autonomic and sleep problems. Each item represents a known side effect from AP
medication and, if present, is allocated a rating of mild, moderate or severe. Owing to the blind nature
of the trial, all participants were offered the ANNSERS interview regardless of allocation. Therefore,
RAs were required to rate each item regardless of whether that particular side effect was attributable
to AP medication, unless there was a very clear non-medication cause. For example, in the example of a
skin rash, if a participant with a known skin allergy to a particular substance reported that only after
coming into contact with the known allergen, a score of absent would be applied. Medically trained
clinicians on the MAPS team were sought for consultation on scoring when required.
Metabolic side effects
At each assessment, RAs completed physical cardiovascular and metabolic screenings to determine any
changes since baseline that may be related to AP medication. RAs measured participants’ height and
weight [to calculate their body mass index (BMI)], waist circumference and blood pressure. In addition,
RAs took three samples of blood for analysis of total cholesterol, low-density lipoproteins (LDLs),
high-density lipoproteins (HDLs), triglycerides, prolactin, glycated haemoglobin (HbA1c) and fasting
plasma glucose (FPG). The blood test results were sent to participants’ psychiatrists (or other responsible
clinician) at each time point. If RAs were unable to obtain a blood sample or if the participant declined a
test, participants’ psychiatrists were also notified.
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Serious adverse events and adverse events
Consistent with Health Research Authority (HRA) guidelines, we determined all of the following
as SAEs:
l death
l an event that is life-threatening
l an event that requires hospitalisation or prolongation of existing hospitalisation
l an event that results in persistent or significant disability or incapacity
l an event that consists of a congenital anomaly or birth defect
l an event that is otherwise considered medically significant by the investigator.
In addition to these, in the MAPS protocol we list serious violent incidents and formal complaints
about treatment. In addition to SAEs, we also recorded AEs as determined as any untoward medical
occurrence in a participant, including occurrences that are not necessarily caused by or related to the
treatment (e.g. self-harm).
Research assistants and therapists reported AEs and suspected SAEs to the chief investigator. Both
the chief investigator and the chairperson of the iDMC reviewed all SAE to determine if they were
related to the trial proceedings. Any SAEs that were considered to be related to trial procedures were
reported to the REC and the participant’s NHS trust. To ensure independent scrutiny of AEs and SAEs,
both the iDMC and the TSC reviewed details of all SAEs at each meeting.
In addition to report of an AE or SAE from a research team member, an independent, non-blinded
researcher screened all participants’ medical records to find any SAEs that may not have been reported.
Potential adverse effects of trial participation
We assessed this using a measure developed in our HTA FOCUS (Focusing on Clozapine Unresponsive
Symptoms) trial.111,119 The optional self-report measure was given to participants at point of exit from
the trial or at point of withdrawal for those who left the trial. The measure contains 27 items (including
‘taking part involved too much hard work’ and ‘I did not feel listened to or believed by MAPS staff’),
which participants responded to on a five-point scale from ‘not at all’ to ‘very much’. In addition, there
was space for participants to describe trial participation in their own words, if wished.
Substantial deterioration
Following each participant’s 3-month follow-up, the percentage change on the PANSS was calculated
using PANSS rescaling methodology.120 If the participant’s mental health had significantly deteriorated
from baseline, participants in the monotherapy arms were offered a switch to the combined treatment
arm. A significant deterioration was operationalised by an involuntary admission to a psychiatric
hospital or an increased rescaled PANSS score of at least 12.5%.
Diagnosis and medical record screen case report form
The participant’s electronic medical records were screened for information pertaining to diagnosis,
details of AP medication prescription (type, dose, start and stop dates and adherence), concomitant
psychological therapies, AEs and SAEs. The medical records were screened by a member of the research
team who was not blinded to allocation. This involved screening progress notes, clinical summaries, care
plans and medicine management information in the participant’s medical records for any relevant AP
information. The records were searched for a date when AP medication had commenced and any periods
when medication was stopped/not adhered to, to determine the period of time that the participant took
AP medication. The medical records were screened at baseline, and at 3, 6 and 12 months (for those who
reached the 12-month follow-up) by a non-blinded member of the research team. In addition, participants’
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diagnoses were considered by consultant psychiatrists from our research team (AJ, DM, MRB and RW)
on the basis of vignettes based on information extracted from PANSS interviews and reviews of
medical records.
Medication adherence (self-report)
In addition to medical record data pertaining to medication adherence, self-report medication adherence
was collected at each follow-up. Participants were asked to confirm if they were prescribed an AP
medicine and to rate compliance using a 0–100 analogue scale. Participants were given the choice to
either complete this online or complete a paper version, which was returned in a sealed envelope to the
trial manager (to main the single blind).
Interventions
Antipsychotic medication
Participants who were allocated to a medication arm of the trial were offered AP medication by their
usual care team psychiatrist. Psychiatrists were asked to initiate AP treatment as soon as possible
following randomisation, and to maintain treatment for preferably 26 weeks, but for a minimum of
12 weeks. Psychiatrists made decisions about the type and dose of AP medication in line with their
usual practice, and were free to change the dose and type of AP medication throughout treatment
if deemed necessary. Psychiatrists were asked to make prescribing decisions consistent with NICE CG
(CG155).55 This recommends that the choice of AP medication should be made jointly between the
clinician, young person and parent/carer, including discussing the possible benefits and side effects
of each drug and providing age-appropriate information; it also recommends that physical health is
monitored throughout treatment.55 Psychiatrists were given the offer of consultation from MAPS team
psychiatrists regarding AP prescription.
Participants in all treatment arms were not restricted from taking up any medications or psychological
therapies offered by the care team throughout their participation, as this would be unethical. To gather
feasibility information on participants’ adherence to their MAPS treatment allocation, a non-blinded
researcher screened participants’ medical records for information on concomitant therapies. In addition,
participants provided self-report data on (1) concomitant psychotherapies and pharmacotherapies and
(2) adherence to allocated treatment via our web-based platform or via paper self-report if preferred
(if via paper self-report this information was returned to a non-blinded MAPS team member).
Psychological intervention
Psychological intervention was delivered by CBTp-trained psychological therapists. Therapists were
employed on a band 7 NHS salary scale, which is representative of CBT delivered within the NHS by
most psychological therapists. In some instances, therapist complement was increased by using local
trial therapists (bands 8a–8c) in addition to the band 7 trial therapists. Participants were offered up to
26 hours of CBT over the first 6 months, plus up to four boosters over the subsequent 6 months, and
up to six FI sessions. Individual CBT commenced as soon as possible post randomisation. Sessions
were delivered at the participant’s preferred venue (often home or school/college) to support the
accessibility and acceptability of the CBT.
The CBTwas manualised121 and informed by an integrative cognitive model of psychosis.122 Therapists
took an assertive outreach approach to engaging participants, and incorporated principles from youth
work and social and vocational interventions. The aims of CBTwere reducing distress (particularly
that arising from psychotic symptoms) and improving quality of life. The CBT emphasised formulation,
normalisation, collaboration between therapist and participant, and evaluation of participants’ appraisals
of and responses to psychological experiences. Therapy addressed the problems and goals agreed by
the participant and therapists. Treatment targets included positive symptoms of psychosis, social issues
(e.g. ‘I have improving relationships’) and/or comorbid difficulties (e.g. anxiety, depression).
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Cognitive–behavioural therapy aimed to involve four phases: engagement, assessment and formulation;
change strategies; longitudinal aspects; and consolidation.119 Key milestones for CBT were as follows:
first session within 1 week of randomisation; a shared list of problems and goals by session 3; a shared
formulation by session 3 (this could be a maintenance formulation); one ‘out in the real world’ session
by session 10; and a longitudinal formulation by session 26. Clients were encouraged to engage in
between-session practice, in line with research on increasing the effectiveness of CBT.123 Participants’
individual formulations informed the choice of specific CBT interventions from a range described in
published treatment manuals.83,124 This results in an individualised therapy that retains standardised
components.
Family intervention was delivered alongside individual CBT by the same therapist. Participants were
offered up to six sessions over 6 months, but did not have to use them if not desired or if participants
had no regular contact with family members. FI was based on the behavioural family therapy
approach:125 a psychoeducational model designed to flexibly address current concerns and problems
relevant to adolescent FEP, such as supporting families with their reactions to the development of FEP
and fostering hope for recovery.
The first session of FI aimed to assess the family’s understanding and appraisals of presenting problems,
sharing of the initial psychological formulation and agreeing problems and goals to be addressed as a
family. Further sessions involved providing psychoeducational, normalising and recovery-oriented
information; facilitating problem-solving and communication skills; and developing relapse prevention
plans. The participant’s care co-ordinator was invited to attend the final session to ensure continuity
and support of goals and strategies following trial participation. Therapists signposted families to
support services and other relevant services if needed.
Training and supervision
Therapists
Therapists received weekly CBT supervision from a central supervisor (AM or SB) to ensure fidelity
to the treatment protocol, and fortnightly clinical supervision from their clinical supervisors/research
site leads to ensure adherence to local NHS policy and manage site-specific clinical issues. All clinical
supervisors were appropriately experienced and trained in CBTp.
Therapists received FI supervision from Anthony P Morrison, Samantha Bowe and Jo Smith to ensure
fidelity to the treatment protocol. Therapists received training in FI from Jo Smith. FI sessions were
recorded with participant consent and utilised for training and fidelity. This process ensured fidelity to
the treatment protocol, informed supervision and allowed corrective action to be initiated if necessary.
Throughout the trial, therapist FI training days were attended by trial therapists and supervisors. After
each session, therapists completed a session record sheet for FI to evidence using core elements of FI
from the treatment protocol.
Therapy sessions were recorded with participants’ consent. Throughout the course of the trial,
therapists submitted session tapes. The central supervisor (SB) rated the tapes on the Cognitive
Therapy Scale-Revised (CTS-R)126 and provided feedback. This process ensured fidelity to the treatment
protocol, informed supervision and allowed corrective action to be initiated if necessary. Throughout
the trial, therapist training days were attended by trial therapists, clinical supervisors, the chief
investigator and site leads. Group-based CTS-R session ratings were completed.
After each session of CBT or FI, therapists completed a session record sheet to evidence using core
elements of CBT or FI and the specific CBT or FI strategies used. These data were analysed to monitor
fidelity to the treatment protocol, including any between-site differences in fidelity. In addition, the
therapists completed an end-of-CBT and an end-of-FI questionnaire.
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Research assistants
All RAs received training from the trial manager and other trial co-applicants on the protocol and
conducting the outcome measures. PANSS training was delivered by the MAPS manager, who has
extensive experience of PANSS training and supervision (e.g. on the HTA-funded FOCUS trial111). Following
an interactive session with the manager and RAs, in which the PANSS interview was explained in detail,
RAs completed role plays of the interview. RAs were also required to watch three PANSS training videos
(as used in the FOCUS111 and COMPARE102 trials) and achieve an interclass correlation coefficient of
≥ 0.80, with a gold-standard rating provided by Professor Thomas Barnes (a PANSS institute-certified
trainer) that was utilised for the HTA-funded FOCUS trial.111
Research assistants also received training from Professor Peter Haddad (a consultant psychiatrist and
MAPS co-investigator) in conducting the ANNSERS interview118 and physical health checks. In addition,
they had training from senior clinicians in clinical risk assessment and clinical assessment skills. All RAs
completed the NIHR good clinical practice training, including the ‘Informed Consent in Paediatric
Research’ module.
To gain competency in venepuncture, RAs were required to attend a theoretical training course that
was run in their NHS trusts by qualified practitioners. They then attended a trust venepuncture clinic,
where they were supervised by a qualified practitioner. The practitioner provided written evidence that
the RA was competent to practise when they were satisfied of the RA’s competency and the RA had
met the trust-specific standard for competency, for example taking 10 satisfactory blood samples from
clinic attendees.
Research assistants received weekly telephone supervision by the trial manager (face to face in the
central site, Manchester). Supervision for all RAs followed a structured agenda of recruitment and
retention; data quality and assurance (including a blind review of RA PANSS scores); and reviewing
blind breaks, SAEs and withdrawals (for further discussion with the chief investigator). The supervision
supported RAs to proactively problem-solve issues with recruitment and assessments; maintain high
data quality standards; and systematically report blind breaks, SAEs and withdrawals. RAs also received
regular clinical supervision from their site’s principal investigator, focusing on clinical assessment and
risk management, procedure and time management, and ensuring adherence to local NHS policy.
Randomisation and blinding
Randomisation was independent and concealed, used randomly sized randomised permuted blocks of
three and six, and stratified by (1) centre and (2) family contact (because participants without regular
family contact would receive CBT only, not FI, if allocated to a PI arm). RAs carried out the randomisations
via a web-based platform developed by the Centre for Healthcare Randomised Trials (CHaRT), a UK
Clinical Research Collaboration registered clinical trials unit (CTU) (#7). CHaRT provided consultation on
the development of the randomisation algorithms. Using the CHaRT platform ensured that investigators
were unable to enrol participants to conditions or predict the allocation sequence.
Participants were randomised within 2 working days of their eligibility being confirmed at baseline.
The trial manager, administrator, therapists, chief investigator and PIs were notified via e-mail of the
participants’ treatment allocations, to allow monitoring of adherence to allocation and provision of
supervision to therapists. Each site had a delegated staff member (either an administrator or a therapist)
who sent allocation letters to participants and their care co-ordinators, psychiatrists and GPs.
The assessors (RAs) were blind to allocation outcomes until all participants’ outcome measures were
completed. RAs and therapists received extensive in-house training on retaining the blind, including
reading and signing a trial-specific standard operating procedure for managing and retaining blinding.
The trial used numerous methods outlined in the standard operating procedure to maintain blinding,
including separate offices, diaries, pigeon holes and databases for RAs and therapists; reminding
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participants, family members and clinicians about the blind; protocols for taking messages and secretarial
support; and encrypting and password-protecting randomisation information. All accidental unblindings
were reported to the trial manager and, where possible, another (blinded) RA would complete the
assessment. The chief investigator, iDMC and TSC regularly monitored unblindings in each centre in
case corrective action was required.
Statistical methods and analysis
Ground rules for statistical analyses
The analysis followed a statistical analysis plan that was agreed by the chief investigator and data
monitoring committee. The statistical analysis plan was published on the CTU’s website prior to pre-
access to data (see www.abdn.ac.uk/hsru/what-we-do/trials-unit/statistical-analysis-plans-611.php).
All main analyses were based on the intention-to-treat principle. Safety and unwanted effects were
analysed based on the treatment received rather than as randomised. For these purposes, PI was
defined as any dose of CBT or FI from the trial therapist. AP was defined as any dose of an AP
medication prescribed by the participant’s responsible psychiatrist. All analysis took place after full
recruitment and follow-up (i.e. there were no interim analyses for efficacy), although the iDMC
monitored trial progress and safety issues throughout the trial’s course. All analyses were carried out
in Stata version 15 (Stata®, StataCorp LP, College Station, TX, USA).127
Sample size
Our proposed sample size was 90 participants (30 participants per treatment arm). We did not perform a
formal power calculation to detect treatment differences because the analysis focus was not hypothesis
testing. Our target sample size was sufficient to gain reliable information to inform sample size estimates
for a larger trial128 and feasibility information about trial procedures.
Primary feasibility outcomes
Descriptive statistics and 95% confidence intervals (CIs) were used to summarise the key success
indicators of the trial, including participant recruitment, checks for absence of selective recruitment of
participants, baseline balance and participant flow. Appropriate summary statistics were the numbers of
participants referred, eligible referrals, consenting individuals and individuals recruited to each arm; the
numbers for drop-out from the allocated interventions; the numbers of withdrawals of consent; and the
number who failed to provide follow-up outcome data. We also calculated the proportion of participants
who received their allocated intervention versus those who did not, and the proportion of participants
who moved to the combined arm owing to deterioration.
Secondary outcomes
Appropriate descriptive statistics were used to summarise baseline and follow-up data, with means
[standard deviation (SD)] or medians for continuous data and frequencies and percentages for
categorical variables. To inform a definitive trial, we conducted a repeated-measures analysis of
the proposed primary outcome (i.e. PANSS score) and the secondary outcome (QPR score) using a
mixed-effects model to account for the discrete timing of the follow-up assessments and adjust for
site and baseline score. For the analysis, missing baseline data were imputed using the centre-specific
mean. The focus of the analysis was on point estimates and associated 95% CIs rather than statistical
significance (p-values); however, we have reported p-values. Owing to the low response rates or small
number of events, the analysis was descriptive. We also assessed the correlations of each measure
across all time points and the variation within the proposed outcome measure (mean and SD), to
inform a sample size calculation for a future definitive trial.
We have provided summary data for treatment adherence and treatment received in each arm to
describe withdrawal from the allocated intervention. We operationalised satisfactory delivery of
therapy as attendance at six or more sessions of CBT. Satisfactory delivery of AP medication was
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operationalised as uptake of an AP medicine for at least 6 consecutive weeks (including a dose below
the BNF lower limits, as this is a frequent clinical practice for young people, and AP medication are
licensed for adults). We have reported descriptive statistics for the components of the PI received,
including the number of sessions and milestones achieved, and completion of between-session tasks.
Missing data
Given that MAPS was a feasibility study, there was no formal analysis to account for missing data.
Qualitative studies
Design
A nested, qualitative study aimed to explore the acceptability and feasibility of the trial and associated
treatment interventions among key stakeholder groups, that is trial participants (young people with
experience of FEP), their parents or carers and local clinicians (particularly those with prescribing
responsibility).This qualitative approach allowed us to gain valuable views of this trial and recommendations
to inform the design of a potential definitive trial. Individual semistructured interviews conducted with
representative samples from each group evaluated views and experiences of recruitment to the trial,
potential barriers to participation and solutions, assessment processes, randomisation to trial treatments
and ongoing care and outcomes. Subjective experiences of receiving trial treatments were explored with
participants and parents/carers, whereas clinicians were asked to share their perspectives on the delivery
of treatments; all interview groups discussed the relative benefits and adverse effects of treatments.
Semistructured topic guides were devised for each of the three stakeholder groups of this interview study,
and all interviews followed the same relevant pattern. Topic guides were considered flexible and open
to amendment throughout the course of this study, as it was expected that novel areas of interest may
emerge, generating additional interview prompts for subsequent interviews, or that original questions may
prove to be inessential and, therefore, removed. For this reason, each topic guide was subject to several
minor amendments between the first and the final interviews in each treatment arm.
All of the interviews were digitally audio-recorded. Interview recordings were returned to and stored
within closed and secure NHS digital network locations. All interviews were transcribed verbatim at
the central site (i.e. Manchester). All names, locations, highly idiosyncratic personal details or any other
potentially identifying information were removed to ensure anonymisation of the interview data.
Young people
Inclusion criteria
All young people interview participants were drawn from the larger sample of MAPS participants.
All MAPS participants had been randomised to one of three treatment arms, as described above.
This interview study aimed to use purposive sampling to recruit an equal number of participants from all
three treatment arms. In addition, it was intended that purposive sampling would ensure a representative
sample with regard to the age range, gender spectrum and ethnic diversity seen in the trial and, where
possible, diversity in terms of engagement with the trial and treatments (i.e. seeking possible positive and
negative perspectives equally).
Recruitment
All potential young people interview participants had provided written consent when they entered the
trial for audio-recording of interviews and publication of anonymised quotations. Potential participants
were not approached if (1) they had not provided informed written consent on trial entry for the
recording of assessments/interviews and/or the use of direct anonymised quotations in the trial
publication (approximately 29% had not), (2) it was not clinically appropriate to approach them
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because of significant levels of distress or risk, or (3) they declined to be contacted. By using purposive
sampling of eligible participants, we aimed to achieve a balanced and representative sample across trial
sites and treatment arms that would reflect the age range (14–18 years) and gender balance of the
total trial sample. We also sought to represent variance in terms of positive, negative and neutral or
ambivalent perspectives on all aspects of the trial. Eligible participants were approached following
completion of their 6-month follow-up assessment and after qualitative researchers had sought
updated clinical risk and well-being information. It was also expected that for most of the participants
allocated to receive PI, the intervention would be complete when the interviews were conducted.
As described, this study intended to systematically seek variance within the interviewee sample;
however, several substantial challenges in recruitment to interviews meant that purposive sampling
was not wholly feasible. Ultimately, a convenience sampling approach was adopted.
In most cases, eligible participants were informed of the optional qualitative interviews by trial
therapists or RAs following 6-month assessments. For a variety of reasons, including clinical concerns
or practical obstacles, several otherwise eligible participants were not invited to or reminded of the
qualitative interviews. All participants informed of the interview study were advised that involvement
was optional, interviews were confidential, interview questions would not require sensitive disclosure,
interviews could usually take place at their preferred time and location, and interviewees would
receive £10 for their contribution to this study.
Procedure
Interviews were conducted by Rory Byrne (north west), Jessica Bird and Sarah Reeve (Oxford); the
semistructured interview schedule was developed by Rory Byrne, Sarah Peters and Wendy Jones in
consultation with the wider research team. Interview questions focused on participants’ experience
of MAPS, especially issues of acceptability and feasibility, to inform a future definitive version of the
same trial design. Key feasibility and acceptability factors included referral into the trial, randomisation
to treatment, attending assessment meetings and acceptability/tolerability of trial treatments.
Interview topic guides were used flexibly, with additional prompt questions to enhance elaboration.
Interviews lasted for an average of 41.5 minutes (range 23.25–53.53 minutes).
Participants
Of the 26 young people who gave their consent to be contacted about the study, 13 took part in an
interview. The remaining 13 did not respond to invitations (n = 9), accepted participation but did not
ultimately meet for interview (n = 2) or declined (n = 2). Participants in the final sample were drawn
from three sites (north-west, n = 8; Oxford, n = 4; Sussex, n = 1) and ranged in age from 15 to 19 years
(mean 16 years). Most identified as female (10/13) and white British (9/13). Two participants were
black African, one was Hungarian and one was Pakistani. Three participants were allocated to AP only,
five to PI only and five received the combined intervention.
Parents and carers
Inclusion criteria
As with the young people interview study, a representative sample of 15–20 parents or carers of
young people taking part in MAPS was sought. Inclusion criteria were purposefully broad to facilitate
maximum variance and represent the widest possible range of perspectives relevant to trial and
treatment acceptability and feasibility. Parents/carers were eligible for inclusion providing that they
had recent involvement in the care or support of a young person participating in MAPS. The only
exclusion criterion was the preference of young people themselves (i.e. a parent or carer was not
invited to an interview if their young person did not want them to be invited).
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Recruitment
Potential parent/carer participants were generally considered for inclusion at or after the 6-month follow-up
stage, although a small number of people were contacted prior to this point. Potential participants
were informed of the interview study directly following interviews with young people, via trial RAs or
therapists, or by staff working with young people (e.g. EIP care co-ordinators). As with the young people
interview procedures, potential participants were advised that interviews were optional and confidential,
would not seek private content and that interviewees would receive £10. It had been intended that
purposive sampling would help to capture a diverse range of views of the trial, including different
randomised treatment allocation; different levels of young people’s engagement with treatments; and
different family member/carer gender, age, ethnicity and relationship with the young person. However,
practical obstacles in the recruitment of family/carer participants meant that the final sample was less
diverse than intended. For example, for ethics reasons it was necessary for young people to agree that
researchers could meet independently with their family member. Several were not agreeable to this.
Parents/carers provided written informed consent prior to commencement of interviews.
Procedure
Family interviews were conducted at participants’ homes by Rory Byrne (north-west) and two
researchers from Oxford. Immediately prior to interviews commencing, written informed consent was
completed and the bounds of interview confidentiality were highlighted. The semistructured interview
topic guide, developed by Rory Byrne, Sarah Peters and David Shiers in consultation with the wider
research team, focused on the young people’s entry to MAPS, experiences of trial processes and
treatments and, where applicable, family members’ own experience of involvement in treatments.
The study topic guide, intended to be used flexibly, was amended at several points to add or
de-emphasise specific questions per ongoing data collection. Once complete, interviews were,
on average, 46.8 minutes in duration (range 25.30–68.34 minutes).
Participants
The total number of family members/carers interviewed was 18; in two cases both mother and father
attended together, so a total of 16 interviews were conducted. In total, 15 out of 16 interviews were
with parents (mother, n = 13; father, n = 4) and one with a grandmother. Participants were recruited
from two trial sites [north-west, n = 6; Oxford, n = 10 (10 interviews, 12 individuals)]. Interviewees
were aged between 37 and 71 years (mean age 49.15 years), and all were white British. In terms of
trial treatment allocations, two interviews were from the AP only group, six from the PI only group
and eight from the combined treatment (AP and PI group).
Clinicians
Inclusion criteria
Inclusion criteria for the clinician interviewees required participants to be qualified mental health
professionals who provided care to young people with FEP in CAMHS or EIP services based in NHS
trust areas in which MAPS was recruiting. There were no time constraints for these interviews;
clinician perspectives were sought during the lifetime of the trial until completion of recruitment.
It was initially intended that recruitment would follow a purposive sampling approach to ensure
variance among the final sample, including professional discipline. However, once recruitment of
young people to MAPS was under way, it became clear that the views of prescribers in particular were
instrumental in many referrals of young people to the trial. Therefore, a subsequent inclusion criterion
required participants to have current prescribing responsibility for young people with experience of
psychosis. Subsequent purposive sampling aimed to achieve variation in clinicians’ service type and
their rates of referral to MAPS.
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Recruitment
Potential clinician interview participants were identified first from established communications with
MAPS staff (e.g. recruitment and referral mailing lists). Additional potential participants were identified
in several instances via personal recommendation from prescriber colleagues. In most cases, potential
clinician participants were initially invited to interviews by e-mail communication, which was followed up
with telephone calls or reminders. Most clinicians who responded to invitations went on to participate in
interviews. As with other interviewees, clinicians provided written informed consent prior to interviews
commencing. Clinician interviewees were not offered a financial reimbursement or reward.
Procedure
Interviews with eligible clinicians were conducted by Rory Byrne (north-west) and a researcher from
the Oxford site, using a semistructured topic guide. Clinicians were asked questions that aimed to elicit
views of trial treatments (AP, CBT and FI), potential barriers to or facilitators of referral of young people
into the trial and potential challenges or benefits related to the trial in clinicians’ ongoing care for young
people who had been referred to MAPS. The interview topic guide was refined over the course of the
study, as new or saturated topics were identified through successive interviews. At completion, the
average interview duration was 39.3 minutes (range 15.29–58.12 minutes).
Participants
Recruitment for clinician interviews followed a purposive sampling framework, criteria for which included
the NHS service setting (CAMHS or EIP), active responsibility for young people in MAPS, age/experience,
gender and ethnicity. Of approximately 50 clinicians who were invited to participate in interviews, 28 did
not respond, three expressed interest but did not ultimately participate and one cancelled an interview
appointment. The final sample comprised 17 clinicians, all with prescribing responsibility for 14- to
18-year-old adolescents across three sites (north-west, n = 12; Oxford, n = 4; Sussex, n = 1). Participants
were predominantly consultant psychiatrists (n = 15/17, plus one advanced practitioner and one specialty
doctor) working in CAMHS (n = 6) and EIP services (n = 9) (two interviewees worked in both service
types), and eight had active prescribing responsibility for young people in MAPS. Participants were aged
between 32 and 63 years (mean age 44.3 years) (three participants did not indicate age), and included
female (n = 8) and male (n = 9), white British (n = 13), Sri Lankan (n = 1), British Iranian (n = 1), white Irish
(n = 1) and white ‘other’ (n = 1) individuals.
Confidentiality and anonymity
All qualitative interviews were conducted individually and face to face to promote interpersonal
engagement and ensure privacy and confidentiality. The exceptions were that several young people
interviewees chose to attend with a friend, in two instances two parents attended the same interview
and one young person attended their parents’ interview. All clinician interviewees attended
individually; two clinician interviews were conducted by telephone.
Prior to commencement of each interview, researchers outlined the bounds of confidentiality and
sought verbal confirmation of consent to proceed. All participants were assured that all feedback
would be welcomed and valuable. This was highlighted particularly to encourage possible negative
feedback about the trial or treatments, as it may be reasonably expected that consenting interview
participants are more likely to represent those with generally positive or neutral views.
Data analysis
The interview study was conducted with leadership and ongoing involvement from individuals with
personal or parental experience of psychosis spectrum difficulties. This involvement was expected to
enhance attention to young person and parent/carer concerns during the conduct and analysis of all
interviews. All interview data were thematically analysed.129 The overarching aim of this analysis was
to inductively code qualitative data at the manifest level (i.e. analysing only the immediate meaning of
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participants’ language) to produce an accessible body of coded data from which meaningful thematic
representations of participants’ perspectives can be reported.
Consistent with established thematic analysis methodology,129 all transcribed interviews were initially read
through in full to enhance familiarity with the data, and initial impressions of the emerging quality of the
data set were recorded in memo form. All interviews then were coded systematically and iteratively within
NVivo qualitative data analysis software (version 11) (QSR International,Warrington, UK). Researchers did
not impose a rigid or literal ‘line-by-line’ coding approach at this stage, but sought to identify and code all
sections of data that either directly answered a relevant interview question or offered additional relevant
information. This led to many areas of data being coded under multiple topic areas, as many relevant aspects
of this research area are inter-related (e.g. the relationship between diagnosis and treatment).
At regular scheduled points during the analysis processes, qualitative researchers met to discuss and
refine coding and analysis strategies through reliability checking and establishing consensus. Periodic
analysis meetings were also conducted with MAPS leads to further develop emerging thematic and
conceptual outputs, and to ensure that valued insights emerging from interviews were transmitted to
the trial team as a whole as quickly as possible. The substantive analysis meetings produced evolving
thematic ‘maps’ or models representing the commonalities along with the diversity expressed in the
views of each respective interview group. Over time, this mapping process elevated or reduced the
prominence of key candidate themes until a fixed and final model of each group’s range of perspectives
was agreed on.
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Chapter 3 Participant baseline characteristics
Used with permission from Morrison et al.103 This is an Open Access article under theCC BY-NC-ND 4.0 license (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Trial recruitment
Overall, there were 705 initial enquiries in relation to potential patients. Initial enquires by site are
presented in Appendix 1, Table 27. Of these, 76 were referred, with the addition of 25 patients who were
directly referred because they gave verbal consent to be contacted. Of the 101 patients referred, 61 were
randomised (PI, n = 18; combined, n = 21; AP, n = 22). This was 68% (95% CI 57% to 77%) of the target
of 90 randomisations. The initial enquiries, referral pathway and referral source by the different centres
are shown in Appendix 1, Tables 27–29. Oxford and Manchester were the highest recruiters, with 25 and
21 participants randomised, respectively. Participants were recruited from six centres between April 2017
and November 2018, and were followed up until April 2019. Figure 1 shows the trajectory of recruitment
from all centres. However, owing to staggered introduction of centres, not all participants were recruited
during this period; Appendix 1, Figure 8, shows the trajectory of recruitment by centre.
Participant flow
The Consolidated Standards of Reporting Trials (CONSORT) flow diagram is shown in Figure 2. Of the
101 referred participants, 29 were excluded; details of the reasons for exclusion are shown in Figure 2.
The main reasons were declining with no reason and that the participant did not engage with the
screening visit. After screening, 11 participants were excluded, the majority of whom had a score
below 4 on PANSS questions P1 and P3 (see Figure 2). Across the three arms, the retention of























































































































































































FIGURE 1 Recruitment over time.
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Baseline characteristics
Baseline characteristics are shown in Tables 2 and 3. Diagnoses that were allocated by trial consultant
psychiatrists on the basis of PANSS vignettes and medical record data can be found in Appendix 1,
Table 30. The mean age of participants across all arms was 16 years; 30 participants were male,
29 were female and two were non-binary. The mean DUP was 16.8 months in the PI arm, 13.2 months
in the combined arm and 11.1 months in the AP only arm. The majority of participants were in high
school, with 53 participants living with parent(s) and/or siblings. The mean PANSS total score was
72.9 in the PI arm, 75.9 in the combined arm and 74.8 in the AP arm.
3-month assessment
• PANSS analysis, n = 17
• Withdrawn, n = 1
• Received allocated
    intervention, n = 10
• Did not receive allocated
    intervention, n = 8
6-month assessment
• PANSS analysis, n = 16
• Withdrawn, n = 1
12-month assessment
• PANSS analysis, n = 11
• Did not reach, n = 3
• Withdrawn, n = 1
3-month assessment
• PANSS analysis, n = 17
• Withdrawn, n = 1
• Received allocated
    intervention, n = 11
• Did not receive allocated
    intervention, n = 10
6-month assessment
• PANSS analysis, n = 17
• Withdrawn, n = 1
12-month assessment
• PANSS analysis, n = 11
• Did not reach, n = 4
• Withdrawn, n = 1
3-month assessment
• PANSS analysis, n = 19
• Withdrawn, n = 0
• Received allocated
    intervention, n = 14
• Did not receive allocated
    intervention, n = 8
6-month assessment
• PANSS analysis, n = 18
• Withdrawn, n = 0
12-month assessment
• PANSS analysis, n = 9
• Did not reach, n = 5





• Below 4 points on PANSS P1 and P3,
    n = 9
• Considered immediate risk to self or
    others, n = 1













• Declined (unknown reason), n = 5
• Disengaged with research and/or
    clinical team, n = 8
• Psychiatrist did not consider 
    AP medication appropriate, n = 3
• Parents refused consent, n = 2
• Preference not to take 
    AP medication, n = 1
• Preference not to receive PI, n = 1
• Did not meet inclusion criteria, n = 6
• Other, n = 3
FIGURE 2 The CONSORT flow diagram. Used with permission from Morrison et al.103 This is an Open Access article
under the CC BY-NC-ND 4.0 license (https://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 2 Baseline characteristics
Characteristic
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Age (years) 18; 16.3 (1.4) 21; 16.2 (1.3) 22; 16.4 (1.3)
Gender, n (%)
Male 8 (44.4) 10 (47.6) 12 (54.5)
Female 10 (55.6) 10 (47.6) 9 (40.9)
Non-binary 0 (0) 1 (4.8) 1 (4.5)
DUP (months) 13; 16.8 (16.4) 16; 13.2 (17.6) 15; 11.1 (9.7)
Highest level of education, n (%)
Secondary 9 (50.0) 11 (52.4) 11 (50.0)
Further 9 (50.0) 10 (47.6) 11 (50.0)
Employment status, n (%)
College student 7 (38.9) 8 (38.1) 9 (40.9)
High school student 5 (27.8) 8 (38.1) 7 (31.8)
Unemployed 4 (22.2) 2 (9.5) 2 (9.1)
Full time 1 (5.6) 1 (4.8) 3 (13.6)
Part time 1 (5.6) 1 (4.8) 1 (4.5)
Voluntary 0 (0) 1 (4.8) 0 (0)
Marital status (single), n (%) 18 (100.0) 21 (100.0) 22 (100.0)
Living arrangements, n (%)
Living with parent(s) and/or siblings 15 (83.3) 18 (85.7) 20 (90.9)
Living in supported accommodation 2 (11.1) 1 (4.8) 1 (4.5)
Living with other family member(s) 1 (5.6) 2 (9.5) 0 (0)
Lives alone 0 (0) 0 (0) 1 (4.5)
Ethnicity, n (%)
White British 14 (77.8) 18 (85.7) 17 (77.3)
Indian 1 (5.6) 0 (0) 0 (0)
Pakistani 0 (0) 1 (4.8) 2 (9.1)
White Asian 0 (0) 1 (4.8) 0 (0)
Black African 1 (5.6) 0 (0) 1 (4.5)
Black Caribbean 0 (0) 1 (4.8) 1 (4.5)
White Irish 0 (0) 0 (0) 1 (4.5)
Other 2 (11.1) 0 (0) 0 (0)
Religion, n (%)
Atheism 7 (38.9) 10 (47.6) 12 (54.5)
Christianity 4 (22.2) 4 (19.0) 4 (18.2)
None 6 (33.3) 3 (14.3) 2 (9.1)
Islam 0 (0) 1 (4.8) 2 (9.1)
Buddhism 0 (0) 1 (4.8) 0 (0)
Other 1 (5.6) 2 (9.5) 2 (9.1)
continued
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TABLE 2 Baseline characteristics (continued )
Characteristic
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
PANSS score
Total 18; 72.9 (9.7) 21; 75.9 (14.8) 22; 74.8 (12.2)
Positive 18; 21.2 (3.8) 21; 21.2 (5.8) 22; 22.9 (6.0)
Negative 18; 15.8 (3.3) 21; 18.5 (6.6) 22; 17.9 (5.6)
Disorganised 18; 20.1 (4.5) 21; 21.0 (5.4) 22; 19.9 (4.6)
Excitement 18; 17.1 (3.7) 21; 17.9 (4.9) 22; 19.3 (4.1)
Emotional distress 18; 25.2 (4.5) 21; 24.8 (5.8) 22; 24.7 (6.7)
QPR 12; 46.1 (9.3) 18; 42.6 (10.1) 15; 42.1 (10.0)
AUDIT 9; 7.7 (7.9) 11; 7.4 (8.6) 12; 6.8 (7.4)
DAST 9; 1.9 (1.8) 11; 2.5 (3.2) 12; 1.6 (2.3)
AQ-10 8; 4.8 (2.1) 10; 5.4 (2.1) 11; 5.2 (1.8)
SPEQ
Paranoia 8; 31.5 (12.9) 13; 42.3 (14.8) 14; 41.8 (14.0)
Hallucinations 9; 23.4 (10.1) 12; 27.0 (6.6) 14; 27.4 (8.8)
Cognitive disorganisation 9; 7.3 (2.9) 12; 9.1 (1.6) 13; 9.2 (2.6)
Grandiosity 9; 6.1 (4.6) 12; 4.9 (6.5) 13; 3.9 (3.1)
Anhedonia 9; 27.2 (9.6) 11; 22.5 (8.7) 13; 18.8 (9.6)
HADS
Anxiety 10; 11.2 (2.6) 13; 14.2 (2.5) 15; 12.7 (4.0)
Depression 10; 9.2 (3.8) 13; 10.2 (4.4) 15; 9.7 (5.1)
ANNSERS
Total 8; 17.5 (10.4) 11; 17.2 (7.1) 12; 15.9 (6.4)
Number of side effects 8; 10.6 (4.8) 11; 11.5 (3.8) 12; 11.2 (5.2)
FESFS: ability
Living skills 9; 13.3 (1.2) 10; 12.6 (1.6) 12; 11.8 (2.5)
Interacting with people 9; 10.6 (2.4) 10; 10.4 (2.6) 12; 9.2 (2.2)
Friends and activities 9; 16.3 (3.9) 10; 13.8 (2.8) 12; 16.0 (2.8)
Intimacy 9; 12.3 (2.4) 7; 13.7 (1.6) 10; 14.0 (3.7)
Family 9; 8.6 (2.6) 10; 8.5 (1.9) 10; 9.1 (1.9)
Relationships and social activities at work 6; 8.2 (1.6) 7; 8.3 (1.4) 7; 7.7 (0.8)
Work 6; 9.8 (2.0) 7; 8.6 (1.6) 7; 9.0 (1.2)
School relationships and social activities at school 6; 8.0 (1.9) 10; 8.5 (1.3) 8; 6.4 (1.9)
Educational 6; 8.3 (1.6) 10; 7.2 (1.7) 7; 7.6 (1.9)
FESFS: frequency
Living skills 9; 12.9 (2.3) 10; 11.7 (2.4) 12; 11.9 (2.4)
Interacting with people 9; 11.0 (1.9) 10; 10.2 (2.7) 11; 9.2 (2.2)
Friends and activities 9; 13.9 (4.1) 9; 13.6 (2.5) 12; 15.1 (2.5)
Intimacy 9; 8.8 (4.1) 9; 9.2 (4.0) 11; 11.6 (5.5)
Family 9; 9.6 (2.5) 10; 8.7 (2.5) 11; 8.9 (2.3)
Relationships and social activities at work 6; 5.3 (3.4) 7; 5.9 (1.9) 7; 5.4 (1.5)
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TABLE 2 Baseline characteristics (continued )
Characteristic
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Work 6; 8.5 (4.6) 7; 8.7 (2.8) 7; 9.1 (2.4)
School relationships and social activities at school 6; 8.8 (1.7) 10; 8.4 (1.9) 8; 6.8 (2.4)
Educational 6; 8.5 (1.4) 10; 7.2 (2.4) 7; 7.6 (2.4)
BMI 10; 23.6 (4.5) 13; 22.5 (3.7) 13; 24.1 (6.4)
Blood pressure (mmHg)
Systolic 10; 108.1 (11.0) 12; 112.2 (10.1) 10; 114.8 (11.5)
Diastolic 10; 67.8 (7.8) 12; 69.6 (9.7) 10; 67.8 (5.7)
Waist circumference (cm) 9; 80.6 (11.4) 12; 76.3 (8.0) 11; 78.3 (13.3)
FPG (mmol/l) 5; 4.6 (0.2) 3; 5.0 (1.1) 6; 4.2 (0.4)
HbA1c 5; 30.4 (1.1) 2; 35.5 (2.1) 7; 30.7 (3.7)
Cholesterol (mmol/l) 6; 3.5 (0.3) 3; 3.9 (0.4) 7; 3.8 (0.6)
LDL (mmol/l) 6; 2.0 (0.2) 3; 2.1 (0.2) 6; 2.1 (0.5)
HDL (mmol/l) 6; 1.0 (0.3) 3; 1.5 (0.6) 7; 1.1 (0.5)
Triglycerides (mmol/l) 6; 1.0 (0.4) 3; 0.7 (0.2) 7; 1.0 (0.8)
Prolactin (IU/ml) 6; 163.2 (79.2) 3; 170.3 (35.9) 7; 268.6 (86.6)
Values are n; mean (SD) unless otherwise stated.
TABLE 3 Diagnosis over the lifetime of the trial
Diagnosis
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Psychosis diagnosis
No 10 (55.6) 5 (23.8) 4 (18.2)
Yes 8 (44.4) 15 (71.4) 18 (81.8)
Missing 0 (0) 1 (4.8) 0 (0)
Psychosis diagnosis: type
Unspecified psychosis 8 14 18
Acute polymorphic psychotic disorder 0 1 0
Comorbid diagnosis (to psychosis)
None 5 (62.5) 8 (53.3) 10 (55.6)
One comorbid disorder 2 (25) 5 (33.3) 6 (33.3)
Two comorbid disorders 1 (12.5) 2 (13.3) 0 (0)
Three comorbid disorders 0 (0) 0 (0) 2 (11.1)
Other diagnoses for those with no psychosis diagnosis
No diagnosis recorded 4 (40.0) 2 (40.0) 2 (50.0)
Other disorder with psychotic features 1 (10.0) 2 (40.0) 2 (50.0)
Other disorder 5 (50.0) 1 (20.0) 0 (50.0)
Values are n (%) or n.
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chapter 4 Outcome and results
Used with permission from Morrison et al.103 This is an Open Access article under theCC BY-NC-ND 4.0 license (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Treatment received and adherence
Overall, in the PI arm and the combined arm, 32 out of 39 (82.1%, 95% CI 66.5% to 92.5%)
participants received six or more sessions of CBT. In the combined and AP arms, 28 out of 43 (65.1%,
95% CI 49.1% to 79.0%) were exposed to AP medication for 6 consecutive weeks (Table 4).
Table 5 shows details of the treatment received (adherence). The treatment received (adherence) was
defined in the PI arm as attending six or more sessions of CBT, in the AP arm as any exposure to AP
medication for 6 consecutive weeks and in the combined arm as attending six or more sessions of
CBT and any exposure to AP medication for 6 consecutive weeks. Of the participants randomised to
TABLE 5 Treatment received (adherence)
Adherence
Treatment arm
PI (N= 18) AP (N= 22) Combined (N= 21)
n (%) 95% CI (%) n (%) 95% CI (%) n (%) 95% CI (%)
Treatment received (adherence)
PI 10 (55.6) 30.8 to 78.5 0 (0) 0 to 15.4a 7 (33.3) 14.6, 57.0
AP 2 (11.11) 1.4 to 34.7 14 (63.66) 40.7 to 82.8 1 (4.8) 0.1 to 23.8
Combined 4 (22.2) 6.4 to 47.6 2 (9.11) 1.1 to 29.2 11 (52.4) 29.8 to 74.3




14 (77.8) 52.4 to 93.6 16 (72.7) 49.8 to 89.3 11 (52.4) 29.8 to 74.3
Did not comply
with treatment
3 (16.7) 3.6 to 41.4 1 (4.5) 0.1 to 22.8 8 (38.1) 18.1 to 61.6
No treatment 0 (0) 0 to 18.5a 3 (13.6) 2.9 to 34.9 1 (4.8) 0.1 to 23.8
Withdrawn 1 (5.6) 0.1 to 27.3 0 (0) 0.0 to 15.4a 1 (4.8) 0.1 to 23.8
Unable to be captured 0 (0) 0.0 to 18.5a 2 (9.1) 1.1 to 29.1 0 (0) 0.0 to 16.1a
a One-sided 97.5% confidence interval.
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 4 Overall adherence
Indicator of adherence n/N (%) 95% CI (%)
Satisfactory delivery of adherent psychological therapya 32/39 (82.1) 66.5 to 92.5
Satisfactory delivery of AP medicationb 28/43 (65.1) 49.1 to 79.0
a Operationalised as attending six or more sessions of CBT.
b Operationalised as any exposure of AP medication for 6 consecutive weeks (this would include a dose below BNF
lower limits given that this is a frequent clinical practice for people of this age and the drugs are licensed for adults).
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the PI arm, 10 (55.6%) received PI exactly as allocated. In the combined arm, 11 (52.4%) participants
received their allocated treatment. In the AP arm, 14 (72.3%) participants received their allocated
treatment. Appendix 1, Table 31, gives reasons for crossovers.
Table 6 provides details of the treatment received (adherence) and the crossover to a different
treatment arm, with those who crossed over owing to deterioration removed. Of those who were
allocated PI who crossed over into the combined treatment, one did so a result of deterioration.
Of those who were allocated to the AP arm who crossed over into combined treatment, two did so
as a result of deterioration.
Secondary outcomes
The PANSS total and subscale scores at each time point are detailed in Table 7 along with the
treatment effects for the three arms. The PANSS percentage improvement is presented in Table 8.
Figure 3 shows the profile for the three treatment arms over the study period. For the comparison
of PI versus AP at 3 months, the PANSS total score was lower in the PI arm (–0.39 points, 95% CI
–8.39 to 7.60 points; p = 0.923). At 6 months this was the same, with a MD of –7.79 points (95% CI
–16.02 to 0.45 points; p = 0.064). At 12 months, PANSS total score was lower in the AP arm, with a
MD of 3.97 points (95% CI –6.80 to 14.74 points; p = 0.470). It is important to note that the number of
participants with a 12-month score is low (PI, n = 11; AP, n = 9). For the PI arm versus the combined
arm, at 12 months the PANSS total score was higher in the PI arm, with a MD of 5.62 points (95% CI
–4.91 to 16.15 points; p = 0.295). For the AP arm versus the combined arm, the PANSS total score was
higher in the combined arm (MD 1.63 points, 95% CI –10.22 to 13.49 points; p = 0.787).
At the 3-month assessment, the number of full blind breaks was three and the number of partial blind
breaks was seven. However, two participants with whom a partial break had occurred were transferred
to a new and independent assessor, which meant that that five assessments were partially unblinded.
At the 6-month assessment, the number of full breaks was three but one of the affected participants
was transferred to a new and independent assessor, which meant that two assessments were unblinded
at the 6-month assessment. At 6 months, the number of partial breaks was seven but one affected
participant was transferred to a new and independent assessor, which meant that six assessments were
partially unblinded.
At the 12-month assessment, the number of full breaks was three but one affected participant
was transferred to a new and independent assessor, which meant that two assessments were
unblinded. At the 12-month assessment, the number of partial blind breaks was four but three
affected participants were transferred to a new and independent assessor, which meant that one
assessment was partially unblinded.
TABLE 6 Treated received compliance (with crossovers as a result of deterioration removed)
Treatment received (adherence)
Treatment arm
PI (N= 17) AP (N= 20) Combined (N= 21)
PI 10 (58.8) 0 (0) 7 (33.3)
AP 2 (11.8) 14 (70.0) 1 (4.8)
Combined 3 (17.6) 0 (0) 11 (52.4)
None 2 (11.8) 6 (30.0) 2 (9.5)
Values are n (%).
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The QPR scores at each time point are detailed in Table 9, along with treatment effects. Figure 4 shows
the profile for the three treatment arms over the study period. For the PI arm versus the AP arm, QPR
scores at baseline show a difference between the PI (46.1) and the AP (42.1) arms. For PI versus AP
at 6 months, the QPR score was slightly higher in the AP arm, with a MD of –2.26 (95% CI –10.24 to
5.73; p = 0.579). The QPR score was higher for the combined treatment arm than for the PI arm at
6 months (MD –2.53, 95% CI –9.47 to 4.41; p = 0.474). For the AP arm versus the combined arm at
6 months, the combined arm had a higher QPR score (MD –0.49, 95% CI –7.18 to 6.20; p = 0.886).
Correlations across all time points for PANSS total and QPR scores are shown in Appendix 1, Tables 32
and 33. The other secondary outcomes are shown in Tables 10–13.
TABLE 8 The PANSS percentage improvement in score
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
> 25% improvement
3 months 7 (41.2) 8 (47.1) 8 (42.1)
6 months 10 (62.5) 11 (64.7) 5 (27.8)
12 months 6 (54.5) 8 (72.7) 6 (66.7)
> 50% improvement
3 months 2 (11.8) 2 (11.8) 3 (15.8)
6 months 5 (31.3) 5 (29.4) 4 (22.2)
12 months 3 (27.3) 3 (27.3) 3 (33.3)
> 75% improvement
3 months 0 (0) 1 (5.9) 0 (0)
6 months 1 (6.3) 1 (5.9) 0 (0)
12 months 1 (9.1) 1 (9.1) 0 (0)
Values are n (%).





























FIGURE 3 Profile of PANSS total scores.
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Values are n; mean (SD).























FIGURE 4 Profile of the QPR scores.
TABLE 10 Secondary outcome: AUDIT, DAST and HADS scores
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
AUDIT
Baseline 9; 7.7 (7.9) 11; 7.4 (8.6) 12; 6.8 (7.4)
3 months 7; 7.7 (7.7) 9; 9.9 (10.0) 12; 6.3 (6.3)
6 months 5; 7.6 (5.6) 8; 6.4 (7.6) 9; 6.1 (4.7)
12 months 4; 8.0 (5.5) 7; 4.7 (2.9) 6; 8.2 (6.0)
DAST
Baseline 9; 1.9 (1.8) 11; 2.5 (3.2) 12; 1.6 (2.3)
3 months 7; 2.0 (1.8) 10; 1.4 (2.1) 12; 1.0 (1.2)
6 months 6; 1.7 (1.4) 9; 2.1 (2.3) 9; 0.8 (1.6)
12 months 4; 1.5 (1.7) 6; 1.8 (1.8) 6; 1.5 (2.5)
OUTCOME AND RESULTS
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TABLE 10 Secondary outcome: AUDIT, DAST and HADS scores (continued )
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
HADS
Anxiety
Baseline 10; 11.2 (2.6) 13; 14.2 (2.5) 15; 12.7 (4.0)
3 months 10; 11.1 (3.9) 10; 11.1 (5.4) 13; 12.9 (4.1)
6 months 7; 10.1 (3.1) 10; 11.8 (4.1) 9; 11.9 (3.6)
12 months 4; 7.8 (3.9) 7; 8.0 (4.2) 7; 8.9 (3.2)
Depression
Baseline 10; 9.2 (3.8) 13; 10.2 (4.4) 15; 9.7 (5.1)
3 months 10; 7.8 (4.0) 10; 6.8 (3.0) 13; 9.3 (5.0)
6 months 7; 6.7 (4.5) 10; 7.3 (3.4) 8; 10.4 (5.4)
12 months 4; 5.3 (2.2) 7; 5.1 (4.2) 7; 5.6 (4.9)
Values are n; mean (SD).
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 11 Secondary outcome: SPEQ score
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Paranoia
Baseline 8; 31.5 (12.9) 13; 42.3 (14.8) 14; 41.8 (14.0)
3 months 9; 34.4 (15.8) 9; 26.9 (15.0) 11; 30.3 (21.2)
6 months 7; 24.1 (11.6) 8; 23.6 (16.2) 8; 31.9 (18.3)
12 months 4; 26.5 (19.2) 6; 20.0 (9.8) 5; 31.4 (18.5)
Hallucinations
Baseline 9; 23.4 (10.1) 12; 27.0 (6.6) 14; 27.4 (8.8)
3 months 10; 22.1 (11.2) 9; 15.1 (6.1) 12; 20.9 (8.7)
6 months 6; 10.8 (9.5) 8; 10.9 (7.9) 9; 17.9 (11.3)
12 months 3; 11.3 (12.1) 6; 6.8 (8.4) 6; 16.3 (7.2)
Cognitive disorientation
Baseline 9; 7.3 (2.9) 12; 9.1 (1.6) 13; 9.2 (2.6)
3 months 10; 6.9 (2.5) 9; 6.2 (3.6) 12; 8.3 (2.6)
6 months 6; 4.8 (3.6) 6; 6.8 (3.5) 8; 8.1 (3.3)
12 months 4; 2.8 (2.5) 5; 3.4 (3.8) 6; 7.8 (2.9)
continued
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TABLE 11 Secondary outcome: SPEQ score (continued )
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Grandiosity
Baseline 9; 6.1 (4.6) 12; 4.9 (6.5) 13; 3.9 (3.1)
3 months 9; 4.9 (6.1) 9; 3.0 (3.0) 11; 4.5 (6.4)
6 months 7; 3.9 (4.2) 8; 1.3 (0.9) 8; 5.3 (9.3)
12 months 4; 4.0 (3.7) 6; 0.7 (1.2) 4; 0.0 (0.0)
Anhedonia
Baseline 9; 27.2 (9.6) 11; 22.5 (8.7) 13; 18.8 (9.6)
3 months 10; 19.3 (10.2) 9; 22.2 (6.9) 12; 25.9 (10.7)
6 months 7; 24.7 (7.3) 8; 25.5 (9.2) 9; 20.2 (12.9)
12 months 4; 14.3 (13.0) 6; 24.3 (9.1) 6; 25.8 (12.4)
Values are n; mean (SD).
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 12 Secondary outcome: FESFS ability
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Living skills
Baseline 9; 13.3 (1.2) 10; 12.6 (1.6) 12; 11.8 (2.5)
3 months 6; 12.3 (2.0) 6; 14.2 (1.2) 12; 12.6 (2.2)
6 months 6; 12.3 (1.5) 7; 12.9 (1.8) 9; 12.6 (2.3)
12 months 4; 14.3 (1.7) 5; 12.8 (2.3) 7; 13.3 (2.6)
Interacting with people
Baseline 9; 10.6 (2.4) 10; 10.4 (2.6) 12; 9.2 (2.2)
3 months 5; 12.2 (1.3) 6; 13.2 (1.5) 12; 10.6 (2.4)
6 months 6; 11.8 (1.9) 6; 10.8 (2.1) 9; 10.4 (2.1)
12 months 4; 13.3 (3.1) 5; 11.4 (1.9) 7; 11.6 (2.1)
Friends and activities
Baseline 9; 16.3 (3.9) 10; 13.8 (2.8) 12; 16.0 (2.8)
3 months 5; 16.8 (1.6) 6; 19.8 (1.8) 11; 16.5 (3.0)
6 months 6; 19.0 (2.6) 7; 15.7 (2.1) 8; 17.1 (3.0)
12 months 4; 19.5 (3.1) 5; 17.0 (3.5) 7; 17.6 (5.1)
Intimacy
Baseline 9; 12.3 (2.4) 7; 13.7 (1.6) 10; 14.0 (3.7)
3 months 6; 12.3 (2.9) 6; 15.5 (2.0) 12; 13.4 (3.5)
6 months 5; 13.4 (2.7) 6; 15.8 (1.8) 7; 12.4 (3.9)
12 months 4; 16.3 (2.8) 4; 15.3 (3.3) 6; 14.0 (2.9)
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TABLE 12 Secondary outcome: FESFS ability (continued )
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Family
Baseline 9; 8.6 (2.6) 10; 8.5 (1.9) 10; 9.1 (1.9)
3 months 6; 9.7 (2.4) 5; 9.6 (1.9) 12; 8.8 (2.4)
6 months 5; 10.2 (1.3) 7; 9.3 (1.7) 9; 9.1 (1.8)
12 months 4; 9.8 (1.5) 5; 9.6 (1.3) 7; 8.7 (1.3)
Relationships and social activities at work
Baseline 6; 8.2 (1.6) 7; 8.3 (1.4) 7; 7.7 (0.8)
3 months 2; 8.0 (1.4) 3; 9.7 (0.6) 5; 8.6 (1.1)
6 months 3; 9.7 (2.1) 3; 9.3 (0.6) 6; 8.3 (1.2)
12 months 3; 8.7 (2.5) 2; 9.5 (0.7) 1; 10.0
Work
Baseline 6; 9.8 (2.0) 7; 8.6 (1.6) 7; 9.0 (1.2)
3 months 2; 9.5 (0.7) 3; 9.0 (1.0) 5; 8.6 (1.1)
6 months 3; 11.0 (0.0) 3; 9.7 (1.2) 6; 9.3 (0.5)
12 months 3; 10.7 (1.2) 2; 10.5 (0.7) 1; 10.0
School relationships and social activities at school
Baseline 6; 8.0 (1.9) 10; 8.5 (1.3) 8; 6.4 (1.9)
3 months 4; 9.5 (2.1) 5; 9.4 (1.1) 9; 7.4 (1.8)
6 months 3; 8.7 (1.5) 6; 7.5 (2.7) 7; 7.7 (1.3)
12 months 2; 8.0 (1.4) 5; 9.6 (1.9) 6; 7.7 (2.5)
Educational
Baseline 6; 8.3 (1.6) 10; 7.2 (1.7) 7; 7.6 (1.9)
3 months 4; 8.8 (1.0) 5; 8.0 (2.9) 10; 8.1 (1.7)
6 months 3; 8.7 (0.6) 5; 8.4 (1.8) 8; 7.3 (1.3)
12 months 2; 11.0 (0.0) 5; 9.0 (1.9) 6; 7.2 (2.9)
Values are n; mean (SD). If only one participant responded, then only n; mean is reported.
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 13 Secondary outcome: FESFS frequency
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Living skills
Baseline 9; 12.9 (2.3) 10; 11.7 (2.4) 12; 11.9 (2.4)
3 months 6; 12.5 (1.6) 6; 14.3 (1.4) 12; 12.3 (2.3)
6 months 6; 13.3 (2.9) 7; 12.7 (1.6) 9; 11.9 (2.0)
12 months 4; 13.3 (1.0) 5; 12.2 (3.1) 7; 12.7 (2.9)
continued
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TABLE 13 Secondary outcome: FESFS frequency (continued )
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Interacting with people
Baseline 9; 11.0 (1.9) 10; 10.2 (2.7) 11; 9.2 (2.2)
3 months 5; 11.6 (3.2) 6; 13.2 (1.2) 12; 10.6 (2.2)
6 months 6; 10.7 (2.7) 6; 11.5 (2.7) 9; 10.8 (1.5)
12 months 4; 11.8 (4.2) 5; 11.2 (3.3) 7; 11.6 (2.2)
Friends and activities
Baseline 9; 13.9 (4.1) 9; 13.6 (2.5) 12; 15.1 (2.5)
3 months 5; 16.6 (1.5) 6; 19.7 (1.6) 11; 16.7 (3.3)
6 months 6; 16.2 (4.5) 6; 16.8 (1.6) 8; 15.1 (2.4)
12 months 4; 17.0 (4.1) 5; 16.6 (3.3) 7; 17.3 (3.5)
Intimacy
Baseline 9; 8.8 (4.1) 9; 9.2 (4.0) 11; 11.6 (5.5)
3 months 5; 11.2 (5.6) 6; 9.2 (5.7) 12; 11.0 (5.8)
6 months 5; 9.2 (6.8) 7; 10.3 (6.3) 9; 7.6 (4.4)
12 months 4; 11.5 (8.2) 5; 10.0 (6.0) 7; 11.6 (4.0)
Family
Baseline 9; 9.6 (2.5) 10; 8.7 (2.5) 11; 8.9 (2.3)
3 months 6; 8.5 (3.2) 5; 10.6 (1.7) 12; 8.5 (2.4)
6 months 6; 9.2 (2.1) 7; 9.9 (1.1) 9; 9.3 (1.7)
12 months 4; 10.0 (1.6) 5; 9.4 (2.1) 7; 9.0 (1.6)
Relationships and social activities at work
Baseline 6; 5.3 (3.4) 7; 5.9 (1.9) 7; 5.4 (1.5)
3 months 2; 7.5 (2.1) 3; 7.7 (3.2) 5; 6.4 (2.7)
6 months 3; 10.3 (2.1) 3; 9.0 (2.0) 6; 5.8 (2.0)
12 months 3; 8.3 (3.8) 2; 9.0 (4.2) 1; 9.0
Work
Baseline 6; 8.5 (4.6) 7; 8.7 (2.8) 7; 9.1 (2.4)
3 months 2; 10.0 (1.4) 3; 9.3 (1.2) 5; 9.6 (2.1)
6 months 3; 11.3 (0.6) 3; 11.0 (1.7) 6; 9.2 (2.3)
12 months 3; 10.7 (1.5) 2; 11.5 (0.7) 1; 11.0
School relationships and social activities at school
Baseline 6; 8.8 (1.7) 10; 8.4 (1.9) 8; 6.8 (2.4)
3 months 4; 9.8 (2.1) 4; 9.5 (2.6) 9; 7.6 (2.6)
6 months 3; 3.3 (5.8) 6; 8.3 (1.2) 6; 7.5 (3.5)
12 months 2; 8.5 (0.7) 5; 9.4 (1.3) 6; 7.8 (3.2)
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Adverse effects
The analysis of adverse effects was by treatment received (safety), which was defined as at least one
dose of AP medication or at least one session of CBT. Table 14 shows the treatment received (safety).
Table 15 shows the deterioration in the PANSS total score at 3 months by treatment received at the
time of deterioration. Overall, nine participants suffered deterioration: four in the PI arm, one in the
combined arm, three in the AP arm and one participant who did not receive any treatment.
TABLE 13 Secondary outcome: FESFS frequency (continued )
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Educational
Baseline 6; 8.5 (1.4) 10; 7.2 (2.4) 7; 7.6 (2.4)
3 months 4; 9.0 (2.7) 5; 8.4 (3.3) 10; 8.1 (2.2)
6 months 3; 3.3 (5.8) 6; 6.2 (2.7) 7; 6.9 (2.3)
12 months 2; 11.5 (0.7) 5; 7.0 (3.2) 6; 6.5 (2.9)
Values are n; mean (SD). If only one participant responded, then only n; mean is reported.
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 14 Treatment received (safety)
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Treatment received (safety)
PI 9 (50.0) 7 (33.3) 1 (4.5)
Combined 8 (44.4) 12 (57.1) 3 (13.6)
AP 0 (0) 0 (0) 15 (68.2)
No treatment 1 (5.6) 1 (4.8) 3 (13.6)
Unable to be captured 0 (0) 1 (4.8) 0 (0)
Values are n (%).
TABLE 15 Deterioration in PANSS total score at 3 months by treatment received (safety) at time of deterioration
Deterioration
Treatment arm
None (N= 1)PI (N= 4) Combined (N= 1) AP (N= 3)
> 12.5% 1 1 2 0
> 25% 3 0 1 1
> 50% 0 0 0 0
Values are n.
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Overall, by treatment received, four (23.5%) participants experienced a SAE in the PI arm, eight
(34.7%) in the combination arm and two (13.3%) in the AP arm. Further details of the SAEs are
provided in Table 16, as well as the AEs. Table 17 shows the potential adverse effects measure and
Table 18 shows the adverse physical effects by treatment received. See Appendix 1, Tables 34–36,
for details by treatment allocation.











Participants with a SAE 4 (23.5) 8 (34.8) 2 (13.3) 4 (23.5) 0 (0)
Total number of SAEs 5 11 2 5 0
Participants with more than one SAE 1 (25.0) 2 (25.0) 0 (0) 1 (25.0) 0 (0)
Details
Voluntary psychiatric admission 0 3 0 0 0
Life-threatening (suicide attempt) 1 1 0 1 0
Serious violent incident 2 1 2 2 0
Admission to a general medical ward 2 1 0 2 0
Otherwise considered medically significant
(overdose of medication)
0 4 0 0 0
Otherwise considered medically significant
(ingested five painkillers)
0 1 0 0 0
Adverse events
Participants with an AE 5 (29.4) 16 (69.6) 13 (86.7) 3 (60.0) 0 (0)
Total number of AEs 10 35 41 3 0
Participants with more than one AE 3 (60.0) 9 (56.3) 9 (69.2) 0 (0) 0 (0)
Details
Self-harm 6 12 7 3 0
Medication side effect 0 17 28 0 0
Other AE 4 5 6 0 0
Distress reported regarding allocation 0 1 0 0 0
Deterioration in PANSS total score
6 months
> 25% 1 (6.3) 1 (5.3) 1 (7.7) 1 (33.3) 0 (0)
> 50% 1 (6.3) 1 (5.3) 1 (14.3) 0 (0) 0 (0)
12 months
> 25% 0 (0) 1 (7.7) 0 (0) 0 (0) 0 (0)
> 50% 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Values are n (%) or n.
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 18 Adverse physical effects by treatment received
Time point
Treatment received




Baseline 6; 16.0 (8.6) 12; 18.7 (8.5) 9; 15.4 (6.8) 4; 15.3 (6.5) 0 (0)
3 months 5; 8.2 (4.0) 10; 13.2 (4.9) 9; 13.6 (6.5) 1; 3.0 0 (0)
6 months 5; 7.4 (3.6) 8; 8.0 (4.6) 6; 13.8 (6.6) 2; 20.5 (7.8) 0 (0)
12 months 4; 5.5 (5.5) 7; 4.3 (3.6) 3; 14.3 (11.2) 2; 12.0 (7.1) 0 (0)
ANNSERS number of side effects
Baseline 6; 10.3 (5.3) 12; 11.9 (3.6) 9; 11.1 (4.8) 4; 10.3 (6.5) 0 (0)
3 months 5; 5.6 (2.3) 10; 8.7 (3.0) 9; 10.4 (5.4) 1; 3.0 0 (0)
6 months 5; 5.6 (1.5) 8; 5.9 (3.1) 6; 10.3 (5.0) 2; 11.0 (2.8) 0 (0)
12 months 4; 3.5 (3.5) 7; 3.4 (3.2) 3; 10.7 (7.8) 2; 9.0 (5.7) 0 (0)
Weight (kg)
Baseline 8; 69.3 (15.8) 13; 62.1 (11.3) 10; 67.8 (17.9) 4; 66.0 (22.5) 1; 60.5
3 months 7; 68.3 (16.1) 11; 69.7 (11.9) 9; 71.8 (17.5) 2; 79.3 (32.4) 0 (0)
6 months 6; 69.2 (13.2) 10; 71.3 (11.7) 7; 77.3 (19.4) 3; 66.0 (15.6) 0 (0)
12 months 5; 69.1 (13.4) 6; 75.4 (8.9) 4; 61.9 (11.8) 2; 78.5 (31.8) 0 (0)
Waist circumference (cm)
Baseline 7; 83.9 (13.2) 12; 75.4 (6.3) 9; 79.9 (14.3) 3; 72.0 (3.5) 1; 75.0
3 months 6; 74.8 (26.4) 11; 81.3 (7.1) 9; 85.0 (16.7) 1; 76.0 0 (0)
6 months 5; 78.4 (11.9) 10; 81.0 (8.3) 6; 85.9 (16.0) 3; 82.0 (10.4) 0 (0)
12 months 4; 84.3 (14.2) 6; 82.8 (3.2) 4; 86.0 (4.1) 1; 77.0 0 (0)
BMI (kg/m2)
Baseline 8; 25.2 (4.3) 13; 22.1 (3.5) 10; 23.0 (4.3) 4; 25.4 (10.8) 1; 21.6
3 months 7; 23.9 (4.7) 11; 24.6 (4.2) 9; 24.5 (4.4) 2; 32.6 (14.9) 0 (0)
6 months 6; 24.3 (4.3) 10; 25.2 (4.2) 7; 26.2 (4.8) 3; 23.5 (2.6) 0 (0)
12 months 5; 24.7 (4.3) 6; 25.1 (3.7) 4; 22.7 (3.7) 2; 32.2 (14.6) 0 (0)
Blood pressure (mmHg)
Systolic
Baseline 8; 107.8 (12.0) 12; 112.5 (9.8) 7; 114.8 (12.0) 4; 114.8 (10.4) 1; 100.0
3 months 7; 108.7 (12.2) 11; 113.4 (10.9) 10; 111.9 (10.5) 2; 113.5 (7.8) 0 (0)
6 months 6; 112.5 (13.4) 10; 113.8 (8.0) 7; 113.9 (13.6) 3; 122.3 (15.6) 0 (0)
12 months 3; 109.9 (11.0) 5; 108.5 (7.0) 3; 108.7 (8.5) 2; 114.3 (6.0) 0 (0)
Diastolic
Baseline 8; 69.0 (8.3) 12; 68.0 (9.4) 7; 68.5 (5.7) 4; 66.0 (5.4) 1; 80.0
3 months 7; 69.6 (7.0) 11; 70.5 (11.1) 10; 66.2 (12.6) 2; 66.5 (2.1) 0 (0)
6 months 6; 71.7 (4.1) 10; 69.5 (6.1) 7; 64.9 (8.8) 3; 69.7 (4.0) 0 (0)
12 months 3; 62.6 (6.0) 5; 65.3 (6.3) 3; 69.1 (6.4) 2; 65.0 (2.8) 0 (0)
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TABLE 18 Adverse physical effects by treatment received (continued )
Time point
Treatment received
PI (N= 17) Combined (N= 23) AP (N= 15) None (N= 5)
Unable to be
captured (N= 1)
Fasting estimates of plasma glucose (mmol/l)
Baseline 2; 4.4 (0.1) 5; 4.8 (0.8) 5; 4.3 (0.3) 2; 4.2 (0.8) 0 (0)
3 months 3; 4.4 (0.2) 2; 4.7 (0.1) 2; 4.3 (0.6) 0 (0) 0 (0)
6 months 2; 5.6 (1.9) 2; 4.5 (0.4) 1; 5.5 1; 5.0 0 (0)
12 months 1; 3.9 1; 4.1 0 (0) 0 (0) 0 (0)
HbA1c levels (mmol/mol)
Baseline 3; 30.7 (1.5) 3; 33.7 (3.5) 6; 30.3 (3.9) 2; 31.5 (2.1) 0 (0)
3 months 3; 31.7 (0.6) 2; 30.5 (2.1) 4; 31.8 (2.2) 0 (0) 0 (0)
6 months 2; 29.5 (0.7) 1; 35.0 2; 34.0 (4.2) 1; 30.0 0 (0)
12 months 1; 40.0 1; 35.0 1; 33.0 0 (0) 0 (0)
Lipids levels (mmol/l)
Cholesterol
Baseline 3; 3.6 (0.2) 5; 3.6 (0.5) 6; 3.9 (0.6) 2; 3.3 (0.1) 0 (0)
3 months 4; 4.1 (0.3) 2; 3.4 (0.4) 4; 4.6 (0.4) 0 (0) 0 (0)
6 months 2; 3.9 (1.3) 2; 4.5 (1.3) 2; 3.9 (0.0) 1; 3.1 0 (0)
12 months 1; 4.1 1; 4.0 1; 3.6 0 (0) 0 (0)
LDL
Baseline 3; 2.1 (0.2) 5; 2.0 (0.3) 5; 2.2 (0.5) 2; 1.8 (0.1) 0 (0)
3 months 4; 2.2 (0.3) 2; 1.8 (0.6) 4; 2.7 (0.4) 0 (0) 0 (0)
6 months 2; 2.4 (0.8) 2; 2.7 (0.8) 2; 2.5 (0.4) 1; 1.5 0 (0)
12 months 0 (0) 1; 2.2 1; 1.9 0 (0) 0 (0)
HDL
Baseline 3; 1.0 (0.4) 5; 1.3 (0.6) 6; 1.1 (0.5) 2; 1.4 (0.1) 0 (0)
3 months 4; 1.0 (0.2) 2; 1.1 (0.4) 4; 1.4 (0.3) 0 (0) 0 (0)
6 months 2; 0.9 (0.4) 2; 1.1 (0.2) 2; 1.1 (0.0) 1; 1.2 0 (0)
12 months 1; 1.1 1; 1.6 1; 1.3 0 (0) 0 (0)
Triglyceride levels
Baseline 3; 1.1 (0.5) 5; 0.8 (0.3) 6; 1.0 (0.8) 2; 0.7 (0.1) 0 (0)
3 months 4; 1.8 (0.3) 2; 0.7 (0.2) 4; 1.2 (0.5) 0 (0) 0 (0)
6 months 2; 1.3 (0.3) 2; 1.8 (1.4) 2; 1.1 (0.1) 1; 0.8 0 (0)
12 months 1; 7.2 1; 0.6 1; 0.7 0 (0) 0 (0)
Serum prolactin levels (µg/l)
Baseline 3; 174.3 (56.0) 5; 173.8 (75.3) 6; 246.7 (70.5) 2; 249.0 (213.5) 0 (0)
3 months 4; 138.5 (40.1) 2; 162.0 (176.8) 3; 503.7 (481.8) 0 (0) 0 (0)
6 months 2; 197.5 (20.5) 1; 130.0 2; 234.0 (90.5) 1; 336.0 0 (0)
12 months 1; 87.0 1; 150.0 1; 200.0 0 (0) 0 (0)
Values are n; mean (SD). If only one participant responded, then only n; mean is reported.
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
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Psychological intervention
The median number of CBT sessions attended was 14 in the PI arm and 15 in the combined arm
(Table 19). In the PI arm, the median number of days to the first recorded CBT session was 15
(IQR 6–44) and in the combined arm it was 14 (IQR 7–19). The number of participants for whom
therapy milestones were achieved and between-session tasks were completed is shown in Table 19.
At the end of CBT, trial therapists were asked to indicate their perspectives about client engagement
with the sessions and with between-session tasks, and the barriers to the delivery of CBT. Therapists
were asked to suggest amendments to the treatment manual for a definitive trial. Nine out of 13
(69.23%) therapists who made a protocol amendment suggestion proposed that a longer therapy
window would be beneficial to accommodate periods of disengagement, impact of risk on delivery of
therapy, accommodate school/college exams and provide a longer engagement window. These data are
presented in Table 20.
TABLE 19 Cognitive–behavioural therapy session
CBT
Treatment arm
PI (N= 18) Combined (N= 21)
Received CBT 17/18 (94.4) 20/21 (95.2)
Number of CBT sessions attended
1–5 3 (17.6) 2 (10.0)
6–10 2 (11.8) 5 (25.0)
11–20 6 (35.3) 12 (60.0)
> 20 6 (35.3) 1 (5.0)
Overall, n; median (IQR) 17; 14 (9, 23) 20; 15 (9, 17)
Overall number of CBT sessions attended by site, n; median (IQR)
Manchester 7; 12 (4, 29) 7; 14 (9, 18)
Oxford 6; 12 (6, 23) 9; 15 (8, 17)
Other sites 4; 18 (14, 25) 4; 14 (17.5, 19)
Milestones
First session within 1 week of randomisation 6 (35.3) 6 (30.0)
Shared list of problems and goals by session 3 17 (100.0) 19 (95.0)
Shared formulation by session 3 16 (94.1) 19 (95.0)
Out in the world session by session 10 1 (5.9) 4 (20.0)
Longitudinal formulation by session 26 10 (58.8) 8 (40.0)
Between-session tasks, n; median (IQR)
Client between-session tasks set 17; 12 (4, 23) 20; 12 (7, 16)
Client between-session tasks complete 17; 9 (2, 17) 20; 7 (4, 10)
Therapist session tasks set 17; 12 (4, 21) 20; 12 (6, 14)
Therapist session tasks complete 17; 11 (4, 19) 20; 8 (5, 12)
Percentage of school- or college-based sessions, mean; SD (range) 31.03; 37.34 (0–100) 28.15; 38.08 (0–100)
Values are n (%) unless otherwise stated.
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Table 21 shows the details of the FI sessions. Nine out of 18 (50.0%) participants in the PI arm, and 12
out of 21 (57.1%) participants in the combined arm, received FI. Table 21 also shows the trial therapists’
perspective regarding their clients’ engagement with between-session tasks and engagement, as well as
barriers to the delivery of FI.
TABLE 20 End of CBT
CBT
Treatment arm
PI (N= 18) Combined (N= 21)
End of therapy session 15/17 (88.2) 19/20 (95.0)
Therapists’ perspective regarding participant engagement with between-session tasks
All of the time 2 (13.3) 1 (5.3)
Most of the time 7 (46.7) 12 (63.2)
Sometimes 6 (40.0) 5 (26.3)
Never 0 (0) 1 (5.3)
Therapists’ perspective regarding client engagement
Very well 4 (26.7) 5 (26.3)
Moderately well 7 (46.7) 9 (47.4)
Not very well 4 (26.7) 5 (26.3)
Therapists’ perspective on barriers to engagement with CBT
Memory problems 0 (0) 2 (10.5)
Attention/cognitive problems 1 (6.7) 8 (42.1)
Negative symptoms 1 (6.7) 4 (21.1)
Tangential/pressured speech 0 (0) 0 (0)
Missed appointments 4 (26.7) 6 (31.6)
Difficulty researching a shared goal 0 (0) 1 (5.3)
Difficulty tolerating strong emotions in session 2 (13.3) 6 (31.6)
Trust issues/guarded 2 (13.3) 3 (15.8)
Thought disorder 0 (0) 1 (5.3)
Non-disclosure owing to minimising problems 3 (20.0) 4 (21.1)
Non-disclosure owing to fears about service response/therapist reactions 1 (6.7) 3 (15.8)
Interference from mood during the session (i.e. low mood) 1 (6.7) 7 (36.8)
Engagement issues 5 (33.3) 9 (47.4)
Unable to make use of talking therapy (i.e. monosyllabic) 0 (0) 5 (26.3)
Stressful life events 4 (26.7) 3 (15.8)
Late attendance so less session time 0 (0) 1 (5.3)
Attendance problems 5 (33.3) 3 (15.8)
Under the influence of alcohol/substances 0 (0) 2 (10.5)
Unusual experiences in session (e.g. voice hearing or persecutory beliefs) 1 (6.7) 4 (21.1)
Values are n (%).
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TABLE 21 Details of the FI sessions
FI
Treatment arm
PI (N= 18) Combined (N= 21)
Received family therapy 9/18 (50.0) 12/21 (57.1)
Number of family sessions attended
1 1 (11.1) 2 (16.7)
> 1 8 (88.9) 10 (83.3)
Overall, n; median (IQR) 9; 3 (2, 5) 12; 4 (2, 5)
Overall number of CBT sessions attended by site, n; median (IQR)
Manchester 3; 2 (1, 5) 5; 4 (3, 5)
Oxford 3; 3 (2, 5) 5; 2 (1, 5)
Other sites 3; 3 (3, 7) 2; 3.5 (2, 5)
Milestones
First session within 4 weeks of randomisation 1 (11.1) 1 (8.3)
End of therapy session 8/9 (88.9) 11/12 (91.7)
Therapists’ perspective regarding participant engagement with between-session tasks
All of the time 0 (0) 1 (9.1)
Most of the time 5 (62.5) 1 (9.1)
Sometimes 3 (37.5) 9 (81.8)
Therapists’ perspective regarding client engagement
Very well 1 (12.5) 1 (9.1)
Moderately well 6 (75.0) 5 (45.5)
Not very well 1 (12.5) 5 (45.5)
Therapists’ perspective on barriers to engagement
Missed appointments 1 (12.5) 2 (18.2)
Difficulty reaching a shared goal 1 (12.5) 2 (18.2)
Difficulty tolerating strong emotions in session 2 (25.0) 1 (9.1)
Trust issues/guarded 1 (12.5) 3 (27.3)
Non-disclosure owing to minimising problems 0 (0) 3 (27.3)
Non-disclosure owing to fears about service response/reaction from therapist 0 (0) 0 (0)
Engagement issues 1 (12.5) 1 (9.1)
Stressful life events 3 (37.5) 3 (27.3)
Participant unwilling to invite family members 2 (25.0) 1 (9.1)
Family members unwilling to be involved 0 (0) 1 (9.1)
Family arguments in session 1 (12.5) 3 (27.3)
Values are n (%) unless otherwise stated.
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Fidelity to the CBT model was evaluated using seven audio-recordings of the therapy sessions
(each therapist had one CTS-R tape rated). Table 22 provides descriptive statistics for the total
fidelity ratings.
Antipsychotic medication
For those allocated to receive AP medication, the median number of days to prescription was 18
(IQR 10–42). Fifteen out of 43 participants did not meet the AP medication success criteria, for the
following reasons: participant declined AP medication (n = 3), clinician did not prescribe AP medication
(n = 3), both participant and family jointly decided to decline AP medication (n = 1) and data could not
be extrapolated from the medical records (n = 8).
Among those who were in receipt of AP medication the mean duration on medication was 31.5 weeks
(SD 14.6 weeks, minimum 8.7 weeks and maximum 52 weeks). Fourteen participants switched from
one AP medicine to another during their involvement in the study. Details of which AP medication
were prescribed and their dose ranges are provided in Table 23.
The return rate of self-reported medication adherence was low. The number of completed measures
and descriptive statistics are presented in Appendix 1, Table 37.
Health economics
EQ-5D-5L scores at all time points are shown in Appendix 1, Table 38. Scores were well balanced
at baseline between the arms. Over the time period the EQ-5D-5L increased but the number of
participants responding was small: [n, mean (SD)] PI arm 4, 0.763 (0.252), combined arm 6, 0.815
(0.250) and AP arm 4, 0.804 (0.133). NHS resource use at baseline and follow-up time points is shown
in Appendix 1, Tables 39–42. At 12 months, one participant (5%) in each of the combined arm and the
AP arm reported having attended hospital outpatient appointments that lasted for ≤ 4 hours and two
participants (11%) in each of the PI arm and combined arm reported having attended an accident and
emergency unit. The number of participants who reported NHS resource use was small.
TABLE 22 Fidelity ratings
Statistic CTS-R fidelity (n= 7)
Mean (SD) 39.71 (3.72)
Range 34–46
Percentage achieving a pass on the CTS-R 85.71%
Note
Scores of ≥ 36 are required for competence.
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TABLE 23 Antipsychotic medication and dose range prescribed
AP medication Frequency of prescriptiona
Actual dose
prescribed (mg) Lowest dose (mg) Highest dose (mg)
Aripiprazole 21 19; 7.3 (2.9) 19; 4.9 (1.5) 20; 10.0 (5.6)
(5, 15) (2, 10) (5, 25)
Risperidone 10 10; 2.0 (0.9) 10; 1.2 (0.6) 10; 2.7 (1.5)
(1, 4) (0.5, 2) (1, 6)
Quetiapine 9 8; 173.4 (109.3) 8; 65.6 (42.1) 8; 281.3 (215.4)
(50, 312.5) (25, 150) (50, 600)
Olanzapine 2 1; 10 1; 10 1; 10
Amisulpride 1 1; 75 1; 50 1; 100
a Number of times prescribed includes either a first or a second AP medication trialled between participants (in contrast
to within).
Values are either n; mean (SD), (minimum, maximum) or n; mean.
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chapter 5 Qualitative results
A total of 46 semistructured interviews were carried out with clinicians with prescribing responsibilityfor young people who experience psychosis (n= 17); young people who participated in MAPS (n = 13);
and family members of trial participants (n = 16; 18 family members). Full participant characteristics are
shown in Appendix 1, Tables 43–45.
Clinician results
Three thematic areas of importance were identified from the interviews with clinicians: an overarching
theme of ‘clinical decision-making’ and two subordinate thematic groupings that describe ‘professional
and organisational influences’ and ‘trial factors’. These thematic areas are illustrated in Figure 5, and are
discussed in detail in the following sections.
Clinical decision-making
A single overarching theme (clinical decision-making) mediated all potential referrals to MAPS.
Underpinning this were two subordinate themes: (1) professional and organisational influences and
(2) factors associated with the trial. The thematic structure is depicted in Figure 1, and is described
with illustrative quotations from participants. Clinicians were concerned with the diagnostic assessment
of FEP and consistently highlighted the need for clinical judgement in this process (partly to ensure
assessment accuracy and partly to evaluate risk). Clinicians described the need for clinical judgement in
determining individually appropriate treatment (weighing likely benefits and costs). Temporal factors
(time and timing) were also important in their clinical decision-making, such as extended assessment
periods to ensure reliable diagnosis or immediate treatment to reduce risk or distress.
Assessment and diagnosis: diagnostic uncertainty and clinical judgement
A central concern among all clinician interviewees was the importance of assessment and diagnosis of
FEP when considering a referral to MAPS. They recognised that reliably identifying a FEP in adolescents
is often very difficult. Along with uncertainty around distinguishing between sub threshold at-risk
mental states and FEP, clinicians also highlighted the importance and complexity of assessing for
neurodevelopmental difficulties, including autism spectrum features and personality, or the impact of
environmental stressors among adolescents in particular:
Sometimes it can be more complicated in a child or an adolescent to make a very confident diagnosis,
because you might have to watch and wait, you might have to see how symptoms develop over time,
often things are not as clear-cut as they might be in somebody who is an adult, and you don’t always get
textbook presentations in children, and also you have other developmental considerations to think about,
such as learning, cognitive ability, there might be difficulties within the family or social settings, they
might be looked-after young people living in a children’s home, you need to take all that into account so,








• Duty of care and safety
• Treatment beliefs
• Organisational context
• Assessment and diagnosis
• Treatment and management
• Time and timing
• Randomisation and control
• Burden or resource
• Improving evidence with
    an uncertain sample
FIGURE 5 Clinicians’ views on factors that influence referral to MAPS.
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Standardised psychiatric and psychological assessments for psychosis, such as the PANSS measure that
was used in MAPS, were viewed as inadequate alone to resolve this diagnostic uncertainty:
I’ll see people who have experiences and are distressed by those experiences who might on a measure like
PANSS might not quite make whatever the particular grade is at that PANSS in time to be part of the
service but who I think very strongly that they would benefit from the service. At the same time, I might
meet young people who would score on such instruments who I think are not best suited by the service
and conceptualising their difficulties in that way is not the best to kind of formulate things forward.
C01
Instead, clinicians stressed the importance of using their own clinical judgement during assessment
processes. Key additional dimensions central to meaningful assessment included risk, distress and
severity of psychosis.
Treatment and management
There was strong consistency in clinicians’ experiences of treatment of adolescent psychosis. AP
medication was commonly viewed as a necessary and helpful first-line treatment for FEP, and AP
prescribing was perceived to be a key responsibility for clinicians:
If I was convinced that somebody had a psychotic illness I wouldn’t withhold antipsychotic medication
to wait for therapy, you know I would see it as sort of my primary function as a psychiatrist to use the
treatments that I can to try and help somebody get better, so if I thought that was appropriate I wouldn’t
sort of wait to do that.
C07
Key considerations for treatment decisions included the young people’s levels of distress and risk,
along with the objective severity of their symptomatology:
As the level of disturbance increases and the level of risk and the level of impairment increases, the
priority is to try and reduce that risk as soon as possible, and antipsychotics can be very helpful with that.
C17
The clinical value of AP medication was nonetheless weighed against the potential serious adverse
effects, particularly when prescribed to children and young people, who were viewed to be more prone
to side effects. This was a further reason why such emphasis was placed on the care that is needed in
conducting a reliable assessment:
You cannot just start medication based on PANSS [score]. You might realise your mistake after a year.
C05
Given that clinicians placed such importance on using their own clinical judgement to make individual
treatment decisions, it was unsurprising that referring to a trial in which treatment was allocated by
randomisation could be challenging:
I’ve referred a couple of people in and actually I found it quite difficult and they were kind of randomised
to the opposite of what I might have chosen to do if I’d had a clinical decision, so that, that did require a
degree of kind of trust.
C11
Time and timing
Clinicians also highlighted the importance of timing in assessment and treatment decisions, making it
clear that, in contrast to the standardised phases of a clinical trial, in the ‘real world’ the timing of
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assessment and treatment decisions is far more varied. In some cases, the importance of timing in
clinical practice relates to the need for urgent treatment to alleviate severe distress or risk:
It partly just really depends on the young person and where we sadly ended up last week was that her,
her positive symptoms, her psychotic symptoms became far more apparent when we did the second
home visit.
C03
Clinicians also discussed the value of prolonging assessment periods to ensure the reliability of a
psychosis spectrum diagnosis, and subsequent treatment decisions:
There’s a degree of uncertainty when we start off about quite what might be happening for the young
person so it’s not always clear-cut for me whether you know medication’s . . . something we’re going to be
prescribing right at the start so you know there’s often a period of assessment before we’d be considering
whether that’d be an option for someone.
C04
Professional and organisational influences
The first of the two subordinate thematic areas constructed from clinicians’ feedback encompasses the
range of underlying influences that underpin and drive their clinical decision-making, which in turn
have implications for referral to a trial such as MAPS.
Duty of care and safety
A dominant idea within this theme was clinicians’ own responsibility for the prescription of AP
medication. Most described caution about both diagnosis and treatment of psychosis in children or
adolescents, especially in relation to AP treatment:
We need to be more careful about these younger people in (a) giving a diagnosis that is as significant as
psychosis and (b) using antipsychotics.
C16
However, some clinicians expressed a concern around the potential harm of not prescribing AP
medication. This often related to the perceived need for immediate pharmaceutical treatment to
alleviate risk or distress, but was also discussed as an important factor in long-term outlook:
If I thought they had a psychosis I wouldn’t wait to treat them, because we know that duration of
untreated psychosis is you know a risk for adverse outcome.
C07
Some also expressed some concern about the delivery of psychological treatment alone to young
people with psychosis. Although this concern involved the absence of AP medication, echoing concerns
detailed above, it was equally grounded in direct observation of suboptimal outcomes from CBT:
I do worry that people who go for a CBT alone approach do worse, I’ve seen them a few years after
they’ve finished their CBT and they want more CBT, they’ve not taken any medication, they’re frankly
psychotic . . . as a clinician that can be quite distressing to see, people who’ve really avoided medication or
had very very tiny bits, have never got completely better, have had grumbling psychotic symptoms, but
they’ve managed them better while they’ve had the high intensity support of a CBT therapist but when
that stops and the person loses that support they continue to have the symptoms.
C12
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Treatment beliefs
Treatment decisions were influenced by clinicians’ prior beliefs about treatment. Clinician interviewees
held a range of views on the relative benefits and risks of AP medication and psychological treatments
(CBT/FI). Along with the professional caution described in relation to treatment risks, interviewees
described perceived benefits of both of the treatment types offered in MAPS. For some, AP treatment
was seen as essential for the most unwell young people, in part because of its perceived capacity to
deliver beneficial effects quickly:
We’ve had a few under-18s who, a couple who weren’t in the trial who were very floridly psychotic and
were actually admitted to paediatric wards because they were so unwell, and there was no doubt there
that the appropriate thing to do was to start antipsychotic medication first.
C11
Antipsychotic medication was also seen by some to be important or even essential in the longer term
to prevent relapse in young people with psychosis or after previous treatments have not helped:
I can think of a few cases where you know we’ve had very young people . . . 14 to 18 [years] who’ve been
admitted to the [adolescent inpatient] unit with kind of bona fide persistent paranoid psychosis with
thought disorder, negative symptoms, horrendous kind of schizophreniform illnesses, and have responded
very well to for example clozapine or other antipsychotics, after other treatments have failed.
C13
Both of the psychological treatments offered within MAPS (CBT and FI) were viewed as valuable.
Participants believed that they could be very helpful for dealing with a range of difficulties, such as
low mood:
. . . if they are experiencing hearing voices but actually the primary problem is actually they’re struggling
more with their mood or engaging with education if we were to do a psychological piece of work that’s
gonna have much more of an impact than medication possibly with that.
C09
However, several clinicians voiced caution around the potentially limited capacity of individual
young people to engage with psychological treatments, a concern not evident in discussions around
AP medication:
. . . particularly quite young people, often that they find it quite difficult to describe their experiences or to
talk about what’s going on so I’m thinking that sometimes that decision between CBT and medication is
about that ability to be able to talk and think and tolerate their distress, and we have had some people
who you know are very distressed and you just can’t really get them to describe their experiences, you
can’t really get them to talk to you very much.
C11
The psychological treatments offered in MAPS (CBT or FI) were sometimes described as a more
appropriate treatment approach than medication for certain (non-psychotic) difficulties:
It’s thinking about what actually are the specific difficulties the young person may be having for example,
if they are experiencing hearing voices but actually the primary problem is actually they’re struggling more
with their mood or engaging with education if we were to do a psychological piece of work that’s gonna
have much more of an impact than medication possibly with that.
C09
It was evident that psychological treatment was viewed as most useful when used in combination
with AP medication, as there was potential for positive interaction between the two treatments.
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That is, as well as providing a benefit in its own right, AP medication could enable young people to
undertake and make the most use of psychological therapy:
When people are at their most unwell, that’s really difficult to even engage with and usually they’re the
people who are saying you know I don’t want CBT . . . and actually medication can sometimes move them
forward to the point where actually they can then engage with the CBT, in a different way.
C08
Organisational context
Clinicians represented both EIP services and CAMHS (also known as Healthy Young Minds), in which
the youngest young people referred to MAPS were seen. Clinicians identified that populations
attending the different services presented differently and had different needs, and moreover that the
expertise and capacity within the services and the treatments available differed:
Often I guess the younger ones . . . in terms of you know their developmental stage, some of the issues
they will present with might be different, and also I think sometimes in that early adolescent period
it’s obviously a time when many people might have, you know, emotional symptoms anyway in the
population, so sometimes kind of teasing out what represents a sort of pathological process can be, you
know, the task for anyone.
C04
Differences between service settings also included important perceived variations in the diagnostic
assessment expertise located in either service type. CAMHS, for example, was seen by several
interviewees to offer more holistic psychological/psychiatric assessments that were more appropriate
for the youngest young people:
EI [early intervention] covers a wide age range and it’s purely staffed by adult psychiatrists, so it’s difficult for
me when I’ve seen say a 15-year-old and felt they were psychotic and then for an adult EI clinician to come
around and say ‘well I think you they’ve got a personality disorder’, when they don’t see, bluntly they’re not
experts in adolescent psychopathology and what an adolescent truly, what a generically psychologically
unwell adolescent looks like because all of them are a bit dysregulated, all of them are a bit chaotic.
C15
There was, however, a perceived strength in the psychosis-specific expertise offered by EIP teams that
was not always available among CAMHS clinicians:
Because a lot of the first-episode psychosis now does not sit within CAMHS . . . the experience of that
within CAMHS has actually reduced, so we don’t have staff members that are used to regularly asking
kids about psychotic symptoms, their experience and comfort levels with that has gone down.
C10
Something that was similar across settings was the lack of availability of PI, and accessing this type of
treatment was viewed as an important organisational driver to referring young people to MAPS:
Sometimes my kind of experience of psychological therapy is coloured by often that it’s something that’s
harder to deliver in as timely a manner as might be ideal and that sometimes it means that it’s coming
online often much later down the line.
01
Trial factors
The second subordinate theme drawn from clinicians’ interviews concerned factors specific to MAPS.
These factors interacted with the clinical influences described above, and could act as facilitators of or
barriers to referral decisions.
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Randomisation and control
Clinicians highlighted some concern around having less control over treatment, especially AP
prescribing, if their young people were in a randomised trial:
What I’d worry about is if you came in and screened everyone who was 14 to 18 [years] with PANSS and
got them all into the trial . . . there’s going to be some false positives where the psychiatrist might not
want to prescribe an antipsychotic but perhaps feel pressure to because of the trial.
C06
It is important to note that clinicians recognised that MAPS did not prevent young people from
accessing alternative treatment resources (e.g. psychotherapy) and did allow medication decisions to
remain in prescribers’ hands, regardless of a young person’s trial allocation:
Yeah there’s certainly been people where I’ve seen them and I’ve decided not to on seeing them, even
though they’re in the trial I’ve decided not to give them antipsychotics.
C16
Burden or resource
Some clinicians suggested that their involvement with MAPS involved a degree of additional workload
or pressure, for example in decision-making or communication around treatment. One clinician recalled
a specific incident of concern around communication with trial staff (subsequent communication of this
concern ensured that further similar situations were unlikely):
Sometimes I’ve seen somebody I’m worried about and then I’ve been e-mailing and there’s not been
anything and a week and a half has gone by and I’m thinking ‘if anything happens now’, I would have
prescribed an antipsychotic when I saw this person, now nothing’s happened, that person has been in
distress coming up to 2 weeks, they’re a bit risky.
C16
However, more frequently clinicians found that the trial offered important additional resources,
especially clinical psychology (CBT/FI). Clinicians valued that the trial frequently offered access to
psychological treatments far more quickly than was typical in services, and that trial-based therapists
had the capacity to offer longer or more comprehensive courses of therapy:
So MAPS is great ’cos one young person who’s got shedloads of psychological therapy who we may have
wished to treat with psychological therapy but without the MAPS trial we would not have been able to
do that.
C01
Improving evidence with an uncertain population
Clinicians perceived that MAPS had the potential to improve the limited evidence base for treating
psychosis in young people. However, some voiced uncertainty around the ultimate value of this trial’s
results. It was recognised, for example, that the level of treatment resource in the trial may be
unrealistic when compared with typical NHS service capacity and, therefore, study results may not be
generalisable to everyday clinical settings:
The study might show that the CBT is effective, but we’re starting CBTp incredibly quickly. I think you
would have to then be able to offer it very quickly if you were rolling it out as a treatment because also
what you’re not testing in the study is waiting 6 months for your CBTp.
C15
The diagnostic uncertainty around young people with psychosis spectrum experiences could also affect
the perceived validity of the trial’s results. Clinicians argued that if trial inclusion criteria do not
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adequately reflect clinician’s own diagnostic judgement then it is difficult to have confidence in
generalising results from the sample included in the trial:
There will be many people in the MAPS study . . . that on reflection haven’t had first-episode psychosis . . .
they might’ve met criteria but actually there’s you know there’s lots of reasons why people could meet
criteria and it doesn’t mean they’re psychotic.
C16
Participants’ results
These findings are organised around the two thematic areas of importance: (1) being part of a trial, and
(2) receiving treatment. Each is described in turn, supported by illustrative quotations from the young
people. See Figure 6 for the thematic structure.
Being part of a trial
Participants described the process of becoming part of a randomised clinical trial. For these young people,
randomisation to treatment had in fact been a relatively minor concern, with aspects of referral and
assessment processes, along with general access to treatment, featuring more prominently in their feedback.
Entry to MAPS
Access to treatment
The over-riding motivation for taking part in the trial was continued help-seeking; that is, participants
were seeking further specialist support, either in addition to local mental health services or more
quickly than services could typically offer. Timely access to the psychological treatments offered in
MAPS was, therefore, often seen as a primary benefit of participation:
With services like that . . . it kind of takes a while to sort of get like anything done really, but I think cos
[RA] like spoke through it all and it was either medication or therapy or both so that would be like
straight away like right there.
Young person (YP) 13
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FIGURE 6 Participant perspectives of MAPS.
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Study information material
Entering the trial was perceived to involve a requirement to engage with a lot of information, the
key sources of which were discussions with trial staff and the study participant information sheet.
Participants viewed both as trusted sources of information; however, the amount of information and
technical details of the participant information sheet could be problematic, as some had difficulties
with comprehension or concentration (‘I disorientate a lot’, YP04). This was seen as especially
challenging for younger participants and those with learning difficulties, such as dyslexia:
When you hand me a big sheet of writing I’ll not read it, because I can’t break it down.
YP03
Several participants indicated that they had not paid much attention to study information (‘I was
younger back then, so I didn’t really read them’, YP09) and had relied on family members, clinicians or
trial staff to explain and retain participant information sheet details:
As long as mum knows what’s going on then she can explain it to me in a way that I will understand.
YP07
All participants had been referred from specialist mental health teams (CAMHS, EIP). A key step in
this process was encounters with clinical service staff who made the referral (e.g. care co-ordinators,
psychiatrists) and RAs who consented participants and conducted baseline assessments. Participants
particularly valued RAs’ emphasis on choice in terms of trial entry, adherence to treatments and
continued engagement with the trial:
They always said you know if at any point you don’t wanna do it, if at any point, you know they made it




Participants frequently highlighted the benefit of RAs’ practical flexibility around assessment meetings,
including offering a choice of meeting locations and times that suited the participant, sending
appointment reminders by text message and rearranging meetings during difficult times:
[RA] was really good . . . where’s good for you to meet where’s you know, and it’s always nice when
someone’s like that cos you know it shows that they actually value your time.
YP10
The interpersonal qualities that RAs demonstrated during assessments were perhaps the most
frequently discussed facilitating factor identified by participants (e.g. ‘warm and welcoming’, YP03).
Feeling comfortable with RAs was considered particularly important for disclosing personal information
and building trust:
I was meeting [RA], and she was like so kind I could’ve like talked to her like with everything, you know.
YP01
Participants were also given a small financial token (£10) at each assessment; this was intended to help
incentivise attendance and demonstrate to participants that their involvement was materially valued.
Feedback from participants was understandably positive about this aspect.
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Barriers to engagement
Participants also discussed aspects of assessments that could be considered barriers to engagement
with RAs. Completing assessment measures, for example, was seen by some as repetitive or ‘boring’
(YP07). Participants also commonly described difficulty in ‘opening up’ (YP09) about their experiences
during these assessments:
Nothing against [RA] but it’s just some things that are like quite personal you know they’re a bit difficult
to talk about.
YP02
Several participants also found it hard to verbalise their concerns owing to difficulties with learning
and comprehension [dyslexia (YP03), autism (YP06) and memory (YP03)]. Specific questions about use
of drugs or alcohol were also viewed by one participant as unwelcome (YP09). A common cost
associated with assessments was unease or physical pain related to blood sampling (optional):
I’ve never had my blood taken before . . . we did try once but yeah she missed my vein . . . so then she had




The relative acceptability of treatment allocations is an essential consideration when assessing the
overall feasibility and acceptability of a clinical trial. Although all of the trial participants demonstrated
acceptance of MAPS treatments by consenting to be randomised, participants’ recall of their entry to
the trial indicated variations in degrees of treatment acceptability. The range of views describing this
variation were characterised overall by a general belief that any treatment type could potentially be
helpful and, therefore, acceptable:
Didn’t know what was like going on with me and stuff like I didn’t understand like why I heard stuff so
I thought . . . if it’d help then I wouldn’t mind any of them.
YP12
Treatment preferences
Although some participants’ treatment preferences prior to randomisation were based purely on
expectation (what may happen), others were informed by previous experience or observation (e.g.
family members’ mental health treatment). Participants often reported that CBT was preferred over AP
medication, and this was commonly influenced by the perceived benefits of ‘talking to someone’, along
with concerns or uncertainty about side effects of the medication:
When I looked like through the different like [medication] side effects and symptoms . . . I started like
freaking out a bit, whereas I think like talking to someone’s a lot easier.
YP02
By contrast, three participants indicated a preference for medication over therapy. For one participant
this was a change of view after undertaking CBT within the trial, whereas the other two participants
preferred medication from the outset. Although concern about AP medication was more common, in
practice most participants accepted or believed that they would have accepted it:
Although I was quite hesitant I think I always said to myself that I’d go in to the appointment and find
out all the side effects, you know the possible help it could provide . . . you know never say never.
YP10
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Three participants voiced a preference for the combined treatment allocation, perceiving that more
treatment would offer stronger benefits. One participant’s preference for combination treatment was
informed by specific prior experience:
I think they work better together . . . I’m on antidepressants and stuff as well, and them alone will not
work fully, but also therapy alone doesn’t work fully because you’re not in the right frame of mind to
accept therapy.
YP03
Few participants expressed any initial views on the FI element of PI, although three participants were
clear that they declined or that they would have declined FI, and two of those rejected FI as they did
not want to worry family members:
I don’t really like worrying anyone so bringing like family or friends along would just you know worry
them a bit more.
YP02
Experiences of treatments
Subsequent experiences of the treatments received were also discussed, and interview questions
aimed to discover whether each treatment had been helpful, unhelpful or harmful, and in what ways.
Antipsychotic medication
Of the nine interview participants allocated to receive AP medication during the trial, eight were
prescribed AP medication and seven took them (three in the AP only arm, four in combined treatment).
Both participants who did not take AP medication were in the combined arm.
Valued changes with antipsychotic medication
All seven participants who took AP medication reported benefits. Six identified both psychosis-specific
and general improvements in psychological well-being. The most common psychosis-specific
improvements reported by participants were reductions in auditory and visual hallucinations:
It was helpful for me to stop seeing, for me to stop seeing shadows and hearing voices.
YP05
Additional psychological benefits included reductions in unwanted cognitive intrusions, along with
social anxiety or paranoia, leading to improvements in social functioning:
When you’ve got like medication that’s making you more stable, then you’re more like logical about
leaving the house and stuff.
YP03
Sedation leading to improved sleep was described in a number of interviews and was considered a
positive effect:
[AP] makes you a lot more like sedated, and like, doesn’t slow down your mind but it just makes you
really tired so . . . I’ll have a better night’s sleep.
YP09
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Unwanted effects of antipsychotic medication
All seven participants who took AP medication also reported side effects. One participant discontinued
their AP medication following the onset of intolerable side effects and concerns from their mum:
My mum’s just told me to stop taking it . . . the voices got louder, and my bones started aching, a lot. I just
changed my attitude where I was getting frustrated easily.
YP05
Unwanted sedative effects (e.g. ‘I felt really really tired’, YP02) were reported by most participants.
Other adverse effects attributed to AP medication included physical symptoms (e.g. ‘really bad
headaches’, YP09) and worsening mood (YP11). Two participants identified increased appetite and
weight gain as unwanted effects; for one of those, this interacted with an ongoing difficulty with eating
(YP03). The perceived stigma of taking AP medication was also mentioned as an adverse effect that
had implications for interacting with others:
It’s hard like if someone’s like ‘do you wanna stay at my house’. I’m like well I’ve gotta bring my
medication . . . will I have to explain what it is, will they think I’m crazy.
YP03
Cognitive–behavioural therapy
Ten participants were allocated to PI (five to PI only, five to combined treatment) and all attended CBT
sessions. One participant’s course of CBT ended early after three sessions, and they requested AP
medication from their psychiatrist.
Engagement with cognitive–behavioural therapy
Most participants who attended CBT sessions found it helpful to have regular opportunities to speak
to a therapist about their difficulties. For some participants, the duration of their course of therapy
allowed ‘a relationship’ (YP03) to form and develop, with therapists’ perceived trustworthiness and
understanding being valued attributes:
I could never talk to anyone, and cos it’s kind of hard to talk to people about things that they’re never
gonna understand but with [therapist] I felt like I can talk to her about anything.
YP13
The flexibility that was offered by therapists when arranging sessions was also valued, particularly
therapists’ capacity to rearrange sessions and to visit participants at home. Similarly, the flexibility that
therapists demonstrated within sessions allowed participants to prioritise salient topics for discussion
(‘seeing and hearing things . . . anxiety . . . family . . . school’, YP08).
Although participants’ discussions of engagement were broadly positive, one participant likened their
therapist to a teacher, having felt ‘spoken down’ to (YP07). Several participants described therapy as
challenging, recalling difficulties with initially ‘opening up’ and sometimes feeling upset by the nature of
discussions during therapy:
I think that it was good that I did that ’cos I kind of came to terms with all of it . . . but yeah while I was
talking and stuff and, it was upsetting.
YP12
Cognitive–behavioural therapy: an active approach
Participants commonly experienced CBT as a more active and interactive therapeutic approach than
they had expected or experienced previously. Therapists’ use of written materials and individual
psychological formulations in CBT was considered particularly helpful. One participant found the
process of goal-setting in therapy unhelpful, leading to frustration and ultimately disengagement (YP04).
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However, most participants identified goal-setting and collaborative working with their therapists as
valued aspects of CBT:
I was like kind of bringing up the issues and I think she was mostly like bringing up possible like solutions
almost like ways around it and things we can do about it.
YP13
Participants also recalled ‘homework’ tasks that they worked on between CBT sessions (e.g. testing
appraisals around distressing experiences). In some cases homework tasks were suggested by
therapists and in others the homework was devised collaboratively (e.g. YP08):
[Therapist] would always ask me to give her homework then she’d give me homework as well . . . that
was really good ’cos it wasn’t just like then we’re meeting like once a week and then nothing’s happening in
that week, we set each other like different tasks to do in between that week . . . it didn’t feel like homework.
YP08
Valued changes with cognitive–behavioural therapy
All but one participant who undertook CBT described resultant changes or benefits. Although some
who benefited were also taking AP medication, the following changes were reported by participants
who did not take AP medication or were described as specific to CBT.
Improved understanding
The most common benefit of CBT that was described by participants (8/10) was improved
understanding of themselves and their psychological experiences. Participants described numerous
aspects of improved understanding and how it arose. Centrally, the active process of talking to a
therapist was seen to help improve self-perception:
Being able to talk about it you feel like you’re not like kind of alone anymore and yeah you feel like there’s
somebody there to listen to you and you’re more understood and you understand yourself a bit more.
YP08, PI only
Some participants attributed improved understanding to more specific CBT elements. For example, many
participants identified normalising their difficulties as useful. Therapists’ active normalisation of psychotic
phenomena most often involved sharing information or stories of others who have had similar experiences:
Watching that [TED (Technology, Entertainment and Design) talk on voice hearing] has absolutely
changed the way I view things and having that in one of the first few sessions I think allowed me to
open up more because you suddenly think well it isn’t just me.
YP10
Several participants described gaining new ways of thinking about the difficulties that they had
experienced and changes in how they responded to distressing thoughts or emotions:
If I was walking down the street I saw kind of everybody as a threat . . . so we decided what if I looked at
them differently . . . would that change how, how bad my anxiety was and if it would have an effect on my
experiences and it did . . . talking about it we were able to make links, connections and then a solution.
YP08
Participants described subsequent benefits in being able to cope with or control their psychological difficulties:
Although I still have like the symptoms and stuff and I still get it every now and then pretty bad, I have
like more like control over it.
YP13
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Reduced symptoms of psychosis
Four participants explicitly reported reductions in auditory or visual hallucinations, and attributed
these improvements to engaging with CBT:
I used to hear my dead uncle . . . and I used to see him and everything, but that’s kind of stopped.
YP01
Several participants also identified improvements in mood-related domains, such as anxiety and anger:
I’m not getting outbreaks or blackouts as much as I used to . . . a blackout is when I get so angry that
I don’t know what I’m doing.
YP06
Improved social functioning
The majority of participants who described PI as beneficial also identified improvements in social
ability and functioning related to the changes detailed previously:
Like being open with people and being able to actually feel confident to get up and go out and see
people . . . before I was basically completely isolated in this house apart from college.
YP13
For several participants this included feeling more able ‘to open up’ (YP10) to others, enabling further
social support.
Challenges of cognitive–behavioural therapy
Although CBT was largely perceived as beneficial, and no participant described the therapy as harmful,
one participant did voice scepticism about CBT leading to sustained improvements that would last
beyond the duration of therapy:
There’s a way of like putting a plaster over it which I feel like therapy does for a while but, it doesn’t
really stop things from happening again.
YP03
Family intervention
There was variability in participants’ engagement with the FI component of the PI, with just 6 out of
10 participants describing some level of FI experience during MAPS.
Valued experiences of family intervention
Participants who attended FI sessions with their family members described several aspects of the
process as helpful. These share similarities with core features of CBT experience, but were also
particular to the family context.
A chance to tell them what I’m going through
Although participants may have previously discussed their psychological difficulties with family
members, such conversations were commonly limited. Therefore, family sessions served primarily to
facilitate such discussions and to develop a shared perspective:
The family session was a chance for me to tell them what I’m going through and a chance for them to tell
me what I’ve been doing wrong, and what I’ve been doing right.
YP06
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Improved understanding
Participants highlighted the value of FI for improving family members’ understanding of participants’
difficulties, and enhancing family members’ ability to offer support with difficulties:
If I like, I’m feeling down or anything and my dad notices I guess he’ll sort of make sure he’s not, he’s not
doing anything to make it worse, and he’s always kind of aware now and always like checking up on me.
YP13
Family members opening up
Family intervention sessions could also facilitate unexpected and helpful disclosures from family
members about similar personal experiences of psychological distress:
It allowed me to have a conversation with my mum that actually when [therapist] left it turned out when
my mum was 21 she had exactly the same thing and she didn’t see people she saw spiders . . . that then
opened up a whole other world of support that I didn’t even realise was there.
YP10
Challenges of family intervention
Several participants who engaged with FI recalled that it had been difficult to begin sessions; one
participant, for example, felt that their family members ‘did not understand mental health’ (YP06),
whereas others felt that discussions in family sessions ‘can be a bit embarrassing’ (YP09) or ‘scary’:
To actually get that conversation started of like I hear people that aren’t there it’s, you don’t know how to
break that to someone, it’s really really hard to put that into words and especially to someone that you
love because what you don’t want them to do is turn around and be like you’re crazy, cos that’s just,
that’s your immediate fear.
YP10
Combined treatment
Five interview participants were allocated to receive AP medication and PI, although two did not take
AP medication. All three participants who continued with both treatments described the combination
of treatments as helpful. Notably, AP medication was perceived to facilitate engagement with PI, with
each treatment helping in different ways, but also interacting beneficially:
In my opinion it’s [combined medication and PI] the best treatment for anything, because the drugs allow
you to feel in a better state of mind to accept therapy, and then when therapy is opening up things you
maybe wouldn’t be comfortable opening up with the drugs help make that more comfortable, so they all
work together.
YP03
Family members’ and carers’ results
Although non-related carers were eligible for interview participation, in practice interviews included
family members only (parents and one grandmother); therefore, the following discussion of interview
findings refers to ‘family members’ throughout. The analysis identified two themes areas of importance:
(1) family role in young person’s entry to MAPS and (2) family views of treatments for psychosis. Each
is described in turn and illustrated in Figure 7.
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Family role in young people’s entry to MAPS
Family members did not always have an active role in the young person’s decision to take part in the
trial, but were commonly motivated to support their young person’s decision and their continued
engagement with trial processes and treatments, while monitoring for impacts on the young person,
both positive and negative:
It was their choice
For some trial participants (14- to 15-year-olds), parental/carer assent was required for initial contact
with trial staff and, therefore, entry to MAPS. Nonetheless, all family members voiced the view that
the decision to enter MAPS had been the young person’s:
It was ultimately her decision . . . we just discussed which she wanted to do, what if it was one
[treatment] or what if it was the other and she just said she knew she needed to have help.
F12
Family support and guidance
Some family members viewed themselves as having an active role that involved offering support and
advice on starting the trial and throughout their young person’s involvement:
Yes it’s been discussed between us but it’s [young person]’s decision . . . if I can help with guidance as a
parent, that’s what I’m here for.
F03
Although allowing the young person to make that initial decision, family members were mindful that
there were constraints to this, which included the urgency of accessing treatment and the time limits
that may have influenced entry to the trial:
I know that he didn’t feel pressurised in any way . . . I think what [psychiatrist] explained was, obviously it
was an opportunity and you know he was free to take it up or not, but it was obviously time limited as
well, the option to opt in was time limited but he chose to opt in so.
F11
1. Family role in young people’s entry to MAPS
‘It was their choice’
• Family support and guidance
• Monitoring
‘Any help was better than nothing’
• Randomisation
Trial procedures




• Unwanted effects and challenges
CBT
• Valued changes
• Unwanted experiences and challenges
FI
• Valued changes
• Challenges of FI
2. Family views of treatments for psychosis
Combined treatment
FIGURE 7 The family perspectives of MAPS.
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In this example, a dad describes how he would have been willing to over-ride his son’s initial entry
decision if he had seen that to be in his son’s best interest:
I think if he had have had fears about it and that we couldn’t have alleviated it I’ve gotta be honest




An important demonstration of family support was evident from descriptions of what could be termed
as ‘monitoring’, in which family members were active in assessing the impacts of trial treatments and
intervening to address important concerns:
The [AP] dose that she was originally put on was too high so I tried that for 2 days and I just went back and
said this isn’t my child, I need it changing, and to be fair the doctor’s worked with me and she reduced the dose.
F04
Any help was better than nothing
Family members’ own motivation to support the young person’s entry to MAPS was frequently
characterised by a sense of urgency in seeking help; entry to MAPS represented a valued opportunity
to access help and support that either was unavailable within local services or could be accessed more
rapidly via the trial:
We thought that it would be a good idea, because I thought that she’d get more help than if she was just
stayed through CAMHS.
F15
This was particularly important when family members perceived psychological therapy or ‘specialist
help’ to be needed. Family members were often aware that these resources were often scarce,
especially psychological support:
As soon as I heard that there was psychology involved or a possibility of psychology . . . it was like right
well at least we’re gonna get a step in the right direction.
F04
Randomisation
The over-riding desire for help, any help, may explain family members’ general acceptance of
randomised allocation to trial treatments:
We didn’t quite know whether it’d be the medication, if it would be the talking therapies or if it would be
both . . . but we were just you know wanting something to start to just help him really.
F13
However, some family interviewees either had not been aware or made clear that randomisation
occurred or had believed that trial treatments would be delivered based on individual needs:
Participant: I didn’t know it was random to be fair, yeah I thought she, she well not it’s not chosen on
merit is it that’s the wrong word but you know chosen because . . .
Researcher: Kind of needs-based.
Participant: On her needs yeah, yeah yeah.
F05
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Two family members who did recall randomisation expressed some concern that this reduced the
control around treatment:
I think the concern was obviously in terms of the, the control, you’re not sure which avenue he’s gonna be
targeted down.
F11
However, more commonly participants seemed reassured that being in the trial did not prevent
discontinuation or change of their young person’s treatment, or withdrawal from the trial:
I’m aware that you know it is a research study but actually if things changed, he could pull out and get
the active treatment he needed at any point.
F11
Trial procedures
Along with discussions of decision-making at entry to MAPS, family members shared views relating to
two additional important aspects of trial experience: study information material and assessments.
Study information material
Family members who recalled the study information material (participant information sheet) generally
found it comprehensible and helpful. Some did express concern that the materials had been difficult
for the young person to understand because of learning or mental health difficulties. However, they
perceived that sufficient support from research staff had been in place to ensure that the young
person was able to make an informed decision about entry to MAPS. There was also concern about
use of the term ‘psychosis’ within the participant information sheet because of the generally negative
perception of psychosis among the public and how this could have an impact on the young person:
Can a young person say to any of their peers or to anybody else, ‘I suffer from psychosis, I’m psychotic,’
no they can’t because everybody just thinks that means that they’re gonna get an axe out of their pocket
and chop them up.
F06
Several family members had first seen the term ‘psychosis’ used in relation to their young person
during entry to MAPS, possibly along with the provision of the study participant information sheet.
CAMHS or EIP teams from which young people had been referred had not used the term, and this
discrepancy was considered problematic:
I could certainly understand why someone might not want to have their child suddenly told they had
psychosis based on a study, without you know, with GPs or CAMHS or however it’s done.
F07
Assessments
Family members were not typically present during assessment meetings between young people and
MAPS RAs. However, several had been present or recalled comments made by the young person about
these meetings. Participants often spoke very positively of the RAs who conducted assessments,
referring to interpersonal and professional qualities that they perceived had ensured that the young
person felt safe and comfortable:
She enjoyed it when [RA] came round . . . there were certain aspects that she didn’t want to talk about
but because she was comfortable with [RA] she spoke about them freely.
F04
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Family members also valued the flexibility RAs showed around arrangements for appointments,
including home visits and text message reminders. A potential disruption to this positive relationship
was the practice of ‘blinding’ (in which the young people were asked to conceal their treatment
allocation from the RA), which one mum identified as somewhat difficult for her daughter.
Although assessment appointments were largely perceived to be acceptable and even helpful, there
were suggestions that they could be overly long. Participants also reported that the nature of
assessment questions could be challenging. For example, one family interview elicited concern about
questions relating to suicidality, although the mum ultimately recognised that these were important
and appropriate. Another negative aspect of the assessments reported by family members was blood
sampling. One parent reported that the young person had considered declining entry to the trial
because they feared this single aspect. Another mum attributed the young person’s recent fear of
blood tests to an unpleasant experience during the trial:
Now he won’t go into the GP and get any bloods done.
F13
Family views of treatments for psychosis
Family members expressed a broad range of individual views of treatments for young people
experiencing psychosis, and discussed several important areas of concern. Family members’ views
of treatment were often complex and included both positive and negative reflections around the
same treatments.
Antipsychotic medication
We interviewed family members of 10 young people allocated to receive AP medication, two allocated
to AP alone and eight to combined treatment (one of whom was not prescribed AP medication). Given
this complexity, analysis has sought to carefully isolate AP-specific features of interview feedback.
Acceptability
Antipsychotic medication, as a single treatment or part of a combination, was ultimately acceptable to
all family interviewees, with several highlighting the importance for them of AP medication in reducing
young people’s extreme behaviour or risk. Some were cautious about its potential to help, and viewed
it as temporary or expressed concern that the young person could become permanently dependent on
AP medication. All family members expressed concern about potential side effects of AP medication.
However, all family members also ultimately accepted AP medication, and indeed three participants
indicated that they may have withdrawn the young person from the trial if AP medication had not
been prescribed:
I would have considered that him not taking antipsychotics would have put his brother and sister at risk,




Most participants described psychosis-specific benefits and more general improvements that they
attributed directly to AP medication. These included reductions in the frequency and intensity of voice
hearing, reductions in paranoia and mania, improved sleep, and feeling calmer and less angry. In several
cases, improvements were described as partial or ongoing, with voices, for example, continuing at
reduced intensity or frequency. Three family members recalled deteriorations when AP medication had
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been temporarily disrupted, and two described temporary deteriorations while young people were
taking AP medication:
Soon after she had started on the medication . . . she said that the voice had told her that if she went to
this place there would be a, a Stanley knife . . . I thought oh my goodness maybe she shouldn’t be on this.
F12
Unwanted effects and challenges
Family members individually discussed idiosyncratic medication side effects reported by the young
people, such as tremors, anger, pacing, agitation, headaches and nausea. More frequently, AP medication
was associated with weight gain and especially sedation:
[AP] slowed his whole thinking down, his whole physical being.
F13
Interviewees also described how young people’s allocation to AP medication often involved them
taking on a new role to ensure continuous maintenance of AP medication. This included organising
prescriptions, managing prescription delays and locating pharmacists who held the specific stock
required. One mum personally administered daily doses in case her son forgot, and another helped by
sourcing and posting AP medication to her son at university.
Cognitive–behavioural therapy
Fourteen out of 16 interviews were with the family member of a young person who had been allocated
to receive CBT, either alone (n = 6) or in combination with AP medication (n = 8). Analysis has sought
to distinguish CBT-specific aspects from more general treatment effects or changes.
Acceptability
Overall, CBT was discussed more positively than AP medication, and was more often a first preference
for treatment (5/16 vs. 2/16). Perceived benefits of CBT included young people having someone to speak
to about their mental health concerns, specialist therapists’ understanding of mental health concerns and
CBT helping young people address historic issues, which in turn might promote longer-term recovery.
However, several family members were cautious about the young person receiving CBT alone; as
mentioned earlier, three family members viewed treatment without AP medication as problematic
enough to consider advising the young person to withdraw from the trial. Some were concerned that
CBT might not be sufficient on its own or would fail to address key concerns (e.g. risk-taking behaviours
or frightening hallucinations). One mum had initially worried that having CBT (with or without AP
medication) could worsen her daughter’s state of mind, based on a previous negative experience of
counselling. There was also concern that CBT might be too difficult for a particularly quiet young person:
He’s you know an adolescent boy, he doesn’t really share a lot or give a lot so I knew the talking therapies
would be really really difficult for him and they still prove to be difficult for him, he finds it really hard to talk.
F13
Valued changes
The most common change associated with CBT that family members identified was ‘improved
understanding’. The young person’s understanding was seen to have improved, especially around
‘making sense of’ and learning to cope with distressing psychological experiences. One common aspect
of ‘making sense’ identified by family members was the normalisation of psychotic phenomena and of
the young person’s own self-perception that occurred during CBT:
I think it’s really good that there was somebody out there who could say actually you know what this is
normal, and there’s lots of people who experience it.
F12
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Improved coping was described in terms of young people’s learning coping strategies that helped them
to ‘deal with’ ongoing psychotic phenomena, and being given helpful materials to keep between and
after CBT sessions. Related to an improvement in coping, family members also reported relatively
common improvements in young people’s capacity for social and occupational functioning. Additional
changes discussed by family members also included specific reductions in psychotic experience,
especially voice hearing, along with general changes in well-being, such as improved mood, motivation
and confidence, and reduced stress and anxiety.
Unwanted experiences and challenges
Adverse experiences or effects of CBT were relatively uncommon, and from family members’ accounts
seemed temporary. For example, one mum saw her daughter become tired and low in mood following
early sessions of CBT, one mum similarly felt that her young person seemed tired because of the
concentration required during CBT and another young person had found a CBT behavioural experiment
(revisiting a difficult location) initially stressful. More commonly, family members discussed challenges
for the young person, including general difficulty engaging with a talk therapy, in one case related to the
sedative effects of AP medication, and for one young person because of a learning difficulty. Finally,
an ongoing uncertainty for several family members was around the durability of benefits attributed to
CBT, and the potential value of continuing therapy longer term. Indeed, four family interviews revealed
degrees of disappointment around CBT ending:
She [therapist] is phenomenal, absolutely phenomenal . . . It’s gonna be such a blow to lose [therapist] . . .
I suspect we probably wouldn’t be in as good a place as if the CBT were to continue even on a 2-monthly
basis for the next 12 months, for example.
F09
Family intervention
Family intervention was offered to all young people receiving individual CBT, although young people did
not always choose to involve family members in their therapy. During the qualitative interviews, 10 out
of 14 eligible participants discussed FI. No family member discussed their initial views of FI acceptability
during interviews; therefore, the following discussion relates to post-treatment views only.
Valued changes
Although family members had been involved in FI sessions (or not) to varying degrees, feedback was
consistently positive and suggested that FI was highly valued. The most common perceived benefits of
FI for family members were gaining an improved understanding of the young person’s psychological
difficulties and improving communication with them. Both were seen to have been facilitated through
FI sessions creating a space for a young person and their family to safely disclose their concerns:
We can all talk openly about it, and bring it to the surface.
F05
Family members noted that therapists had consistently sought young people’s consent before raising
specific topics with family members:
I don’t think [therapist] ever spoke about anything that [young person] didn’t want her to talk about.
F03
Additional benefits of FI included normalising psychosis, being introduced to novel practical approaches
that helped family members experience simulations of voice hearing, therapists allowing time for family
members to raise questions of their own and sourcing helpful information or materials for family
members between sessions.
QUALITATIVE RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
Challenges of family intervention
Although FI was primarily described positively, some family members had found it very distressing to
witness the young person’s disclosures during the sessions (‘I never actually knew that she was suicidal’
F04). However, in each such case family members said that they were content to tolerate such distress
as part of an ultimately beneficial process:
[Young person] was amazing and needed my strength . . . it was probably one of the hardest things I’ve
had to do sitting listening and I didn’t want to . . . but she didn’t want to have to go through it, and as a
parent it was like ‘suck it up, deal with it’ kind of thing.
F02
An additional challenge of FI was finding extra time for sessions and between-session family activities.
Finally, several family interviewees were disappointed not to have been involved in FI, as they felt such
sessions would have been helpful.
Combined treatment
Acceptability
Overall, family members most frequently expressed a first preference for combined treatment (9/16),
and it is noteworthy that there were no negative views of the combined allocation:
That’s the golden ticket really isn’t it.
F06
For some, this was because the combination simply meant more treatment, hence a greater likelihood
of some benefit, greater benefit or a quicker treatment response:
We were so glad [young person] got both . . . I think [young person] and I both felt ‘throw everything at it’,
because [young person] didn’t want to be ill.
F08
Some considered how the different treatments could work in complementary ways:
We felt well actually pills can perhaps just help for the time being but the talking therapies will really try
and help him understand why he is where he is today you know, just raise his awareness about things
and just help him really move on.
F13
Valued changes
Feedback about young people’s experiences of combined treatment was commonly positive. Apart from
one instance of AP medication being seen to have somewhat hindered a young person’s engagement
with CBT, family members generally perceived that AP medication had helped young people to engage
with the psychological component:
The medication calmed her mind, helped her focus on the sessions.
F02
Four family interviews expressed the common view that, although AP medication conferred early
benefits (e.g. reduced distress and improved sleep), the CBT component of combined treatment in
particular was likely to confer longer-term improvements because it addresses both the historic
concerns and the ongoing management of distressing experiences:
We felt well actually pills can perhaps just help for the time being but the talking therapies will really try
and help him understand why he is where he is today . . . and just help him really move on.
F13
DOI: 10.3310/hta25040 Health Technology Assessment 2021 Vol. 25 No. 4
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Morrison et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
79
Several family members did not associate specific elements of combined treatment with specific
beneficial effects, but perceived that the combination had been more helpful, more quickly, than either
treatment would have been alone:
I think the medication’s taken him so far and then the CBT’s sort of boosted him the rest of the way . . .
we’d have got there but I think it would’ve taken longer.
F12
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Chapter 6 Discussion, conclusions and
recommendations
Summary
This study aimed to obtain both the quantitative and the qualitative data required to determine
the feasibility and acceptability of conducting a definitive trial to evaluate the effectiveness of
psychological therapy, AP medication or a combination of the two in adolescents with FEP. To obtain
these data, we conducted a feasibility PROBE trial over a 2-year period. In addition, we conducted
qualitative interviews with three target stakeholder groups: prescribers (predominantly psychiatrists),
trial participants and family members of trial participants. We outline each specific objective for the
study and provide a summary of the learning relating to each, but first we will make some statements
about the key learning from this study.
Research to inform an evidence base for the treatment of adolescent psychosis is limited.62,63 There is a
limited number of robustly conducted trials, with few head-to-head comparisons of AP medication
short study duration for AP medication, no available data on the long-term adverse effects of AP
medication and a paucity of evidence for PIs.62,63,84
The MAPS trial has demonstrated that it is possible to identify, engage and retain adolescents with
psychosis in a robustly conducted RCT. Findings from the feasibility trial and the qualitative interviews
warrant a full-scale definitive trial. However, amendments to the trial design are required to ensure
recruitment to target, to maximise value for money and generalisability and to minimise the risk of
crossovers from the monotherapy arms to the combined treatment arm, and vice versa.
Key learning from the study includes costing dedicated time for an EIP psychiatrist and/or CAMHS
psychiatrist to be employed to work on a definitive trial. Protected time from psychiatry at each site
would facilitate their role in the assessment of a young person experiencing a FEP on entry into EIP
services, addressing concerns regarding diagnostic uncertainty, clinical equipoise and suitability of AP
medication for each potential participant. In addition, it would facilitate protected time for study
outpatient prescribing slots, ensuring commencement of AP medication in a similar period to PI, which
should also help reduce crossover from AP arms to PI monotherapy or no treatment.
Analysis of the qualitative data indicated that stakeholders consider AP medication and PI to
have differing effects on outcomes and that the combined treatment may bring additional benefits,
such as AP medication increasing a young person’s ability to engage in therapy. AP medication was
considered to have the greatest benefit for psychiatric symptoms, and PI for a better understanding
of psychological difficulties and self. Given that AP medication and PI are two distinct treatments
with different mechanisms of action, this finding is understandable and it has been argued that
CBT should not be seen as a quasineuroleptic by researchers and clinicians.130 This has implications
regarding selection of the most appropriate primary outcome for a definitive trial. However, in
contrast, there is a signal from our quantitative data on psychiatric symptoms and user-defined
recovery (often reflecting improved understanding) of little variability between the treatments on
both of these outcomes; however, this should be interpreted with caution given that MAPS was not
powered to evaluate the effectiveness or efficacy of these three treatments. A full discussion of these
learning points is provided below, in Tables 24–26.
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TABLE 24 Lessons learnt, challenges faced and recommendations for a definitive trial: trial feasibility data
Activity Lessons learnt/challenges faced Recommendation for a definitive trial
1a Trial set-up
Identification of a local
psychiatrist in EIP
service/CAMHS as
a site lead or as
co-site lead
Referral pathways data indicate that the
model taken to recruitment in Oxford
improves the accuracy of referrals (with
regard to eligibility) and produces a greater
number of randomisations. The Oxford
model was for the local EIP service or
CAMHS psychiatrist to consider trial
suitability as part of EIP/CAMHS initial
assessment
Each site requires at least one local EIP
service or CAMHS psychiatrist who is
identified as a site lead, endorses that there
is clinical equipoise regarding the best
treatment options for FEP and has
protected time for assessment of new cases
into EIP services for young people in the
inclusion age range. This will improve the




Significant difficulties were experienced in
obtaining ETC to cover delivery of therapy
at the Birmingham site, resulting in this
site initially being dropped (as it was not
possible for the site to be initiated without
therapist provision). This caused significant
challenges to recruitment while the
management team identified a new site
to replace Birmingham
To facilitate a definitive trial commencing
on time, ETC issues should be addressed
and CBT therapists, supervisors and
psychiatrists (screening assessment and




The commissioning arrangements for
CAMHS and EIP services were variable
across the sites included in this study. In
some instances, CAMHS and EIP services
were commissioned by different NHS trusts
and, as such, care co-ordination and
prescribing responsibilities were split across
these NHS trusts. This interface could result
in communication delays between services
regarding referral to the trial, agreement
regarding FEP status and clinical
equipoise regarding treatment
Prior to site selection, a scoping exercise
should be carried out to better understand
the interface between the CAMHS and EIP
services to ensure that the interface would
facilitate agreement regarding FEP status,
referral to the trial and prescribing for




The best recruiting site (Oxford) had
more than one lead EIP clinician identified
to support the study. This facilitated
conversations with team leaders regarding
the study, identification of participants and
navigating the variability between the study
inclusion criteria and the EIP team inclusion
criteria. Site leads in Oxford included
representation from both psychiatry
and psychology
Each site requires support from more
than one clinical lead in EIP. Leads should
be placed in EIP services, should have
management responsibility and should
ideally provide representation from both
psychiatry and psychology
MHRA approval In addition to REC and HRA approval, it is
likely that a definitive trial would be a
CTIMP and, therefore, it would require a
clinical trial authorisation from the MHRA
approval and a EudraCT number
Researchers for a definitive trial should
become familiar with the processes
required for approval from the MHRA,
including the time frames for approval,
costs for application for MHRA approval,





It would facilitate recruitment to target if
site selection included an audit of the
number of young people with a FEP
accepted into EIP services in the year prior
to site selection
Potential sites should obtain business
intelligence data from the trust’s medical
records to determine the acceptance into
EIP rate for young people within the age
range specified in the inclusion criteria
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TABLE 24 Lessons learnt, challenges faced and recommendations for a definitive trial: trial feasibility data (continued )
Activity Lessons learnt/challenges faced Recommendation for a definitive trial
1b Trial design/procedures
Trial design A proportion of participants did not receive
the intervention exactly as allocated for
reasons related to TAU options and
participant preference and choice
We make recommendations throughout
this chapter to address real-world factors
that may result in participants not receiving
the intervention exactly as allocated.
However, there are likely to be a number of
factors outside the remit and scope of the
research team, including patient preference
and choice and what is offered as part of
TAU. For this reason, we recommend a
pragmatic effectiveness trial examining
care pathways that will examine how these
treatments work in NHS settings. If an
efficacy trial was deemed to be the most
appropriate approach to a definitive trial,
a four-arm trial with a placebo condition
may be appropriate
Liaison with prescribers Qualitative research with prescribers
indicates that the decision to refer to the
study is sometimes influenced by treatment
beliefs based on their clinical experience
Liaison with prescribers should address this
issue. Prescribers should be provided with
a handbook that speaks to the current
evidence base regarding treatments for
young people with FEP. This information
should be developed in consultation with
prescribers to ensure that it fully addresses
their treatment beliefs and concerns. In
addition, the handbook should make it
clear that the prescribers retain clinical
responsibility and, therefore, decision-making
about AP prescription throughout the trial.
Embedding the trial within the clinical team
will ensure excellent communication links
regarding participants and this will in turn
strengthen relationships, thus addressing any
concerns prescribers may have about the trial
Screening approach We collated a large number of initial
enquiries through services screening their
medical records for potential participants
(n = 705). The conversion rate to referrals
was low (n = 76)
We identified, from the best recruiting sites
(Oxford and Manchester), that a more
effective approach to recruitment was for
EIP staff to consider all new referrals into
EIP services. This was a more effective
approach as there was a decreased risk
that the young person would have received
AP medication in the past 3 months (an
exclusion criterion for the trial). It was most
effective in Oxford, where the screening at
entry into EIP services was carried out by a
psychiatrist who was able to confirm FEP
status and clinical equipoise
Qualitative data indicate that prescribers
expressed that diagnostic uncertainty is
greater with young people. They expressed
that they had to balance this diagnostic
uncertainty with a duty of care and
decision-making regarding appropriateness
of AP medication
Ensuring confidence in the screening
process is crucial to ensuring referrals
into the trial. The emphasis of recruitment
should be on screening all new referrals
into EIP services for young people in the
age range. A psychiatrist (consultant or staff
grade) who is well placed professionally to
determine FEP status, address issues of
diagnostic uncertainty, consider clinical
equipoise and discuss the option of the
trial should conduct this screening
continued
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TABLE 24 Lessons learnt, challenges faced and recommendations for a definitive trial: trial feasibility data (continued )




Qualitative data indicated that some young
people and family members had not been
informed (by their service) that their mental
health difficulties were understood to be
psychosis. For this reason, for some the first
time they received this information was via
the consent process into the study
Potential participants should be made
aware of how their experiences are
understood by clinical services, i.e. if this is
in the context of psychosis this should be
discussed before a referral to the trial to
ensure that the young person and their
family understand what this means
As suggested, we recommend that the
screening is carried out by a psychiatrist
who would be qualified to determine if the
young person was experiencing psychosis.
The psychiatrist would be well placed to
facilitate discussions about psychosis with
the young person and family
Designing participant
information sheets
Qualitative interview data from both
participants and family members suggest that
the information sheets contained too much
information or language that would be
difficult for some young people to understand
For a definitive trial, the amount of
information in the participant information
sheets should be reduced and different modes
of communication about the trial should be
considered, for example short animations that
break down the various aspects of the trial
Funding costs should cover producing
high-quality, youth-oriented information
about the trial. PPI should be central in
the development of these resources
Inclusion criteria The overall recruitment rate was lower than
anticipated and the rate of ineligibility at the
initial enquiry stage was higher than expected
Qualitative data around treatment from
clinicians indicated that psychiatrists
expressed the greatest concern about
prescribing, or not, to the younger end
of the age range. This suggests that this
concern may be less prevalent in relation
to older adolescents
For a definitive trial, the upper age limit
should be increased from 18 to 25 years.
Current definitions of adolescence often
extend to 25 years of age, e.g. the WHO’s
definition of youth. This would widen the
potential pool of participants and capture
the full range of adolescence as defined
by the WHO
Increasing the upper age limit to 25 years
may also prove beneficial for reducing
crossovers
Exclusion criteria The overall recruitment rate was lower than
anticipated and the rate of ineligibility at
the initial enquiry stage was higher than
expected. Just under one-quarter of the
14- to 18-year-olds identified at the initial
enquiry stage had taken an AP medicine
within the past 3 months, making them
ineligible for the trial
For a definitive trial, the exclusion criteria
should be modified to match those of
trials of AP medication with a similar
wash out period, e.g. a maximum 2-week
AP exposure to ensure washout before




Qualitative interviews conducted with
clinicians indicated a hesitation to enter
certain young people into the trial (and
hence a definitive trial) owing to clinical
evaluation that the young person should
have an AP medicine, i.e. because of
significant risk, and this could not be
guaranteed because of randomisation
The inclusion and exclusion criteria should
reflect these opinions and that research
teams at each site include some
involvement from EIP psychiatrists
Deterioration criteria Overall, the deterioration rates were low.
There was little difference between the
monotherapy arms in the rates of
deterioration. However, deterioration
contributed to the number of treatment
crossovers
Crossovers should be minimised in a
definitive trial. Given the low rates of
deterioration and the absence of evidence
of difficulties associated with allocation to
PI monotherapy, we propose that the
deterioration criteria are removed from a
definitive trial with the recognition that
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TABLE 24 Lessons learnt, challenges faced and recommendations for a definitive trial: trial feasibility data (continued )
Activity Lessons learnt/challenges faced Recommendation for a definitive trial
clinical services will be monitoring the
well-being of the participants and that we
would not ask them to withhold treatment




Qualitative research with prescribers indicated
some concern that given the diagnostic
uncertainty in the population the sample of
participants would be heterogeneous. This may
limit the generalisability of the results for a
definitive trial
One option to reduce heterogeneity would
be the inclusion of a diagnostic checklist at
the baseline assessment to determine if the
sample would meet ICD-10 or DSM-V
criteria for a schizophrenia spectrum
diagnosis
However, we highlight that this may
unnecessarily stigmatise the young person
by applying diagnostic labels
Approach to participant
engagement
Flexibility regarding appointments is crucial
to engagement. Qualitative data from
participants and family members indicated
that the assertive outreach approach taken
on this study (flexibility regarding time of
appointment, choice of location, text or
letter reminders and flexibility regarding
rearrangement of appointment) was valued
A definitive trial requires sufficient RA and





Although follow-up rates were excellent
at the end of treatment (6 months), the
long-term follow-up of participants at
12 months was lower than at end of
treatment. Youth-specific factors, including
school and college exams, moving away to
university, preference to book appointments
via parents (who are often managing
multiple appointments and commitments)
and frequently changing mobile telephone
numbers and/or e-mail addresses, should
be considered for a definitive trial. We
endeavoured to maintain contact with
participants for this study between 6 and
12 months to update their contact details
and provide a £5 token of appreciation
To improve follow-up rates long term a
larger number of brief check-ins with a
token of appreciation of trial participation




The rate of blind breaks was low, indicating
that our approach to maintenance was
successful
A definitive trial should have rigorous
approaches to maintaining the blind as
outlined here in Chapter 2. Qualitative
feedback from participants and family
members, of whom at least a minority
expressed unease around maintaining the
blind and felt limited in their disclosures to
RAs, also suggests reconsidering the format
of essential outcome measures. For example,
self-report rather than interview formats
could eliminate some unease around
blinding, and could potentially enhance
absolute accuracy of important disclosures
continued
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TABLE 24 Lessons learnt, challenges faced and recommendations for a definitive trial: trial feasibility data (continued )




Risk of selection bias was low and the
centralised web-based platform hosted
by the CTU was suitable for use in a
definitive trial
A web-based, centralised (with the CTU)
platform should be used to randomise
participants and reduce the risk of
selection bias
If the upper age limit is increased from
18 to 25 years, we recommend stratification
by < 18 years or ≥ 18 years to ensure a
balance of children vs. young adults
CTIMP, Clinical Trial of an Investigatory Medicinal Product; ETC, excess treatment cost; MHRA, Medicines and
Healthcare products Regulatory Agency.
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 25 Lessons learnt, challenges faced and recommendations for a definitive trial: trial outcomes
Activity Lessons learnt/challenges faced Recommendation for a definitive trial
Primary outcome The PANSS had excellent completion rates
at the end of treatment, which suggests that
PANSS is an acceptable assessment to young
people with psychosis and an appropriate
primary outcome for a definitive trial
The completion rate of other secondary
measures was lower. One explanation
for this is that all measures other than
the PANSS were deprioritised if the
participant expressed that the assessment
was too burdensome. For this reason, the
assumption that it is not possible to collect
the other secondary outcome measures
should be approached with some caution
and a brief self-report measure, such as
the QPR, is likely to be an acceptable
primary outcome measure
Qualitative data from participants and
family members suggest that the two
monotherapies may work in different ways
and have different treatment effects. PI
broadly led to improved understanding
and coping with psychosis and, in some
instances, both participants and family
members reported improved communication
as a result of PI. AP medication broadly
led to improved symptoms, psychological
well-being and for some participants
an improved ability to engage with PI.
However, quantitative analysis of PANSS
and QPR scores provides a signal that
there is little difference between the three
treatments on either the PANSS or the QPR
Based on our data, we can recommend the
PANSS as the primary outcome for a
definitive trial. However, the quantitative
data suggest little difference between the
treatments on PANSS or the treatments on
QPR; therefore, another option for the
primary outcome would be the service
user-defined recovery outcome measure
the QPR. The QPR has the benefit of
being brief, i.e. only 15 items (reducing
participant burden), self-reported (the
preferred method of reporting for service
users) and evaluating service user-defined
recovery outcomes (a priority for service
users). It is also one of three mandatory
patient-reported outcome measures
recommended for routine use in EIP services
Given the suggestion from qualitative
data that AP medication and PI may have
different treatment effects, we recommend
that a definitive trial include a process
evaluation to understand how each
treatment works and consider interaction
effects between treatments
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TABLE 25 Lessons learnt, challenges faced and recommendations for a definitive trial: trial outcomes (continued )
Activity Lessons learnt/challenges faced Recommendation for a definitive trial
Burden of assessments Our data demonstrate that there was a low
response rate to the secondary outcome
measures. This indicates that the number of
assessment measures was burdensome for
this population
The burden of assessments was reflected in
the qualitative data from participants. Data
indicated that for some the assessment
battery was repetitive or boring. In addition,
difficulties with memory and difficulties with
learning (e.g. dyslexia, autism spectrum
disorder) can affect engagement with the
questionnaires for some of the young people
in this population
More specifically in relation to blood tests,
the qualitative data from participants
indicate that for some participants there
was unease about the blood tests and this is
reflected in the small number of blood test
results reported in the quantitative data
The assessment battery should be reduced
in quantity of measures. We propose that
the essential measures to retain are PANSS
(to assess psychiatric symptoms), QPR
(to assess user-defined recovery) and
adverse effects (to assess the comparative
safety of the interventions)
The low uptake of blood tests and physical
health checks may limit the ability of a
definitive trial to form judgements about
the relative risks from those particular
adverse effects in the different treatment
arms. We believe that RAs may not
be best placed to obtain body and blood
measurements. We recommend that time
is costed for the research psychiatrist to
obtain the physical health measurements or
another trained health-care professional,
i.e. a nurse. The research psychiatrist would
be well placed to complete the physical
health measurements, as they are trained
medical professionals with the necessary
skill set for taking blood and performing
physical health checks. As the prescriber
they would be required to complete the
checks for two-thirds of the participants
before commencing them on AP medication
and for the duration that they remain on
AP medication. In addition, as members of
the research team and the clinical team they
would be familiar with all participants and
would have met them as part of screening,
thereby increasing the chance of engagement





There were a number of challenges in
relation to the measurement of side effects
of AP medication. Overall completion rates
were low for the ANNSERS. Baseline data
suggested false positives given that
participants were medication naive at
baseline and yet the average number of side
effects noted was between 7 and 11 at
baseline. It is likely that the number of false
positives is an artefact of the measure being
administered by a researcher who is blind to
allocation and the overlap between side
effects and other conditions (e.g. fatigue,
weight gain, headaches, sleep disturbance)
We recommend that side effects of AP
medication be recorded via self-report
methods to remove the risk of false
positives. Given the feedback on burden
of assessments, we recommend that the
assessment of side effects should be brief.
The Systematic Monitoring of Adverse
events Related to TreatmentS (SMARTS)131
is an 11-item self-report measure of AP
medication side effects that balances
brevity with assessing the most common




A definitive trial should consider
systematically monitoring drug levels to
determine medication adherence
Health economics The rates of missing data for health
economics were high at follow-up. At
6 months, missing data were 36.1% for
the EQ-5D-5L and 63.9% for the health
economics service use questionnaire
To answer the question of cost-effectiveness
of the three treatments, health economic
data would be a priority. For this reason,
adjustments should be made to the design
to ensure the completeness of health
economic data collection
continued
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TABLE 25 Lessons learnt, challenges faced and recommendations for a definitive trial: trial outcomes (continued )
Activity Lessons learnt/challenges faced Recommendation for a definitive trial
To maximise health economic data we
recommend that service use data are
obtained by self-report methods from
participants and followed up with additional
details from the medical record service data.
In addition, trial management supervision
should include close monitoring of the
completeness of the data as they are
collected, so that any missing items
on a form can be followed up. Use of
the medical record data will require
consideration of the ability of each trust’s
business intelligence department to extract
data from the medical record system.
Ground work with business intelligence
should take place early on in the trial set-up
phase to identify the most streamlined
method of obtaining medical data. The
health economist should be included in
these discussions. We recommend that
these data be periodically extracted from
the records throughout the trial to ensure
ongoing oversight of health economic data
completeness by the iDMC
Data extraction from
medical records
We used the electronic medical records to
extract data regarding treatment received
status (given that the AP prescription was
made by the clinical team, not the research
team, this information was on the medical
records and not a study CRF), and
information regarding AP prescription,
diagnosis and AEs (to minimise the risk of
surveillance bias)
Screening the medical records was time-
consuming and the task could not be
performed by the RA given they were blind
to allocation. Funding did not cover time for
a non-blind member of the research team
to screen the medical records. Therefore,
obtaining these data were challenging.
Business intelligence systems were not
compatible to extracting the information
required and, in some instances, the data
in the records were limited (resulting in
missing data for some variables relating
to medication)
There are a number of solutions to this
challenge
Time costed for a local psychiatrist to
screen and prescribe could also include
completion of a CRF that details diagnosis
and details of medication treatment. If
medication is amended or if crossovers
occur, the psychiatrist could complete a
CRF. The CRF would be located in the same
data management system as the participant
assessment measures and PI CRF. This
would allow the trial management group to
monitor completion rates of these data. It
would allow the iDMC to review quality of
these data and monitor crossover rates
Medical record data would be required
regarding AEs to supplement self-report
(because the events may be reported to the
clinical and not the research team). As part
of the site selection, discussions should be
held with BI at each trust to set up systems
to extract details of AEs via the local
systems. For example, use of the NHS
Datix adverse incident and near-miss
reporting system
It is likely that health economic data would
be required from the medical records for
a definitive trial of cost-effectiveness.
Discussions with BI during site selection
phases should identify systems for
extracting these data
BI, Business Intelligence; CRF, case report form; iDMC, independent Data Monitoring Committee.
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 26 Lessons learnt, challenges faced and recommendations for a definitive trial: acceptability and feasibility of
treatments: for young people with a FEP
Activity Lessons learnt/challenges faced Recommendations for a definitive trial
Ensuring swift access to
treatments
The median number of days to prescription
of AP medication was 18 (IQR 10–42).
In total, 27.3% of the AP monotherapy
participants crossed over to ‘no treatment’
The clinical team psychiatrist made the AP
prescription. We endeavoured to support the
timely offer of an outpatient appointment
to discuss AP medication through contact
with the psychiatrist after randomisation to
notify them of the outcome, but the research
team was unable to control the time to
initiation of AP medication. However, a trial
therapist delivered PI and initiation of this
was monitored by the trial through therapist
supervision
A definitive trial should mirror MAPS
and employ trial therapists to deliver PI,
thereby facilitating swift action to offer the
treatment post randomisation
Matched study procedures should be in
place for both treatments (AP and PI).
Locating prescribing of AP medication
with a local EIP or CAMHS psychiatrist
with protected MAPS outpatient time will
facilitate swift access to treatment and
monitoring of drug levels at follow-up.
This may also improve rates of crossover
from AP monotherapy to ‘no treatment’.
In addition, this would reduce the
crossovers from combined to PI only, as
some evidence of prescribers deciding not
to because participants were showing a
good response to CBT by the time of
outpatient appointment
Option of a combined
treatment
Qualitative data from participants and family
members indicated a general preference for
as many treatment options as possible in the
short term, i.e. combined treatment. There
was some variation among participants and
among family about the long-term value of
PI or long-term risks of AP medication, so
the more help the better was not always a
long-term preference. Typically, clinicians
preferred AP medication first but valued PI
as additional help for ‘secondary’ issues, but
AP medication was a short-term preference
for the majority of family members and for
some participants
A three-arm design that includes a
combined arm should be retained for a
definitive trial to provide reassurance
to participants and family members that
there is the potential for a loved one to be
randomly allocated to a combined treatment
Prescribers concerns
regarding the adverse
effect profiles of AP
medication
Clinician qualitative data indicated that,
although clinicians shared a common belief
in the value of AP medication, they had
concern about the adverse effects of AP
medication for this population
For a definitive trial, the research team
should produce a handbook for clinicians to
define the parameters for prescribing for the
trial. This could highlight to clinicians that
a low dose of AP medication is acceptable
and that this can be below BNF limits. The
handbook could contain information on
the current evidence base for each AP
and the relative side effect profile
A handbook would promote standardisation
of prescribing and support psychiatry
decision-making
We recommend that the handbook
be produced in consultation with a
reference group of psychiatrists from
EIP and CAMHS with expertise of
working with young people
continued
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Trial outcomes
We collected demographic data and a range of potential primary and secondary outcomes to inform
a definitive trial. The PANSS is a suitable choice of primary outcome measure for a definitive trial
for a number of reasons. The completion rates of the PANSS were excellent at the end of treatment
(6 months) and clearly met the prespecified progression criteria. The PANSS is a valid and reliable
measure106 and it is the most commonly used primary outcome measure in psychosis trials. Therefore,
use in a definitive trial, it would allow comparison of data with the wider evidence base and synthesis
into systematic reviews and meta-analyses of treatments for psychosis. A review132 of 24 psychosis
study outcome measures found that the PANSS was the most acceptable to service users. However,
the PANSS is a clinician-rated measure and the same review of commonly used outcome measures
for psychosis studies indicated that service users have a general preference for outcome measures in
self-report format,132 and service users have expressed that global, recovery-oriented outcomes are as
important to deliver as changes in psychiatric symptomatology.133 Our service user-defined measure of
recovery (QPR) had lower completion rates at the end of treatment; however, this may be a result of
the approach to minimising participant burden, that is, when participants expressed difficulty or unease
with assessment battery burden, all measures other than the PANSS were deprioritised.
TABLE 26 Lessons learnt, challenges faced and recommendations for a definitive trial: acceptability and feasibility of
treatments: for young people with a FEP (continued )




The qualitative data suggest general
acceptance of AP medication from
participants and family members, but in
some instances a preference for PI.
Concerns about the side effects of AP
medication were expressed. However, in
some instances, both participants and family
members expressed a clear preference for
AP medication over PI
A three-arm design for a definitive trial
would recognise the variety in treatment
preferences. Any strong preferences for or
against the treatment options should be
discussed at screening (with the research
psychiatrist) and with the RA during the
informed consent process to ensure that
participants are genuinely content to be
randomised to a treatment. This is of
importance for both recruitment and
retention to a definitive trial
Family perspectives on
the acceptability of FI
Although we did not mandate FI in this
study, some family members said that they
considered it a good optional extra and
family members who did not receive FI
reported that it would have been useful.
However, participants indicated a more
diverse range of important views about FI,
from clear acceptability to clear refusal.
This emphasises the need to continue
considering FI as an optional element of PI
For a definitive trial, FI should form part of
the PI as an optional aspect of PI
Standardised and detailed information
should be produced for both participants
and families about FI to improve decision-
making about receiving FI. Information
should be age appropriate, i.e. use
appropriate media such as short animations
Feasibility of achieving
CBT milestones
There was an excellent rate of both
development of a problem list/goal and
sharing a formulation by session 3
Rates of ‘out in the real world’ sessions and
completion of longitudinal formulations
were lower
The rates of first session of CBT being
within 1 week of randomisation were low
The initial training for therapists should
include a focus on the implementation of
real-world sessions. Training should also
emphasise rapid access and this should
be monitored in a definitive trial via
supervision
Crossover from a PI
monotherapy arm to a
combined arm
In total, 50% of the crossovers from a PI
monotherapy arm to a combined arm were
a result of the participant meeting the
deterioration criteria
Removal of deterioration procedures would
reduce this crossover
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
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At baseline and follow-up, the completion rates of secondary outcomes measures (other than the
PANSS) were low, which indicated that the assessment battery should be significantly reduced for
this population, with only the most essential outcomes retained. See Table 25 regarding the proposed
outcomes for a definitive trial.
Limitations
Although all steps were taken to ensure a thorough approach to screening participant medical records
for medication adherence data, this approach was reliant on clinicians’ records. It is possible that
medication adherence may be overestimated by clinicians or by participants when reporting AP use,
and in a definitive trial medication non-adherence may mask effectiveness and safety implications.
We make recommendations with regard to this below.
Generally, the rate of completion of secondary outcome measures was low, including health economic
measures (e.g. the EQ-5D-5L), which limits any interpretation of the appropriateness of this measure
for a definitive trial.
The small sample size obtained means that we lacked statistical power and there will be considerable
uncertainty regarding estimates of treatment effects. It is possible that there is also uncertainty
regarding generalising from our rates of recruitment, retention and treatment adherence given the
small sample size.
Specific learning points and recommendations
The specific objectives relate to the following domains:
l trial feasibility (recruitment, retention, clarification of the selection criteria for a definitive trial,
suitability of randomisation and masking procedures)
l trial outcomes (validity and relevance of the outcome measures and estimation of plausible sample
size parameters)
l acceptability and feasibility of the treatments, including treatment manuals and staff training
l economies of scale for a definitive trial.
In relation to recruitment, retention and acceptability of the treatments, we prespecified green/amber/
red progression criteria in our study protocol as a mechanism to assess the feasibility of a definitive
trial. Approval for our prespecified progression criteria was granted from both the iDMC and the
study funder. Recruitment success was measured by determining the proportion of the target sample
size achieved: green criterion ≥ 80%, amber criterion 79–60% and red criterion < 60% of the target
sample size of 90 participants. Retention success was measured by the proportion of participants who
completed an end-of-treatment PANSS assessment: green criterion ≥ 80%, amber criterion 79–60%
and red criterion < 60% of participants followed up at this assessment point. Satisfactory delivery of
adherent therapy was determined by the proportion of participants allocated to PI who received six
or more sessions of CBT: green criterion ≥ 80%, amber criterion 79–60% and red criterion < 60% of
participants having six or more sessions. Satisfactory delivery of AP medication was determined by the
proportion of participants receiving an AP medicine for 6 or more consecutive weeks: green criterion
≥ 80%, amber criterion 79–60% and red criterion < 60% of participants receiving AP medication for
this period of time. It should be noted that we included an AP dose below the limits in the BNF given
that this is frequently the approach for young people owing to the drugs being licensed for adults.
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Trial feasibility
With regard to the progression criteria, we achieved a 50/50 mix of green and amber progression
zones. Overall, these results indicate that it would be possible to conduct a definitive trial, but some
modifications to the trial design are required. We provide information on these modifications in full in
Table 24. Recruitment was in the amber progression zone, suggesting that modifications are required
to recruit to target in a definitive trial. Two out of the four original sites recruited well, with the Oxford
site over-recruiting and the Manchester site recruiting to 91% of the target. Site selection is crucial to
ensuring recruitment to target for a definitive trial, and a number of considerations must be made in
selecting the sites, as outlined in Table 24. In addition, further refinement of the inclusion criteria could
have important implications for recruitment to target. Adherence to ≥ 6 consecutive weeks of AP
medication prescription for participants in an arm that contained AP prescription was in the amber
zone; however, we make specific recommendations for how this could be addressed in a full-scale trial.
Both retention of participants at the primary end point (end of treatment) and adherence to six or more
sessions of CBT for those participants in an arm that contained CBT were in the green zone. Retention
of participants at the primary end point (6 months, end of treatment) was excellent. However, retention
at the 12-month follow-up was lower (27–47%); we make specific recommendations for improving this
in a full-scale trial, although a substantial proportion of these missing data were because of a planned
variable follow-up rate in which participants recruited within the final 3 months of recruitment between
August and October 2018 (12 participants, 19.7% of the sample) were never intended to receive a
12-month assessment.
Acceptability and feasibility of treatments
Evaluation of data on adherence to treatments indicates that both PI and AP medication are acceptable
treatments, and it would be feasible to deliver both in a definitive trial. Although the data indicate
greater adherence to a dose of PI (six sessions or more), adherence to AP medication (6 or more
consecutive weeks) was lower. However, adherence to AP medication was within the amber zone for
the progression criteria, suggesting that it would be feasible to deliver in a definitive trial with some
amendments as outlined in Table 26. Adherence to AP medication within our trial compares well with
the general literature on AP adherence, which finds high levels of non-adherence, including in RCTs.
We obtained data from medical records to characterise the prescribing of AP medication for the
sample, self-report data from trial therapists to evaluate the quality of therapy delivered (both CBT
and FI), including therapy milestones and change strategies used during therapy, and CTS-R ratings
for fidelity to the CBT model. In addition, end of CBT and end of FI questionnaires completed by
therapists provided data on treatment manual amendments for a definitive trial.
Qualitative interviews provided an in-depth understanding of participants’ experiences of the
treatments and the acceptability of the treatments to both young people and family members. Several
key lessons were learnt that inform treatment delivery in a definitive trial. We present the lessons
learnt in Table 26.
Economies of scale
Each site had one full-time RA costed to work on the study. As outlined in Chapter 2, the RAs were
tasked with liaison and recruitment from clinical teams and research assessments including the PANSS,
psychometrics and physical health checks. Possible economies of scale include dropping the physical
health checks from the RA tasks and reducing the number of assessment measures. This would reduce
the length and/or number of research assessment visits per follow-up. However, for a number of
reasons, we recommend that for a definitive trial a full-time RA be retained for each site. First, as
outlined earlier, an assertive outreach approach was highly valued by participants and it is likely
that this contributed to excellent follow-up completion rates at 6-month assessment. To offer an
assertive outreach approach regarding the time, location and rearrangement of appointments plus
text, telephone and letter reminders (with the associated paperwork to document participant contact)
flexibility is required and this would be limited in a part-time role. Second, we recommend that more
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check-in telephone calls are scheduled to facilitate engagement and long-term follow-up; again this
would require sufficient diary capacity. Third, with improved screening methods and accuracy of
screening, as well a higher age limit of 25 years, we envisage an increased number of baseline visits.
To ensure swift access to entry to the trial (and, therefore, treatment) a RA would require flexibility
and capacity in their diary to act quickly in response to a referral from a psychiatrist.
Conclusions
This study aimed to assess the feasibility of undertaking a definitive trial to compare AP monotherapy,
PI monotherapy and a combined treatment. All of our study objectives were achieved and many
important lessons for a definitive trial were learnt. The feasibility trial methods and feasibility findings
can be generalised to other UK settings, given the representation of CAMHS and EIP service users.
However, we cannot generalise the findings to other countries that may have different service settings
for adolescent psychosis and, in particular, areas in which there are no EIP services.
Collectively, the results suggest that a definitive pragmatic effectiveness trial examining care pathways
is warranted, but some amendments are required to the trial design. Improvements to the trial design
include screening processes for recruitment, amendments to the inclusion/exclusion criteria, reduction
of treatment crossovers and reduced participant burden (from assessment measures). Our liaison with
clinical services has highlighted that EIP services and CAMHS are under considerable pressure from
funding issues and increased workload, especially because of the access and waiting time standards
requiring assessment, and delivery of NICE-compliant care for those taken onto the caseload within
2 weeks of referral. However, we advise that the current pressures on EIP services to respond to
access and waiting time standards may help recruitment to a definitive trial, as it is clear from our
qualitative studies that clinicians, parents and young people all viewed the trial as a way of accessing
help as quickly as possible. Including this study, we have conducted two similar three-arm feasibility
trials (one in adults102), and to inform a definitive trial we will combine these trials using a two-stage
fixed-effect individual patient data meta-analysis. The analysis will focus on the effects on PANSS total
and QPR total at 6 months to provide information for sample size calculations for a definitive trial.
Our evaluation of the literature presented in Chapter 1 demonstrates that the research question
regarding the clinical effectiveness and cost-effectiveness of AP medication versus PI versus a
combined treatment remains important and warrants a definitive trial to improve the evidence
base for treatments of FEP in young people.
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Manchester 215 (30.5) 21 (3.0) 236 (33.5)
Oxford 171 (24.3) 30 (4.3) 201 (28.5)
Sussex 22 (3.1) 9 (1.3) 31 (4.4)
Lancashire Care 131 (18.6) 13 (1.8) 144 (20.4)
Norfolk and Suffolk NHS
Foundation Trust
35 (5.0) 1 (0.1) 36 (5.1)
Newcastle 21 (3.0) 1 (0.1) 22 (3.1)
Birmingham 34 (4.8) 1 (0.1) 35 (5.0)
























Manchester 34 (33.7) 10 (34.5) 24 (33.3) 3 (27.3) 21 (34.4) 7 (38.9) 7 (33.3) 7 (31.8)
Oxford 33 (32.7) 7 (24.1) 26 (36.1) 1 (9.1) 25 (41.0) 7 (38.9) 9 (42.9) 9 (40.9)
Sussex 11 (10.9) 1 (3.4) 10 (13.9) 6 (54.5) 4 (6.6) 1 (5.6) 2 (9.5) 1 (4.5)
Lancashire
Care





1 (1.0) 1 (3.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Newcastle 1 (1.0) 0 (0) 1 (1.4) 0 (0) 1 (1.6) 0 (0) 0 (0) 1 (4.5)
Birmingham 1 (1.0) 0 (0) 1 (1.4) 0 (0) 1 (1.6) 0 (0) 0 (0) 1 (4.5)
Values are n (%).
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TABLE 29 Referral source









EIP service 83 (82.2) 24 (70.6) 26 (78.8) 11 (100.0) 19 (95.0) 1 (100.0) 1 (100.0) 1 (100.0)
CAMHS 11 (10.9) 6 (17.6) 5 (15.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
At-risk mental
state service
2 (2.0) 1 (2.9) 0 (0) 0 (0) 1 (5.0) 0 (0) 0 (0) 0 (0)




3 (3.0) 3 (8.8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Joint CAMHS
and inpatient
1 (1.0) 0 (0) 1 (3.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)


























































































































































































FIGURE 8 Recruitment over time by centre.
TABLE 30 Consultant-allocated diagnoses
ICD-10 diagnosis n (%)
F20.0 (Paranoid schizophrenia) 14 (22.9)
F20.81 (Schizophreniform disorder) 5 (8.2)
F22.0 (Delusional disorder) 1 (1.6)
F23.0 (Brief psychotic disorder) 7 (11.5)
F23.2 (Acute schizophrenia-like psychotic disorder) 2 (3.3)
F28.0 (Other psychotic disorder not due to a substance or known physiological condition) 1 (1.6)
F29.0 (Unspecified psychosis not due to a substance or known physiological condition) 27 (44.3)
Missing 4 (6.6)
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TABLE 31 Reasons for crossover: treatment received (adherence)
Reason for crossover
Treatment arm
PI (N= 8) Combined (N= 10) AP (N= 8)
Unknown 3 (37.5) 7 (70.0) 5 (62.5)
Deterioration 1 (12.5) 0 (0) 2 (25.0)
Participant declined 2 (25.0) 1 (10.0) 0 (0)
Clinician did not consider AP medication 0 (0) 1 (10.0) 1 (12.5)
Participant and family declined 0 (0) 1 (10.0) 0 (0)
Participant preference 1 (12.5) 0 (0) 0 (0)
Voluntary admission to a psychiatric inpatient unit 1 (12.5) 0 (0) 0 (0)
Values are n (%).
TABLE 32 Correlation for PANSS across all time points
Time point
Time point
Baseline 3 months 6 months 12 months
Baseline 1 0.4045 0.3029 0.3317
3 months 0.4045 1 0.6869 0.1740
6 months 0.3029 0.6869 1 0.2035
12 months 0.3317 0.1740 0.2035 1
TABLE 33 Correlation for QPR across all time points
Time point
Time point
Baseline 3 months 6 months 12 months
Baseline 1 0.6824 0.5273 0.1647
3 months 0.6824 1 0.6921 0.2756
6 months 0.5273 0.6921 1 0.4284
12 months 0.1647 0.2756 0.4284 1
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TABLE 34 Adverse events and deterioration in PANSS total score by allocation
AE
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
SAEs
Participants with a SAE 7 (38.9) 4 (19.0) 3 (13.6)
Number of SAEs 10 5 3
Participants with more than one SAE 2 (28.6) 1 (25.0) 0 (0)
Details
Voluntary psychiatric admission 1 1 1
Life-threatening (suicide attempt) 2 0 0
Serious violent incident 2 1 2
Admission to a general medical ward 2 1 0
Otherwise considered medically significant
(overdose of medication)
3 1 0




Participants with an AE 8 (44.4) 11 (52.4) 18 (81.8)
Number of AEs 13 27 49
Participants with more than one AE 4 (50.0) 6 (54.5) 11 (61.1)
Details
Self-harm 7 8 13
Medication side effect 0 15 30
Other AE 5 4 6
Distress reported regarding allocation 1 0 0
Deterioration in PANSS total score
6 months
> 25% 1 (6.3) 0 (0) 3 (16.7)
> 50% 0 (0) 1 (5.9) 1 (5.6)
12 months
> 25% 1 (9.1) 0 (0) 0 (0)
> 50% 0 (0) 0 (0) 0 (0)
Values are n (%) or n.
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TABLE 35 A measure of potential adverse effects of trial participation by allocation
Adverse effect measure
Treatment arm













Number who responded 8 (44.4) 8 (38.1) 6 (27.3)
Taking part hasn’t helped me with my problems 2 (25.0) 0 (0) 0 (0) 1 (12.5) 0 (0) 0 (0)
Taking part made my problems worse 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part made me feel more anxious 0 (0) 0 (0) 1 (12.5) 0 (0) 0 (0) 0 (0)
Taking part took up too much time 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part led to my mood becoming very low 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part made me feel more angry and irritable 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
I did not feel ready to talk about my problems 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part made me think too much about bad things
that have happened in the past
0 (0) 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part meant I stopped looking after myself properly 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part made me feel more suspicious 0 (0) 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part required too much energy or motivation 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part increased my thoughts of killing myself 0 (0) 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0)
I did not feel listened to or believed by MAPS staff 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part made my voices or visions worse 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part was making me fall out with my family
or friends
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part was having a bad effect on my self-esteem 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part was making me want to harm myself 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
I did not like or feel I could trust the MAPS
team members
1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
I felt embarrassed talking about my problems with
people I had not met before
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part made me have thoughts of harming
other people
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part was making me feel hopeless about
the future
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part meant I had to increase my medication to cope 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part involved too much hard work 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part made me worry that people would think
badly of me because of my diagnosis
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part made me fall out with my doctor or care team 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Taking part made me worry about losing control of
my mind
1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
My problems have improved to the point whereby I no
longer feel I need helpa
1 (12.5) 1 (12.5) 1 (12.5) 0 (0) 0 (0) 2 (33.3)
a Indicates an improvement.
Values are n (%) or n.
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TABLE 36 Adverse physical effects by allocation
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
ANNSERS total score
Baseline 8; 17.5 (10.4) 11; 17.2 (7.1) 12; 15.9 (6.4)
3 months 7; 11.0 (4.3) 8; 12.0 (5.9) 10; 12.5 (7.0)
6 months 6; 9.0 (4.0) 7; 6.7 (4.1) 8; 15.5 (7.0)
12 months 5; 5.6 (4.8) 6; 4.0 (3.9) 5; 13.4 (8.8)
ANNSERS number of side effects
Baseline 8; 10.6 (4.8) 11; 11.5 (3.8) 12; 11.2 (5.2)
3 months 7; 7.1 (2.7) 8; 8.1 (3.5) 10; 9.7 (5.6)
6 months 6; 6.3 (2.0) 7; 5.3 (3.0) 8; 10.5 (4.3)
12 months 5; 3.6 (3.0) 6; 3.3 (3.5) 5; 10.0 (6.2)
Weight (kg)
Baseline 10; 66.1 (13.9) 13; 62.8 (12.3) 13; 68.2 (18.8)
3 months 8; 66.7 (15.2) 9; 71.4 (12.6) 12; 72.8 (18.1)
6 months 8; 69.8 (11.4) 9; 72.5 (13.1) 9; 72.8 (19.0)
12 months 6; 69.7 (11.7) 5; 76.0 (10.4) 6; 67.4 (19.0)
Waist circumference (cm)
Baseline 9; 80.6 (11.4) 13; 76.8 (7.8) 11; 78.3 (13.3)
3 months 8; 83.2 (13.6) 8; 76.0 (19.0) 11; 82.8 (15.8)
6 months 8; 80.0 (10.6) 8; 82.0 (9.1) 8; 83.4 (14.3)
12 months 6; 83.2 (11.1) 4; 83.8 (3.6) 5; 84.2 (5.4)
BMI (kg/m2)
Baseline 10; 23.6 (4.5) 13; 22.5 (3.7) 13; 24.1 (6.4)
3 months 8; 24.0 (4.7) 9; 24.4 (4.3) 12; 26.0 (6.6)
6 months 8; 24.9 (4.1) 9; 25.0 (4.2) 9; 25.3 (4.5)
12 months 6; 24.5 (3.7) 5; 25.5 (4.2) 6; 25.9 (8.7)
Blood pressure (kg/m2)
Systolic
Baseline 10; 108.1 (11.0) 12; 112.2 (10.1) 10; 114.8 (11.5)
3 months 8; 107.3 (9.3) 9; 115.1 (12.7) 13; 112.4 (9.4)
6 months 8; 111.3 (11.5) 9; 118.0 (11.1) 9; 113.9 (12.2)
12 months 5; 106.7 (9.4) 3; 112.8 (3.3) 5; 110.9 (7.4)
Diastolic
Baseline 10; 67.8 (7.8) 12; 69.6 (9.7) 10; 67.8 (5.7)
3 months 8; 69.8 (5.3) 9; 70.7 (12.9) 13; 66.4 (11.0)
6 months 8; 70.3 (3.4) 9; 69.9 (6.8) 9; 66.3 (8.3)
12 months 5; 63.2 (7.3) 3; 66.0 (2.9) 5; 67.5 (5.2)
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TABLE 36 Adverse physical effects by allocation (continued )
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Fasting estimates of plasma glucose levels (mmol/mol)
Baseline 5; 4.6 (0.2) 3; 5.0 (1.1) 6; 4.2 (0.4)
3 months 4; 4.5 (0.2) 1; 4.8 2; 4.3 (0.6)
6 months 3; 5.3 (1.4) 1; 4.2 2; 5.3 (0.4)
12 months 2; 4.0 (0.1) 0; 0 0; 0
HbA1c levels (mmol/mol)
Baseline 5; 30.4 (1.1) 2; 35.5 (2.1) 7; 30.7 (3.7)
3 months 3; 30.7 (1.5) 2; 32.0 (0.0) 4; 31.8 (2.2)
6 months 2; 32.0 (4.2) 1; 30.0 3; 32.7 (3.8)
12 months 2; 37.5 (3.5) 0; 0 1; 33.0
Lipids levels (mmol/mol)
Cholesterol
Baseline 6; 3.5 (0.3) 3; 3.9 (0.4) 7; 3.8 (0.6)
3 months 4; 4.0 (0.4) 2; 3.5 (0.6) 4; 4.6 (0.4)
6 months 3; 4.0 (1.3) 1; 4.8 3; 3.6 (0.5)
12 months 2; 4.0 (0.1) 0; 0 1; 3.6
LDL
Baseline 6; 2.0 (0.2) 3; 2.1 (0.2) 6; 2.1 (0.5)
3 months 4; 2.3 (0.3) 2; 1.6 (0.4) 4; 2.7 (0.4)
6 months 3; 2.4 (0.8) 1; 2.9 3; 2.2 (0.7)
12 months 1; 2.2 0; 0 1; 1.9
HDL
Baseline 6; 1.0 (0.3) 3; 1.5 (0.6) 7; 1.1 (0.5)
3 months 4; 0.9 (0.2) 2; 1.3 (0.1) 4; 1.4 (0.3)
6 months 3; 0.9 (0.3) 1; 1.2 3; 1.1 (0.1)
12 months 2; 1.3 (0.3) 0; 0 1; 1.3
Triglycerides
Baseline 6; 1.0 (0.4) 3; 0.7 (0.2) 7; 1.0 (0.8)
3 months 4; 1.5 (0.5) 2; 1.2 (0.8) 4; 1.2 (0.5)
6 months 3; 1.6 (1.1) 1; 1.5 3; 1.0 (0.2)
12 months 2; 3.9 (4.7) 0; 0 1; 0.7
Serum prolactin levels (µg/l)
Baseline 6; 163.2 (79.2) 3; 170.3 (35.9) 7; 268.6 (86.6)
3 months 4; 170.8 (86.3) 2; 97.5 (85.6) 3; 503.7 (481.8)
6 months 2; 156.5 (37.5) 1; 212.0 3; 268.0 (87.0)
12 months 2; 118.5 (44.5) 0; 0 1; 200.0
Values are n; mean (SD). If only one participant responded, then only n; mean is reported.
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TABLE 37 Self-report medication adherence
Time point
Treatment arm
Combined (N= 21) AP (N= 22)
3 months
Completed measure 2 (9.5) 3 (13.6)
Prescribed AP medication
Yes 2 (100) 2 (66.7)
No 0 (0) 1 (33.3)
Percentage of time adhered to AP medication,
mean (SD); median (IQR)
86 (9.9); 96.5 (86, 100) 100 (0); 100 (100, 100)
6 months
Completed measure 5 (23.8) 2 (9.1)
Prescribed AP medication
Yes 3 (60.0) 2 (100)
No 2 (40.0) 0 (0)
Percentage of time adhered to AP medication,
mean (SD); median (IQR)
73 (27.5); 74 (45, 100) 92.5 (3.5); (90, 95)
12 months
Completed measure 5 (23.8) 3 (13.6)
Prescribed AP medication
Yes 4 (80.0) 1 (33.3)
No 1 (20.0) 2 (66.7)
Percentage of time adhered to AP medication,
mean (SD); median (IQR)
73.8 (43.1); 92.5 (47.5, 100) 100 (0); 100 (100, 100)
Values are n (%) unless otherwise stated.
TABLE 38 The EuroQol five-dimension, five level version, results
Time point
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Baseline 8; 0.686 (0.204) 11; 0.623 (0.239) 12; 0.620 (0.260)
3 months 5; 0.796 (0.085) 7; 0.764 (0.179) 12; 0.543 (0.268)
6 months 6; 0.637 (0.338) 7; 0.868 (0.058) 9; 0.763 (0.203)
12 months 4; 0.763 (0.252) 6; 0.815 (0.250) 4; 0.804 (0.133)
Values are n; mean (SD).
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 39 NHS resource use at baseline
Resource use
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Planned hospital overnight stay
No 9 (50) 10 (48) 12 (55)
Yes 1 (6) 1 (5) 1 (5)
Missing 8 (44) 10 (48) 9 (41)
Attended hospital outpatient appointments that lasted for ≤ 4 hours during the last 12 months
No 6 (33) 6 (29) 9 (41)
Yes 4 (22) 5 (24) 4 (18)
Missing 8 (44) 10 (48) 9 (41)
Attended hospital outpatient appointments that lasted for > 4 hours (but not overnight) during the last 12 months
No 9 (50) 10 (48) 12 (55)
Yes 0 (0) 1 (5) 1 (5)
Missing 9 (50) 10 (48) 9 (41)
Attended an accident and emergency unit during the last 12 months
No 3 (17) 7 (33) 6 (27)
Yes 6 (33) 4 (19) 7 (32)
Do not know 1 (6) 0 (0) 0 (0)
Missing 8 (44) 10 (48) 9 (41)
Attended primary and community-based health services during the last 12 months
No 0 (0) 1 (5) 0 (0)
Yes 10 (56) 9 (43) 13 (59)
Do not know 0 (0) 1 (5) 0 (0)
Missing 8 (44) 10 (48) 9 (41)
GP visit
No 0 (0) 2 (10) 5 (23)
Yes 10 (56) 9 (43) 7 (32)
Do not know 0 (0) 0 (0) 1 (5)
Missing 8 (44) 10 (48) 9 (41)
GP visit at home
No 9 (50) 11 (52) 13 (59)
Missing 9 (50) 10 (48) 9 (41)
GP nurse visit
No 6 (33) 9 (43) 10 (45)
Yes 2 (11) 2 (10) 3 (14)
Missing 10 (56) 10 (48) 9 (41)
continued
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TABLE 39 NHS resource use at baseline (continued )
Resource use
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
GP nurse home visit
No 8 (44) 11 (52) 12 (55)
Yes 0 (0) 0 (0) 1 (5)
Missing 10 (56) 10 (48) 9 (41)
Visited a walk-in centre
No 7 (39) 8 (38) 12 (55)
Yes 1 (6) 3 (14) 0 (0)
Do not know 0 (0) 0 (0) 1 (5)
Missing 10 (56) 10 (48) 9 (41)
Values are n (%).
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 40 NHS resource use at 3 months
Resource use
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Planned hospital overnight stay
No 6 (33) 4 (19) 13 (59)
Yes 0 (0) 2 (10) 0 (0)
Missing 12 (67) 15 (71) 9 (41)
Attended hospital outpatient appointments that lasted for ≤ 4 hours since last visit
No 2 (11) 4 (19) 6 (27)
Yes 4 (22) 3 (14) 5 (23)
Do not know 0 (0) 0 (0) 2 (9)
Missing 12 (67) 14 (67) 9 (41)
Attended hospital outpatient appointments that lasted for > 4 hours (but not overnight) since last visit
No 6 (33) 5 (24) 10 (45)
Yes 0 (0) 1 (5) 1 (5)
Do not know 0 (0) 0 (0) 2 (9)
Missing 12 (67) 15 (71) 9 (41)
Attended accident and emergency unit since last visit
No 1 (6) 4 (19) 8 (36)
Yes 5 (28) 3 (14) 4 (18)
Do not know 0 (0) 0 (0) 1 (5)
Missing 12 (67) 14 (67) 9 (41)
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TABLE 40 NHS resource use at 3 months (continued )
Resource use
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Attended primary and community-based health services since last visit
Yes 6 (33) 7 (33) 13 (59)
Missing 12 (67) 14 (67) 9 (41)
GP visit
No 0 (0) 2 (10) 5 (23)
Yes 6 (33) 5 (24) 8 (36)
Missing 12 (67) 14 (67) 9 (41)
GP visit at home
No 6 (33) 7 (33) 12 (55)
Yes 0 (0) 0 (0) 1 (5)
Missing 12 (67) 14 (67) 9 (41)
GP nurse visit
No 5 (28) 6 (29) 7 (32)
Yes 1 (6) 1 (5) 6 (27)
Missing 12 (67) 14 (67) 9 (41)
GP nurse home visit
No 6 (33) 7 (33) 11 (50)
Yes 0 (0) 0 (0) 2 (9)
Missing 12 (67) 14 (67) 9 (41)
Visited a walk-in centre
No 4 (22) 7 (33) 10 (45)
Yes 2 (11) 0 (0) 2 (9)
Do not know 0 (0) 0 (0) 1 (5)
Missing 12 (67) 14 (67) 9 (41)
Values are n (%).
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 41 NHS resource use at 6 months
Resource use
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Planned hospital overnight stay
No 6 (33) 5 (24) 9 (41)
Yes 0 (0) 1 (5) 0 (0)
Do not know 0 (0) 1 (5) 0 (0)
Missing 12 (67) 14 (67) 13 (59)
continued
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TABLE 41 NHS resource use at 6 months (continued )
Resource use
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Attended hospital outpatient appointments that lasted for ≤ 4 hours since last visit
No 4 (22) 5 (24) 4 (18)
Yes 2 (11) 1 (5) 5 (23)
Do not know 0 (0) 1 (5) 0 (0)
Missing 12 (67) 14 (67) 13 (59)
Attended hospital outpatient appointments that lasted for > 4 hours (but not overnight) since last visit
No 6 (33) 5 (24) 7 (32)
Yes 0 (0) 1 (5) 2 (9)
Do not know 0 (0) 1 (5) 0 (0)
Missing 12 (67) 14 (67) 13 (59)
Attended accident and emergency unit since last visit
No 2 (11) 3 (14) 6 (27)
Yes 4 (22) 4 (19) 3 (14)
Missing 12 (67) 14 (67) 13 (59)
Attended primary and community-based health services since last visit
No 1 (6) 0 (0) 0 (0)
Yes 5 (28) 6 (29) 9 (41)
Do not know 0 (0) 1 (5) 0 (0)
Missing 12 (67) 14 (67) 13 (59)
GP visit
No 1 (6) 2 (10) 2 (9)
Yes 4 (22) 5 (24) 7 (32)
Missing 13 (72) 14 (67) 13 (59)
GP visit at home
No 5 (28) 7 (33) 8 (36)
Yes 0 (0) 0 (0) 1 (5)
Missing 13 (72) 14 (67) 13 (59)
GP nurse visit
No 3 (17) 5 (24) 5 (23)
Yes 2 (11) 2 (10) 4 (18)
Missing 13 (72) 14 (67) 13 (59)
GP nurse home visit
No 5 (28) 7 (33) 9 (41)
Yes 13 (72) 14 (67) 13 (59)
Missing 0 (0) 0 (0) 0 (0)
Visited a walk-in centre 3 (17) 7 (33) 9 (41)
No 2 (11) 0 (0) 0 (0)
Yes 13 (72) 14 (67) 13 (59)
Missing 0 (0) 0 (0) 0 (0)
Values are n (%).
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 42 NHS resource use at 12 months
Resource use
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Planned hospital overnight stay
No 4 (22) 5 (24) 4 (18)
Do not know 0 (0) 1 (5) 0 (0)
Missing 14 (78) 15 (71) 18 (82)
Attended hospital outpatient appointments that lasted for ≤ 4 hours since last visit
No 4 (22) 5 (24) 3 (14)
Yes 0 (0) 1 (5) 1 (5)
Missing 14 (78) 15 (71) 18 (82)
Attended hospital outpatient appointments that lasted for > 4 hours (but not overnight) since last visit
No 4 (22) 6 (29) 4 (18)
Missing 14 (78) 15 (71) 18 (82)
Attended accident and emergency unit since last visit
No 2 (11) 4 (19) 3 (14)
Yes 2 (11) 2 (10) 0 (0)
Do not know 0 (0) 0 (0) 1 (5)
Missing 14 (78) 15 (71) 18 (82)
Attended primary and community-based health services since last visit
No 0 (0) 1 (5) 0 (0)
Yes 4 (22) 5 (24) 4 (18)
Missing 14 (78) 15 (71) 18 (82)
GP visit
No 2 (11) 2 (10) 1 (5)
Yes 2 (11) 4 (19) 3 (14)
Missing 14 (78) 15 (71) 18 (82)
GP visit at home
No 4 (22) 6 (29) 4 (18)
Missing 14 (78) 15 (71) 18 (82)
GP nurse visit
No 3 (17) 4 (19) 3 (14)
Yes 1 (6) 2 (10) 1 (5)
Missing 14 (78) 15 (71) 18 (82)
GP nurse home visit
No 4 (22) 6 (29) 3 (14)
Yes 0 (0) 0 (0) 1 (5)
Missing 14 (78) 15 (71) 18 (82)
continued
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TABLE 42 NHS resource use at 12 months (continued )
Resource use
Treatment arm
PI (N= 18) Combined (N= 21) AP (N= 22)
Visited a walk-in centre
No 4 (22) 5 (24) 4 (18)
Yes 0 (0) 1 (5) 0 (0)
Missing 14 (78) 15 (71) 18 (82)
Values are n (%).
Used with permission from Morrison et al.103 This is an Open Access article under the CC BY-NC-ND 4.0 license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 43 Clinicians’ qualitative study participant characteristics
Study ID
Characteristic







C01 Psychiatrist CAMHS and EIP Male 49 3 49:43
C02 Advanced
Practitioner
EIP Male 42 – 46:07
C03 Psychiatrist CAMHS Female 45 – 34:52
C04 Psychiatrist EIP Female 41 1 53:09
C05 Specialty doctor EIP Male 45 1 53:04
C06 Psychiatrist EIP Male 34 2 50:29
C07 Psychiatrist CAMHS Female 39 1 46:40
C08 Psychiatrist EIP Female 34 – 33:28
C09 Psychiatrist CAMHS and EIP Male 36 – 23:07
C10 Psychiatrist CAMHS Female Missing – 58:12
C11 Psychiatrist EIP Female 50 – 15:29
C12 Psychiatrist EIP Female Missing 3 50:29
C13 Psychiatrist EIP Male 32 – 40:26
C14 Psychiatrist CAMHS Male 63 1 20:54
C15 Psychiatrist CAMHS Male 32 – 40:32
C16 Psychiatrist EIP Male 36 14 24:24
C17 Psychiatrist CAMHS Female Missing – 26:54

















































































































































































































































































































































































































































































































































































































































DOI: 10.3310/hta25040 Health Technology Assessment 2021 Vol. 25 No. 4
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Morrison et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,


























































































































































































































































































































































































































































































































































































































































































































































Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk
This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care
Published by the NIHR Journals Library
